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EXPLORING BIOLOGICAL HETEROGENEITY AND ITS CONSEQUENCES
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by
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ABSTRACT
This dissertation explores the effects of heterogeneity across different biological
scales in cancer as well as normal cells.

At the tissue scale, we investigated the

variability present in the tumor microenvironment and its effect on patient
chemotherapeutic outcomes using a mathematical model of drug transport. We found that
parameters such as tumor blood perfusion and radius of blood vessel had an impact on
the tumor cytotoxicity. This indicated that the physical microenvironment of the tumor is
an important regulator of the tumor response to chemotherapy. At the cellular scale, we
investigated the heterogeneity present on the membrane landscape of ErbB2 and ErbB3,
two receptors that are upregulated in cancer, using a spatial stochastic model of receptor
dimerization and phosphorylation. We found that membrane domains played an
important role in regulating signaling emanating from this receptor dimer. In our next
study, we developed a 3-D spatial stochastic model of pre-BCR, a receptor which is
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crucial in the development of B lymphocytes and also upregulated in a subset of patients
with B-Cell Precursor Acute Lymphoblastic Leukemia, to investigate the effects of ligand
independent (tonic signaling) originating from this receptor. We populated our model
with single particle tracking data from two different leukemic cell lines which had
different dimer off rates and diffusion coefficients, along with experimental
measurements. Other important signaling molecules such as Lyn and Syk, which are
active in this pathway, were also included in the model. We found that the variability in
characteristics between the two cell lines led to differences in downstream signaling
events from the receptor. The cell line with the lower dimer off rate formed higher order
oligomers and had more overall molecule phosphorylation compared to the other. Thus,
this spatial stochastic model was able to shed light on threshold signaling events which
take place during tonic signaling.
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CHAPTER 1: INTRODUCTION

1.1 OVERVIEW
Heterogeneity in form and function has been found to exist across multiple
different scales in biological systems (Altschuler and Wu, 2010; Allison and Sledge,
2014; Chang and Marshall, 2017). At the cellular scale, clonally identical cell populations
have been found to exhibit differential gene expression of the same protein, thus giving
rise to phenotypic diversity (Elowitz et al., 2002; Ozbudak et al., 2002). Stochastic
generation and degradation of proteins and compartmentalization of molecules during
cell division also contribute to non-genetic sources of heterogeneity in cells (Huh and
Paulsson, 2011). At the organelle scale, rates of biochemical reactions occurring inside
structures such as the mitochondria and endoplasmic reticulum can be affected by the
size and shape of these structures (Marshall, 2012). At the tissue scale, the geometrical
shapes of mammary epithelial tubules have been found to affect the positioning of ductal
branches during pubertal mammary morphogenesis (Nelson et al., 2006). A
computational model of prostate cancer exploring tumor growth has found that
malignancy of tumors is affected by the geometry of the tumors, as well as the anatomy
of the organ in which the tumor resides (Lorenzo et al., 2016). Thus, heterogeneity has
been found to exist across all scales in normal as well cancerous tissues (Editorial, 2010).

1.2 MOTIVATION
Since the existence of heterogeneity is well established, this poses some
interesting questions such as to whether they are harmless or they render cells or groups
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of cells with evolutionary or survival advantages (Editorial, 2010; Ackermann, 2015).
Understanding the consequences of such heterogeneity is particularly important in
diseases like cancer as tumor cells can exploit heterogeneity present in the tumor microenvironment for growth and escape from patient therapies (Junttila and de Sauvage,
2013; Allison and Sledge, 2014). Even patients with the same type of cancer can inherit
or develop different tumor heterogeneities leading to varied response to chemotherapeutic
drugs (Harry et al, 2010.; Tonkin et al., 1985; Wei et al., 2013). Thus, for optimal
treatment outcomes, it is important to not only understand the consequences of such noise
but also to develop methods to identify the heterogeneities as they can differ from patient
to patient (Meacham and Morrison, 2013; Pascal et al., 2013a; Wang et al., 2016).
Conversely, heterogeneity can also be a beneficial trait in normal cells, for example, nonhomogenous distribution of molecules or receptors in different domains on the plasma
membrane can help to regulate signal transduction pathways in the cell (Lagerholm et al.,
2005).
In this dissertation, we explore the heterogeneity present on the tissue scale
(macroscopic) as well as at the cellular scale (microscopic) in the context of cancer. In
Chapter 1, we explore the effects of heterogeneity present in the tumor microenvironment of patients and its effect on the outcome of chemotherapy. The
heterogeneity that exists is dependent upon the amount of blood vessel perfusion of the
tumor as well as the geometry of the blood vessels. Using a mathematical model of drug
transport, we predicted the fraction of dead tumor in patients who had been administered
chemotherapy. We then retrospectively compared it to the actual fraction of dead tumor
measured in these patients to validate the model. Patient histological samples that
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displayed higher levels of blood vessel perfusion also exhibited higher fractions of dead
tumor indicating that the patient vasculature, which is inherently varied between patients,
affects treatment outcomes. Thus, this model highlighted the effects of a heterogeneous
tumor microenvironment on tumor survival and consequently patient therapeutic
outcomes.
In Chapter 2, we investigate the effects of a heterogeneous membrane landscape
on the signal transduction pathways of ErbB2 and ErbB3, two receptors belonging to the
epidermal growth factor receptor (EGFR) family. These two receptors are often found
upregulated in cancer and together form a potent oncogenic unit by activating key
survival and proliferative cellular pathways. We found that in normal cells, spatial
segregation of these two receptors into different in silico membrane domains
downregulates the signals arising from dimer events between them. Additionally, we also
found that strength of the confinement of domains affected receptor signaling based on
the amount of overlap between the two receptor domains. Thus, in a non-cancerous
setting, membrane domains add an additional layer of regulation of the potent
ErbB2/ErbB3 signaling pathway.
In Chapter 3, our focus was on generating a mathematical model of tonic
signaling (ligand independent signaling) arising from the pre-BCR. The pre-BCR is
expressed early in the developmental pathway of B lymphocytes, where it is crucial for
the survival and differentiation of progenitor B lymphocytes. This receptor is also
characteristic of a subset of patients with B-Cell Precursor Acute Lymphoblastic
Leukemia (BCP-ALL), where the tumor exploits the tonic signaling pathway for its
survival and proliferation. Single particle tracking (SPT) methods have revealed that
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these receptors have transient, but frequent dimerization events with each other. We
investigated tonic signaling emanating from this receptor using two different BCP-ALL
cell lines and found characteristic differences between them in diffusion coefficients and
dimer off rates. We created a spatial stochastic model of pre-BCR aggregation to explore
the membrane landscape of pre-B cells during tonic signaling in more detail. We found
that the individual differences along with the presence of membrane domains impacted
aggregate size, receptor phosphorylation and downstream activation of signaling
molecules in both the cell lines.
The overall goal of this work was to explore heterogeneity present at different
biological scales and its impact on behavior of cells or tissues in cancerous or normal
settings. Below is a more detailed description of the heterogeneity present in the tissue
scale as well as the cellular scales in particular biological systems.

1.3

HETEROGENEITY

AT

THE

TISSUE

SCALE

IN

TUMOR

MICROENVIRONMENT
Genetic variability has been established as a key feature among tumor cells and
has been identified as the primary driver of oncogenic mutations (Hanahan and
Weinberg, 2000; Meacham and Morrison, 2013). However, research in the past two
decades has alluded to us other accessory participants that promote this cancerous
phenotype, which include cells in the surrounding stroma as well as the vasculature and
the lymphatic system (Hashizume et al., 2000; Nagy et al., 2009; Goel et al., 2011;
Hanahan and Weinberg, 2011). Lymphocytes such as T and B cells and tumor associated
macrophages (TAMs) have been found to be associated with tumor cells and a certain
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subset of these cells such as the T regulatory (Tregs) and B regulatory cell (Bregs) have
displayed tumor promoting capabilities by downregulating anti-tumor responses
(Balkwill et al., 2012). Quiescent vascular endothelial or lymphatic endothelial cells can
be activated to produce new blood or lymphatic vessels through the binding of growth
factors secreted by the tumor cells as wells as through a hypoxic tumor
microenvironment (Balkwill et al., 2012). This ensures the tumor a supply of nutrients
while it proliferates and helps it to metastasize to distant locations in the body. Thus, the
tumor microenvironment forms a dynamic heterogeneous spatial landscape, whose
interactions with the tumor cells need to be investigated thoroughly as the
microenvironment can significantly impact tumor growth and alter patient responses to
therapies (Junttila and de Sauvage, 2013; Yuan, 2016).
In vitro and in vivo studies have shown that the microenvironment of the tumor
plays a key role in drug penetration into the tumor and might be a potential reason for
chemotherapeutic resistance or failure in patients (Kuh et al., 1999; Tunggal et al., 1999;
Tannock et al., 2002; Kyle et al., 2004; Primeau et al., 2005; Grantab et al., 2006; Kyle et
al., 2007; Sinek et al., 2009; Grantab and Tannock, 2012; Rejniak et al., 2013). Systemic
delivery of drugs into the tumor sites involves the transport of drugs through the tumor
vasculature, extravasation across the blood vessel and transport across the interstitium
within the tumor (Jain, 1989; 2005). There are three main physiological barriers that
hinder the transportation of drugs into the tumor and these are variations in the amount of
blood supplied to the tumor, an increase in the interstitial fluid pressure (IFP) and large
transport distances travelled by tumor drugs to reach the tumor site. These barriers play
an important role in drug delivery as they can limit the amount of drug transported into
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the tumor, thus, reducing the effectiveness of the chemotherapeutic treatment, leading to
residual tumor cells and cancer regrowth (Au et al., 2001; Gottesman, 2002; Jang et al.,
2003; Minchinton and Tannock, 2006; Sanga et al., 2006; Junttila and de Sauvage, 2013).
A heterogeneous vasculature in the tumor microenvironment can give rise to necrotic,
semi-necrotic and well vascularized regions with irregular vessel diameters and leaky
vessels leading to lower blood flow to the tumor site (Hobbs et al., 1998; Jang et al.,
2003; Minchinton and Tannock, 2006; Tredan et al., 2007; Stylianopoulos and Jain,
2013). High IFP is often associated with solid tumors due to lack of lymphatics and
leakiness of the tumor blood vessels leading to limited extravasation of drugs from the
blood vessel and worse patient prognosis (Jain, 1987; Baxter and Jain, 1989; Curti et al.,
1993; Milosevic et al., 2001; Jang et al., 2003; Heldin et al., 2004; Minchinton and
Tannock, 2006; Sven and Josipa, 2007; Li et al., 2011). Penetration of drugs into the solid
tumor has been shown to be obstructed by high tumor cell density where tumors with a
lower tumor cell fraction and more interstitial space had a more rapid diffusion of drugs
into the tumor (Au et al., 2001).
Systemic chemotherapy is a commonly used treatment strategy for various types
of cancers (Carlson et al., 2009; Edwards et al., 2012; Kim et al., 2013; Wei et al., 2013).
However, due to the existence of heterogeneity present in the microenvironment,
response to chemotherapy has been variable even in the same type of cancer. For
instance, response rates ranging from 8% to 85% have been observed for colorectal
cancer treated with 5-fluorouracil and response rates ranging from 8% to 60 % have been
observed for head and neck cancer treated with methotrexate (Tonkin et al., 1985). Thus,
predicting chemotherapeutic outcomes is important to optimize treatment of cancer
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patients as prolonged continuation with ineffective therapies can lead to an increased
burden of toxicity and expense for the patients along with a delay in surrogate beneficial
treatments (Dose Schwarz et al., 2005; Harry et al., 2010). Current methods for assessing
tumor response to chemotherapy include unidimensional response evaluation criteria to
solid tumors (RECIST) through the use of tumor imaging techniques such as magnetic
resonance imaging (MRI), computed tomography (CT), ultrasound, chest X-ray etc.
(Therasse et al., 2000). These methods have been modified from the previous
bidimensional measurements recommended by the World Health organization (WHO)
(Organization, 1979). However, many of the techniques used for tumor assessment are
proven to be inadequate, while others can only be utilized after sufficient time has passed
at which changes in tumor can be evaluated (Rubbia-Brandt et al., 2007; Glazer et al.,
2010; Thoeny and Ross, 2010; Egger et al., 2013). Hence, there is a lack of robust
quantitative measurements of tumor response that can predict chemotherapeutic
outcomes even before the commencement of therapeutic regimen for patients.
In chapter 2 of this dissertation, we employ a “mathematical pathology” approach,
a translational modeling approach emphasizing the development of mechanistic models
that are able to predict chemotherapeutic outcomes dependent on patient-specific
measurable parameters.

1.4 HETEROGENEITY AT THE MEMBRANE LEVEL
Cell signaling is initiated through ligand-receptor or receptor-receptor binding on
a cell’s surface. This surface known as the plasma membrane serves as a platform for
initiating signaling events that have a variety of downstream effects on cell fate and
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behavior (Groves and Kuriyan, 2010). Critical decisions to grow, survive, metastasize or
undergo apoptosis are relayed through the plasma membrane into the cells
(Radhakrishnan et al., 2012). Given the role that these surfaces play in cell signaling, it is
important to investigate how the membrane themselves are regulated. While the
composition of these membranes have been well defined, our understanding of their
functioning and their effect on cell signaling remains rudimentary (Grecco et al.).
The membrane platforms were initially thought to be a homogenous signaling
environment with receptors and other macromolecules randomly distributed on the cell
surface. Singer and Nicolson in their landmark paper, described the membrane as a fluid
mosaic of globular proteins embedded homogenously in a phospholipid by layer (Singer
and Nicolson, 1972). However, it was soon observed that the plasma membrane was a
heterogeneous landscape containing “domains” or “patches”, ranging from 0.1 µm to 1.0
µm, which could transiently trap specific proteins and lipids (Kaizuka et al., 2007; Chung
et al., 2010; Treanor et al., 2010a; Wilson et al., 2011; Radhakrishnan et al., 2012; Goñi,
2014). Domains enriched in increased levels of cholesterol and glycospingolipids are
known as lipid rafts and they are estimated to have a diameter ranging from less than
0.1µm to 0.2 µm (Pike, 2003; Lidke and Wilson, 2009).

Domains formed by the

underlying actin cytoskeleton are known as corrals and they can range from 0.1 µm to 0.3
µm (Kusumi et al., 1993; Kusumi and Sako, 1996; Kusumi et al., 2005; Hoppe and LowNam, 2014). These domains can trap a variety of receptors such as the G-protein-coupled
receptor (GPCRs), epidermal growth factor receptors (EGFR), platelet derived growth
factor (PDGF) receptors and endothelin receptors among others (Smart et al., 1999; Pike,
2003).
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Determining the role of these domains on regulating signal transduction pathways
has been a major subject of interest in the field of membrane biology (Pike, 2003;
Marguet et al., 2006; Day and Kenworthy, 2009; Owen et al., 2009). It has been
postulated that membrane domains could positively or negatively inhibit reaction
networks by compartmentalizing molecules belonging to specific pathways in different
domains (Pike, 2003). Experimental evidence for confinement of receptors and their
signaling molecules in domains or clusters have been found in a variety of important
receptor systems such as the T cell receptor (TCR) (Bunnell et al., 2002; Douglass and
Vale, 2005; Gaus et al., 2005; Lillemeier et al., 2006; Kaizuka et al., 2007; Dinic et al.,
2015), the high affinity Immunoglobulin E receptor (FcϵRI) (Field et al., 1997; Andrews
et al., 2009a), the B cell receptor (BCR) (Tolar et al., 2009; Treanor et al., 2010b) and
the Epidermal growth factor receptor (EGFR) family (Nagy et al., 2002; Yang et al.,
2007; Chung et al., 2010).
In chapter 3 of this dissertation, we specifically investigated the consequences of
a heterogeneous membrane landscape consisting of specific domains on two receptors
belonging to the EGFR family- the ErbB2/HER2/NEU and ErbB3/HER3 receptors
(Yarden, 2001). Other members of this family include the EGFR/ErbB1/HER1 and
ErbB4/HER4 (Roskoski, 2014). The EGFR family are receptor tyrosine kinases (RTK)
that contain an extracellular ligand binding domain, a transmembrane domain and an
intracellular kinase domain (Ullrich and Schlessinger, 1990). There is no known ligand
for ErbB2 and ErbB3 binds two ligands- Neuregulin-1 (Nrg-1) and Neuregulin-2 (Nrg-2)
(Burden and Yarden, 1997; Roskoski, 2014). Seven different ligands including the
epidermal growth factor (EGF) and transforming growth factor- a (TGF-a) bind to
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ErbB1, while the ErbB4 also binds seven ligands including Nrg-1, Nrg-2, Neuregulin-3
(Nrg-3), and Neuregulin-4 (Nrg-4) (Roskoski, 2014). The EGFR family regulates cell
growth, differentiation, apoptosis, adhesion and migration (Yarden and Sliwkowski,
2001). Specifically, inactivation or deficiency of EGFR/ErbB1 can lead to impaired
epithelial growth and differentiation, affecting the development of skin, lungs,
gastrointestinal tracts, kidney, liver as well as impaired neural development during
embryonic or post-natal growth (Miettinen et al., 1995; Threadgill et al., 1995; Sibilia et
al., 1998). Likewise, ErbB2, ErbB3 and ErbB4 have been implicated in development and
differentiation of neural and cardiac tissue (Gassmann et al., 1995; Lee et al., 1995;
Meyer and Birchmeier, 1995; Burden and Yarden, 1997; Liu et al., 1998). Thus, the
EGFR family plays a crucial role in normal development of tissues and organs in an
organism.
The EGFR family activates a variety of downstream signaling pathways that are
involved in cell proliferation and survival such as the phosphatidylinositol 3-kinase
(PI3)/Akt (PKB) pathway, the Ras/Raf/MEK/ERK1/2 pathway, and the phospholipase C
(PLCg) pathway (Yarden and Sliwkowski, 2001; Roskoski, 2014). Upon ligand binding,
the EGFR family can form homodimers and heterodimers with each other, followed by
transphosphorylation of tyrosine residues by the kinase domains of the partner receptors
(Hubbard and Till, 2000). These phosphotyrosines then serve as docking sites for a wide
variety of downstream signaling molecules such as the growth factor receptor bound
protein 2 (Grb2), p85 and the Shc adaptor protein among others (Wilson et al., 2009;
Roskoski, 2014). Amongst the four ErbB receptors, ErbB3 has a weak catalytic activity
and it requires hetero-dimerization with another ErbB receptor, mainly ErbB2, for its
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phosphorylation and upregulation of its kinase activity (Guy et al., 1994; Zhang et al.,
2009; Shi et al., 2010; Steinkamp et al., 2014).
As crucial as the ErbB receptors’ roles remain in normal development, they have
also been implicated in many cancers (Yarden and Sliwkowski, 2001). Overexpression of
ErbB2 has been found in cancers of the breast, gastrointestinal tract, lung, ovaries, cervix
and the salivary gland and has been associated with worse patient prognosis (Slamon et
al., 1987; Ross and Fletcher, 1998; Yarden and Sliwkowski, 2001; Baselga and Swain,
2009).

Aberrant signaling from the overexpressed ErbB2 receptors result in tumor

survival and proliferation (Baselga and Swain, 2009). ErbB3 has been found to be coexpressed with ErbB2 in breast cancers, as well as melanoma, and the ErbB2/ErbB3
heterodimer has been implicated in transformations of normal cells in to tumor as well as
increased cell spreading and motility (Alimandi et al., 1995; Wallasch et al., 1995;
Chausovsky et al., 2000; Vaught et al., 2012; Zhang et al., 2013). ErbB3 expression in
tumors have also been found to promote resistance to tyrosine kinase inhibitor therapies
in patients (Sergina et al., 2007; Huang et al., 2013; Sato et al., 2013; Lee et al., 2014).
Thus, the ErbB2/ErbB3 heterodimer pair is considered to be one of the most potent ErbB
dimer pairs involved in carcinogenesis (Pinkas-Kramarski et al., 1996; Tzahar et al.,
1996; Baselga and Swain, 2009).
Since the ErbB2/ErbB3 heterodimer plays an important role in cancer
progression, we wanted to further study the dynamics of this signaling unit in the context
of a heterogeneous membrane landscape. Images obtained from immunoelectron
microscopy have showed that ErbB receptors localize distinctly to separate regions of the
plasma membranes in breast cancer cells (Yang et al., 2007). Upon stimulation with a
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ligand, receptors such as ErbB2 and ErbB3 were found to be co-clustered, indicating an
increase in proximity for receptor binding events to occur (Yang et al., 2007). One
possible explanation for the segregation of ErbB receptors in different compartments
before stimulation would be to regulate any spurious signaling that might occur due to the
proximity of signaling dimers with each other (Yang et al., 2007). Yang et al. also
postulated that in normal cells, separation of ErbB receptors in distinct areas or domains
might serve to limit any unnecessary signaling originating from the ErbB heterodimers
(Yang et al., 2007). In chapter 3, we have attempted to answer how confinement of
receptors in different domains and the strength of the confinement in those domains
affects ErbB signaling in an in silico membrane landscape.

1.5 HETEROGENEITY AT THE RECEPTOR LEVEL
The B lymphocytes belong to the adaptive immune system and perform important
functions such as antibody and cytokine production and co-stimulation of T cells (LeBien
and Tedder, 2008). Their development initiates in the bone marrow where progenitor B
cells have to progress through various checkpoints to ensure their survival and
differentiation into mature B cells (Rajewsky, 1996). The first checkpoint encountered by
the progenitor B cells is at the pre-B cell stage where surface expression of a precursor-B
cell receptor (pre-BCR) is required for transition into the next developmental stage (von
Boehmer and Melchers, 2010). The structure of the pre-BCR consists of the two
immunoglobulin heavy chains (IgH) that pair with two surrogate light chains (SLC)- l5
and VpreB, along with the heterodimeric signaling unit Iga (CD79a) and Igb (CD79b)
(Benschop and Cambier, 1999). The immunoglobulin heavy chain gene locus undergoes
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somatic recombination for the rearrangement of the variable (V), diversity (D) and
Junction (J) gene segments to produce a wide repertoire of antigen binding sites on the
IgH (Tonegawa, 1983; Alt et al., 1984). Signaling from the transiently expressed preBCR is necessary for the transition of early progenitor B cells from the pre-BI to the preBII developmental stage, for the positive selection of early B cells that have successfully
assembled the IgH and are capable of pairing with the light chains, Iga and Igb subunits
for signaling, for the negative selection of cells that react to self-antigen and could give
rise to potential autoimmune responses, for allelic exclusion to occur so that only one of
the alleles of the IgH gene transcribes and translates the IgH protein in a given cell and
for proliferation and downregulation of the SLC in a negative feedback loop (Herzog et
al., 2009; Mårtensson et al., 2010).
A recent study from Wilson’s group provided evidence for ligand independent
aggregation and signaling of pre-BCRs that were mediated through their SLCs(Erasmus
et al., 2016) . This signaling, also known as ‘tonic’ signaling, generates responses that
lead to early B cell survival and proliferation (Monroe, 2006). Pre-BCR aggregation leads
to recruitment of src family kinases (SFK) such as Fyn, Lyn and Blk which
phosphorylate tyrosine residues on the immunoreceptor tyrosine-based activation motifs
(ITAM) present on the Iga and Igb. Phosphorylation of the ITAMs create further
docking sites for the SFKs and Syk family kinase along with other downstream adaptor
proteins such as Grb2 and BLNK. This induces activation of the PLCg2 pathway which
regulates calcium release from the endoplasmic reticulum (ER) and the entry of
extracellular calcium into the cell (Kurosaki et al., 2000). Mobilization of calcium in
these cells is essential for upregulation of enzymes such as calcineurin that are dependent
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on calcium (Geier and Schlissel, 2006). Calcineurin activates the family of transcription
factors called nuclear factor of activated T cells (NFAT) proteins which are responsible
for upregulation of genes involved in production of signaling proteins, cytokines, cell
surface receptors and other molecules (Rao et al., 1997; Geier and Schlissel, 2006).
Additionally, tonic signaling also activates the ERK/MAPK pathway for pre-B cell
survival and proliferation (Fleming and Paige, 2001; Geier and Schlissel, 2006).
There is a general failure in precursor B cell development in pre-B cell acute
lymphocytic leukemia (B-ALL). This can be associated with downregulation of the
expression of pre-BCR on the cell surface (Rickert, 2013; Müschen, 2015). It has been
suggested that up to 85% of B-ALL cases lack pre-BCR expression on the cell surface
and some studies have indicated a tumor suppressor role for this receptor as
reconstitution of the receptor or its signaling unit (Iga) led to apoptosis (Trageser et al.,
2009; Chen et al., 2015; Müschen, 2015). However, there is a subset of ALL cases
(~13.5%) where pre-BCR surface expression is maintained and the B cell tumor exploits
the tonic signaling pathway to induce high expressions levels of B-cell lymphoma 6
protein (BCL6), a protein which is critical for survival and proliferation of B cells (Duy
et al., 2010). In these subsets, inhibitors against Syk, Src and Btk tyrosine kinases, all
important players in the tonic signaling pathway, led to apoptosis of pre-BCR+ ALL cells
(Bicocca et al., 2012; Geng et al., 2015). Therefore, understanding the regulation of this
pathway might lead to more molecular targets for therapeutic intervention.
In chapter 3 of this dissertation, we explore how tonic signaling emanating from
two different BCP-ALL cell lines (697 and Nalm6) is affected by a heterogeneous
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membrane landscape as well as different propensities for pre-BCR aggregation on the
pre-B surface.

1.6 SPATIAL STOCHASTIC MODELING OF BIOLOGICAL SYSTEMS
As discussed in the above sections, existence of heterogeneity across multiple
biological scales is more the norm than the exception. Powerful imaging techniques such
as single particle tracking (SPT) have allowed us to observe the organization of
molecules on the plasma membrane and enabled measurements of diffusional dynamics
and protein interactions across temporal and spatial scales (Owen et al. 2009b; Saxton
and Jacobson 1997; Lidke and Wilson 2009). Parameters generated from such imaging
techniques can be combined with computational modeling to gain a deeper understanding
of the processes that regulate signal transduction pathways. They can also enable the
production of experimentally testable hypothesis of cell fate and behavior. Modeling of
molecular events that are stochastic in nature and where the molecules occupy different
spatial niches can be simulated using a variety of spatial stochastic methods (Andrews,
Dinh, and Arkin 2009). In this section, we will review some of the modeling techniques
that are employed for spatial stochastic modeling of molecular reaction and diffusion
events.

1.6.1 Spatial Gillespie method
Daniel Gillespie, in his landmark papers, presented the stochastic simulation
algorithm (SSA) for simulating reaction events in spatially homogenous chemical
systems (Gillespie, 1976; 1977). In the SSA, after the initialization of the chemical
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system, random numbers are generated to ascertain the type of reaction to occur as well
as the time of the occurrence. The system is then updated with the reaction event and the
time step. This process is repeated until the simulation time ends or the reactant
molecules have been depleted such that no new reactions can occur. Lumsden and
Stundzia extended the SSA by accounting for diffusion of molecules in a spatially
inhomogeneous environment (Stundzia and Lumsden, 1996). The spatial inhomogeneity
was achieved through segregation of the total volume into sub volumes or a coarse
lattice, inside which the molecules could react and also diffuse across the lattice with a
certain probability (Stundzia and Lumsden, 1996). Several simulation programs avail the
spatial Gillespie method and include programs such as MesoRD, SmartCell and GMP
(Ander et al., 2004; Hattne et al., 2005; Rodriguez et al., 2006; Andrews et al., 2010).

1.6.2 The microscopic lattice method
This method involves incorporation of reactant molecules into a much smaller
lattice than the coarse lattice mentioned above, such that the lattice can have single
reactants or be completely empty (Andrews et al., 2010). Simulation programs making
use of this method include the GridCell and Spatiocyte (Boulianne et al., 2008; Andrews
et al., 2010; Arjunan and Tomita, 2010). The reactants undergo random motion and can
diffuse from their volume spaces into neighboring spaces for reaction events.

1.6.3 Particle based methods
In particle based methods, molecular species are represented as point like particles
that occupy distinct spatial positions (Andrews et al., 2010). At each simulation time step,
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Dt, molecules are randomly diffused using “jumps” or displacements that are generated
from a Gaussian probability density function (Andrews et al., 2009b). Diffusion of
molecules is followed by scanning of the landscape for binding events with other
molecules. If a reaction is possible, a binding event is recorded, otherwise the particles
are updated in the next time step. A number of publicly available software packages that
use particle based method for simulation of reaction events include packages such as
Smoldyn, MCell and Green’s function reaction dynamics (GFRD) (Stiles and Bartol,
2001; Andrews and Bray, 2004; van Zon and Ten Wolde, 2005; Erban, 2014). However,
GFRD is different from Smoldyn and MCell in that it uses a variable time step for its
reaction events (van Zon and Ten Wolde, 2005; Andrews et al., 2010; Erban, 2014). In
chapters 3 and 4 of this dissertation, we implemented a spatial stochastic algorithm based
on the modeling approach used in Smoldyn (extension of the Smoluchowski model),
where a fixed time step is used for each particle update (Andrews and Bray, 2004; Erban,
2014). This approach has also been used previously by our group to study the dynamics
of EGFR and ErbB2/ErbB3 receptors (Pryor et al., 2013; Pryor et al., 2015). Below is a
description of the modeling technique used in this dissertation.

1.6.3.1 Defining the simulation space and reaction network
In our model, the 2D (chapter 3) and 3D (chapter 4) simulation spaces were
generated using the software Matlab and populated with molecules with a specific density
based on their cellular density and the simulation area/volume. The reactions between
molecules consisted of first order reactions such as molecule dissociation,
phosphorylation, dephosphorylation and domain escape reactions, as well as second order
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reactions such as molecular associations. The rules representing reactions events between
molecules were programmed in Fortran.

1.6.3.2 Molecule diffusion
We used Brownian dynamics (BD) to simulate particle diffusion in x, y and z
plane. In BD, molecules are treated as point like particles which undergo random motion
and can undergo reaction events upon collision (Andrews et al., 2010). For diffusion,
particle “jumps” or displacement are generated, when random numbers chosen from a
normal distribution are multiplied by the root mean square (RMS) of the molecule
(Andrews and Bray, 2004; Erban, 2014). The RMS is denoted by taking the square root
of the product of twice the diffusion coefficient of the molecule multiplied by the time
step (𝑅𝑀𝑆 =

2 ∗ 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ∗ Δt ) (Erban, 2014; Pryor et al., 2015).

In our simulation at time = t, a molecule has 3 spatial coordinates in the x, y and z
plane: x(t), y(t), z(t). At the next increment of time (increased by Δt), the molecule will
have positions: x(t+ Δt), y(t+ Δt) and z(t+ Δt). Thus, to calculate the new positions, we
apply the following principles (Andrews and Bray, 2004):
x(t+ Δt) = x(t) + 2 ∗ 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ∗ Δt * ξx
y(t+ Δt) = y(t) + 2 ∗ 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ∗ Δt * ξy
z(t+ Δt) = z(t) + 2 ∗ 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ∗ Δt * ξz
where, ξx, ξy and ξz are random numbers obtained from a normal distribution. For the
initial set up for the simulations, coordinates for the molecules are generated randomly in
Matlab at time 0. These initial coordinates are then fed into the code written in fortran,
which is the main programming core and new coordinates are generated according to the
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above principles at time increments of Δt. In chapter 3, molecules diffuse in the x and y
plane only whereas in chapter 4 molecules can also diffuse in the z plane.

1.6.3.3 Confinement zones/domains
The simulation space in our model contains coordinates for confinement zones or
domains on the simulation membrane. These domains represent lipid rafts or corrals that
might transiently trap receptors and affect their corresponding diffusion and signaling
events. The coordinates for these domains are obtained by processing receptor trajectories
through the domain reconstruction algorithm (DRA), developed and described in detail
by Pryor et al., (Pryor et al., 2015). We have implanted the DRA in reconstruction of
receptor domains in chapter 4. Briefly, the DRA ranks the receptor trajectories into “slow
moving” (receptors confined in a domain) and “fast moving” (receptors not confined in
any domain) trajectory points based on their jump sizes over various time frames. The
slow moving points are further grouped together by comparing whether their distance
from each other is less than the reference distance L. Once a group of slow moving points
has been identified, contours can be built around them and coordinates of receptors
domains extracted. The coordinates of the domains are then read into the main simulation
program by Fortran, along with the initial coordinates of the receptors. Upon diffusion in
the simulation membrane, a receptor can find itself trapped in these domains.

1.6.3.4 Simulation boundary conditions
In our simulations, two kinds of simulation boundaries exist: periodic boundary
conditions and reflective boundary conditions (Pryor et al., 2015). Periodic boundary
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conditions exist at the edges of the simulation space (x and y plane). If a molecule is
close to the edge of the in silico membrane space and the jump is predicted to displace
the molecule outside the simulation space, then the jump is divided between the distance
travelled before (J1) and the distance travelled after the molecule crosses the edge (J2). In
such cases, the molecule travels through the first distance (J1) and completes the rest of
the jump distance (J2) by entering the simulation space from the opposite edge of the
simulation space. This ensures that the molecules stay inside the simulation space.
Reflective boundary conditions exist at the edges of the membrane domains.
Receptors are free to enter their domains, but have to pay a “penalty” to leave their
domains. This penalty is in the form of an escape rate probability, which is estimated
through SPT data. If a receptor reaches the edge of a domain boundary, the receptor
jumps are divided between the distance travelled before (J1) and the distance travelled
after the receptor crosses the membrane boundary (J2). A random probability of escaping
is generated and if it is not met, then the receptor is simply reflected back into the
membrane domain with the second jump distance (J2). If, however, the probability of
escape is met then the receptor crosses the membrane boundary.

1.6.3.5 Reaction kinetics
For reaction kinetics, we chose similar principles used in Smoldyn
(Smoluchowski dynamics with revisions). Reaction kinetics are based on whether
reactions are first order or second order reactions. First order reactions include molecule
dissociation, phosphorylation and dephosphorylation. Second order reactions include
molecule association (formation of dimers or higher order oligomers).

First order
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reaction probabilities are calculated along using the following method (Pryor et al.,
2015):
P(First order reaction) =First order reaction rate *Δt
For second order reactions, we employ the use of a parameter called the binding
radius. If two molecules are within the binding radius of each other, then the molecules
can form dimers or higher order oligomers upon collision. The binding radius takes into
account the reaction on rate, diffusion coefficient and the time step. The unbinding radius
for two molecules is 5 times the binding radius and this is done the ensure that there are
not too many rebinding events between molecules.
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Chapter 2: Predicting chemotherapeutic outcomes in colorectal cancer
(CRC) using a mathematical model of drug transport
2.1 NOTES
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2.2 ABSTRACT
The physiological barriers in a three dimensional microenvironment of the tumor
play a significant role in transporting the drug molecules across the tumor. Herein, we
describe a mathematical model of drug transport that takes into account these
physiological barriers and based upon physical laws of diffusion, helps to predict
chemotherapeutic outcomes in cancer patients. We retrospectively extracted data from
histopathological sample of patients that had colorectal cancer (CRC) metastases in the
liver. The extracted data were used to populate our mathematical model of drug transport
that predicts the fraction of tumor killed based on the following measurable patient
specific parameters: radius of blood vessels, blood volume fraction and diffusion
penetration length traversed by drugs after extravasation from blood vessels. This
predicted value of fraction of tumor killed indicates the effectiveness of the
chemotherapy in cancer patients. To validate our model, the parameters radius of blood
vessels and diffusion penetration length were derived by fitting our model to
histopathological measurements of fraction of tumor killed after chemotherapeutic
intervention in human patients with CRC metastatic to the liver (coefficient of
determination R2 = 0.86). To test the model feasibility in clinical settings, blood volume
fraction values obtained through in vivo contrast enhanced computed tomography from
the same cohort of patients were used to calculate fraction of tumor killed, where our
model was accurately able to predict patient outcomes (average relative error = 24%).
Thus, in a clinical setting our model may help in devising patient specific treatment
strategies that will help in improving chemotherapeutic outcomes as well as reducing
patient expenditure and drug toxicity.
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2.3 INTRODUCTION
Predicting chemotherapeutic outcomes in cancer patients is an essential part of
overall patient treatment strategy (Cianfrocca and Goldstein, 2004). Based on such
predictions, patients who are responding to a certain treatment could be treated
accordingly and alternative treatment strategies could be explored for others. This would
help in ensuring patient centric care through reduced drug toxicity and optimized
utilization of healthcare resources (van 't Veer and Bernards, 2008; Wei et al., 2013).
The extent to which a chemotherapy is effective depends not only on the potency
of drugs, but also on the transport of these agents into the tumor sites in effective doses
(Kim et al., 2013). This transport of drugs into the tumor site is a complex process taking
place over several temporal and spatial scales such as the organ, tissue and cells, and
intracellular scales (Kim et al., 2013). At each of these scales, chemotherapeutic drugs
face multiple physiological barriers such as variation in the amount of blood supplied to
the tumor, an uneven extravasation from the blood vessels, high interstitial fluid pressure
(IFP) and large transport distances that they need to overcome in order to reach the tumor
site (Jain, 1990; Frieboes et al., 2009). The role of these physiological barriers in
impacting the effectiveness of chemotherapies is not well understood. It has been
suggested that in order to improve drug penetration into the tumor microenvironment,
these physiological barriers must be targeted (Minchinton and Tannock, 2006; Tredan et
al., 2007).
Colorectal cancer (CRC) is the third leading cause of cancer related death in the
United States (Siegel et al., 2014). Among patients with CRC, about 50% will develop
hepatic metastases at some point during their disease (Kanas et al., 2012). Although
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chemotherapy is routinely administered for the treatment of such metastatic cases, the 5
year survival rates for these patients has been less than 1% and they often have to
undergo liver sectioning to increase their chances of survival (Leonard et al., 2005;
Gallinger et al., 2013). In such cases, it is important to predict the outcome of
chemotherapy so that if a tumor is non-responsive, the treatment can be modified to
ensure maximization of net treatment benefits (Cui et al., 2008; Schirin-Sokhan et al.,
2012). There is an unmet need for predicting tumor response to chemotherapy in patients
with CRC liver metastases as most of the current techniques used for this purpose are
ineffective or only applicable after chemotherapy is initiated (Rubbia-Brandt et al., 2007;
Glazer et al., 2010; Egger et al., 2013). We have previously developed and validated a
steady state diffusion barriers model of drug transport (Pascal et al., 2013b). Herein, we
will further revise and validate this model by utilizing a larger set of patient data.
Revising and validating our mathematical model will enable more accurate predictions of
tumor responses before initiating a chemotherapeutic treatment, hence helping make
evidence-based treatment decisions. The purpose of this study is to predict fraction of
tumor killed (fkill) based on heterogeneous physiological barriers present in the tumor
microenvironment that affect tumor response to chemotherapy using mathematical
models of drug transport. We define tumor response to chemotherapy as fkill, which in our
mathematical model is calculated through the following patient-specific parameters:
radius of blood vessels (rb), blood volume fraction (BVF) and diffusion penetration
length (L). We will use histopathological samples of cancer patients to help validate our
mathematical model.
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2.4 MATERIALS AND METHODS
2.4.1 Steady state diffusion barriers model
The steady state diffusion barriers model consists of differential equations that
mathematically describe the process of diffusion and rate of uptake and their parameters.
We acquired a biophysical description of the vasculature and tissue architecture present
in the tissue surrounding a tumor to form the basis on which we could design our
mathematical model that would show the transport of drug within a tumor.
The liver consists of hexagonal shaped lobules and the portal triad (portal artery,
portal vein and the bile duct) that transport blood, oxygen, nutrients and bile in the
hepatocytes (Rubin E, 2009). We assume that the portal triad can be described effectively
as a cylinder and the drug is transported from this cylinder through two physical
processes- diffusion and drug uptake- into the surrounding tissue (Figure 2.1). In the
model, concentration of local drug within the tumor is obtained by solving an equation
that describes diffusion and uptake of drugs into the tumor after transport from the blood
vessel has occurred. 𝑓89:: is dependent on the concentration as well as the effectiveness of
the drug at this concentration within the tumor. Hence, 𝑓89:: is calculated by integrating
the effectiveness of the drug around the cylindrical volume which envelopes the blood
vessel/drug source. Here, the maximum predicted 𝑓89:: for each patient is dependent on
only 3 parameters- 𝑟< , 𝐵𝑉𝐹 and 𝐿 - all of which can be obtained from patient
histopathology data. We used the following equation on patients with CRC liver
metastases (Pascal et al., 2013b):

𝑓89:: = 2 ∙ 𝐵𝑉𝐹 ∙ 𝐿

BCD ∙ EF GH I JEF GH I ∙ BCD
BCD ∙ GH ∙ EK GH I ∙ LJBCD

(1)
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where 𝐾N and 𝐾L are modified Bessel functions of the second kind of 0 and 1 orders
respectively, 𝑓89:: is the fraction of tumor killed, 𝑟< is the radius of blood vessel, 𝐵𝑉𝐹 is
the blood volume fraction and 𝐿 is the diffusion penetration length.
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Figure 2.1: A portal triad in the liver, described as a cylinder with radius r. Drug is transported into
the surrounding tissue from the portal triad by diffusion and drug uptake by cells.
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2.4.2 Extraction of data from histopathological samples
H&E stained microscopic slides of randomly selected human liver specimen were
obtained from a cohort of 27 patients with colorectal cancer (CRC) metastatic to liver at
the MD Anderson Cancer Center (MDACC). Six patients were not included in the final
analysis because they lacked dead tumor tissue. Based on the assumption that histologic
sections are isotropic, fraction of tumor killed f kill was directly measured as fraction of
tumor killed in histologic assessments along with measurements of radius of blood
vessels rb , and blood volume fraction (BVF) for each patient (20 slides per patient).
Measurements were manually performed using GNU Image Manipulation (GIMP) and
illustrations of measurement of rb are in Figure 2.2. In order to calculate the fraction of
dead tumor area, dead areas of tumor were colored red, live areas of tumor were colored
blue and the portions that were not tumor i.e. normal were colored green. Fraction of
dead tumor area was set as:

f kill = # of red pixels / (# of red pixels+ # of blue pixels+ # of green of pixels)
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Figure 2.2: Example of measurements from histopathological specimens of patient data. (A) Example
of portal triad with blood vessel measurements. (B) Example of a histologic section. (C) Segmentation
of the histologic section B for calculation of the fraction of dead tumor area: dead tumor (red); live
tumor (blue); no tumor (green). (D) Segmentation of a histologic section for calculation of blood
volume fraction: blood vessels (red).
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We compared f kill

values between pathologist’s measurements and our

measurement of f kill . A cumulative Distribution Frequency (CDF) graph was generated
to compare the f kill values (Figure 2.3A). From the graph we concluded that the
pathologist f kill values were shifted by some value to the right from our measurements
because when pathologists take their measurements of f kill , they don’t take into account
whether normal tissue is destroyed and only see what is dead and live tumor. This needed
to be corrected because our f kill values should correlate with what the pathologist
measure in real life. That value by which our f kill values needed to be shifted by was
calculated by taking the difference between the average of the f kill measured by us and
average of the f kill measured by the pathologist and that value came to be 0.108411284.
Another CDF graph was generated to compare our new f kill , with the added value
(Figure 2.3 B). These new f kill values were then further used to do the fitting in
Mathematica.
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Figure 2.3: Cumulative Distribution Frequency (CDF) graphs. (A) Cumulative Distribution
Frequency (CDF) graph of fkill values comparing measurements from pathologist versus from
computer program (GIMP). (B) Corrected Cumulative Distribution Frequency (CDF) graph of fkill
values.
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2.4.3 Test of model predictivity
To test the model predictivity based on three parameters rb , BVF, and 𝐿, the
following mathematical equation was applied to this cohort of patients:

# 2 ⋅ BVF ⋅ K (r L) − 2 ⋅ K (r (L ⋅ BVF )) &
1 b
1 b
fkill = BVF ⋅ L ⋅ %
(
BVF ⋅ rb ⋅ K 0 (rb L)⋅ (1− BVF)
$
'

[1

rb and 𝐿 were obtained from the regression analysis of the MDACC cohort. The model
was fitted to the measured f kill values and their corresponding BVFs and a graph was
generated by comparing the predictions of Eq.1 to the direct measurements of kill (Figure
2.4). Least-squares fitting of Eq. 1 was performed using Mathematica routine
“NonlinearModelFit” to the kill fraction and BVF measured in liver metastasis in the
MDACC patient cohort. This resulted in estimates of parameters rb and 𝐿 (diffusion
penetration length), which produced the best fit.
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Figure 2.4 : Fitting the model to patient data demonstrates biological accuracy of the functional form
of Eq. 1. Symbols: measurements with standard deviations from histopathology images of 21 patients
with CRC metastatic to liver. Standard deviations calculated by measuring variability in patient
data. Red: least-square fit of Eq. 1 to the data (R2 = 0.86).
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2.4.4 Prospective application of the model based on pretreatment CT scans
Contrast CT scans performed according to standard clinical protocols were
acquired prior to chemotherapy on 18 scans performed according to standard clinical
protocols were acquired prior to chemotherapy on 18 patients at MDACC according to
institutional review board-approved protocols. The simple average of three Hounsfield
Unit (HU) measurements in representative areas within the entire tumor was calculated at
the each phase of the test for each patient i.e., a late arterial phase (30-35 s after start of
contrast injection), a portal venous phase (50-55 s), and a delay phase (minutes, variable
timing).
The pre-treatment CT measurements (HU) at the arterial phase were found by linear
regression analysis to correlate to the measurements of BVF (blood volume fraction)
performed from post-treatment histology (Figure 2.5):
BVF = 0.00091672 CT (HU),

[2]

with coefficient of determination R2 = 0.63 (Devore, 2011), p-value = 0.00008, from
Mathematica routine “LinearModelFit” (Wolfram Research, 2008) and GraphPad Prism
(GraphPad Software, 2007). CT measurement error of 25% was estimated from
corresponding data of contrast enhancement in the aorta, and thus represents variability in
physiology and contrast dosing in CT protocol across patients. Even with a limited
number of subjects, the statistical significance (p-value = 0.00008) is expected since CT
measurements reflect perfusion of tissue, which relies on the volume fraction of blood
vessels. Analysis using the portal-venous measurements produced similar results. We
multiplied the regression coefficient with the CT scan data to find the individual
corresponding predicted BVF. The BVF, rb , and L values were then inserted into Eq. 1 to
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obtain the predicted f kill values (Figure 2.6). An error of 25% was found in the CT
measurements and this was estimated by comparing the corresponding measurements
from contrast enhancement of aorta (standard deviation in aorta/average of aorta). Thus
error bars for the model predictions based on the CT scan data were calculated using this
25% error estimated in CT measurements. The upper and lower limit came from ± 25%
of the predicted BVFs and this gave rise to an upper and lower limit for f kill , which were
then used in the calculation of standard error in predicted f kill . The average relative error
between the model prediction fkill (P) and the measured kill value fkill (M) was calculated
as: < ( f kill (P) - f kill (M)) / f kill (M) > . Outliers more than 2 SD away were removed from
the calculation of the relative error.
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Figure 2.5: Calculation of regression coefficient between CT scan data and 𝑩𝑽𝑭.
coefficient = .00091672.
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38

2.5 RESULTS

2.5.1 Fitting the mathematical model to patient data by a regression Analysis
identifies biologically realistic parameter values
The regression analysis resulted in estimates of the two parameters: rb and L from
the MDACC cohort of patients. Each of these estimated values is consistent with
measurements from human anatomy. The radius of the blood vessels in the portal triad,

rb ≈ 15.8 μm obtained from this fitting was consistent with published data (Wiedeman,
1963; Muraca, 1994) and with our histopathology (Figure 2.2). The diffusion penetration
length from regression analysis is L ≈ 151 µm. Using Mathematica (Wolfram Research,
2008), statistically significant p-values were obtained for both rb and L. (Figure 2.4,
inset).

2.5.2 Prospective application of the mathematical model in vivo
To establish whether our model could predict chemotherapy outcome based only on
standard pre-treatment contrast-CT imaging, we carried out the following series of steps.
First we performed an analysis on the histopathology from post-treatment specimens on
the MDACC cohort of patients. This validated the predictive power of Eq. 1 specifically
for this cohort of patients (Figure 2.4, red curve: R2 = 0.86). Here we used the same value
of diffusion penetration distance L and portal radius rb obtained from regression analysis
on all patients, which again point to uniformity of these parameters across patients thus
generating the hypothesis that future clinical translation would primarily rely on patientspecific calculation of the parameter BVF. To test this hypothesis we calculated a linear
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correlation constant for histopathology BVF and contrast-CT Hounsfield units, which
allowed us to obtain a BVF value from the contrast enhancement of the CT images for
each individual (Eq. 2). Inputting this value into Eq. 1 produced accurate kill-ratio
predictions (Figure 2.6, open circles) that compared well to the actual measurements from
histopathology post-treatment (Figure 2.6, filled circles), with an average relative error of
the predicted fraction killed of ≈ 24% (Methods).
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Figure 2.6: Prospective, patient-specific model predictions match outcomes of fraction of tumor
killed by chemotherapy in the MDACC cohort of patients with CRC metastatic to liver. Predictions
of Eq. 1 using 𝑩𝑽𝑭 parameter calculated from pre-treatment contrast-CT perfusion measurements
(open circles). Multiple measurements from histopathology post-treatment per patient indicated by
standard deviation (filled circles). Model input parameters 𝒓𝒃 (radii of blood vessels in liver portal
triad) and 𝑳 (drug diffusion penetration distance) from Fig. 1.4
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2.6 DISCUSSION
The mathematical model presented here was able to predict fraction of tumor
killed in patients with CRC metastatic to liver quite accurately. The average relative error
between model predictions and fraction of tumor killed was only 24%, with patient
parameters obtained directly from CT scan data. Given the pressing need for potential
and robust biomarkers to predict chemotherapy outcomes in patients, our results here
provide an unprecedented approach of mitigating this need at a much earlier stage in
cancer treatment than some of the other techniques. Imaging techniques such as CT scan,
magnetic resonance imaging (MRI) and positron emission tomography (PET) are used to
detect changes in tumor in response to chemotherapeutic drugs, however, these changes
are quantifiable only about halfway through the treatment, and the patient might have
already by this time been exposed to a significant amount of toxicity from the drugs and
incurred patient related expenses (Koh and Padhani, 2006; Cui et al., 2008). Other
techniques like using Apparent Diffusion Coefficient (ADC) values obtained from
diffusion weighted-MRI have the potential to gauge tumor response at an earlier stage
(Koh and Padhani, 2006; Vandecaveye et al., 2006; Cui et al., 2008) and this technique
has already been used to assess tumor response to chemotherapy in hepatic metastases
(Theilmann et al., 2004; Koh et al., 2007; Cui et al., 2008). Our approach of using
“mathematical pathology” not only helps to predict the tumor response to drugs before
the start of any treatment, thus lessening the cost and toxicity that the patients might be
exposed to, but also provides an understanding of the physiological barriers that are
responsible for the resistance of drugs to chemotherapy. The model helps to highlight the
biological barriers as important players that hamper drug delivery and ones that need a
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further thorough investigation along with the genetic and cellular reasons for
chemotherapy resistance. This model has shown that patient specific physiological
features such as blood vessel radius and blood volume fraction play significant roles in
determining the amount of drug supplied to the tumor and in a clinical setting these
parameters can easily be measured through CT scans and used in the mathematical model
for prediction of tumor killed. Thus, patient specific strategies can be developed and
patient dosage and timing can be primed for optimal results for each individual. This
model can be used alone in the clinical setting to predict the fraction of tumor killed or
used with other methods of predicting tumor size such as using the ADC from diffusion
weighted- MRI. This study also lays future groundwork to evaluate the effects of other
drug carriers such as nanoparticles on drug delivery and tumor size since nanoparticles
might prove to be more effective carriers of drugs than just free drug alone. Additional
layers of complexity involving other factors or physiological barriers can be added to the
model, as the research on physiological barriers continues, and this will result in even
more accurate predictions of the tumor response to chemotherapy in the future.
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3.2 ABSTRACT
Important signal transduction pathways originate on the plasma membrane, where
microdomains may transiently entrap diffusing receptors. This results in a non-random
distribution of receptors even in the resting state, which can be visualized as “clusters” by
high resolution imaging methods. Here, we explore how spatial in-homogeneities in the
plasma membrane might influence the dimerization and phosphorylation status of ErbB2
and ErbB3, two receptor tyrosine kinases that preferentially heterodimerize and are often
co-expressed in cancer. This theoretical study is based upon spatial stochastic simulations
of the two-dimensional membrane landscape, where variables include differential
distributions and overlap of transient confinement zones (“domains”) for the two receptor
species. The in silico model is parameterized and validated using data from single particle
tracking experiments. We report key differences in signaling output based on the degree
of overlap between domains and the relative retention of receptors in such domains,
expressed as escape probability. Results predict that a high overlap of domains, which
favors transient co-confinement of both receptor species, will enhance the rate of heterointeractions. Where domains do not overlap, simulations confirm expectations that homointeractions are favored. Since ErbB3 is uniquely dependent on ErbB2 interactions for
activation of its catalytic activity, variations in domain overlap or escape probability
markedly alter the predicted patterns and time course of ErbB3 and ErbB2
phosphorylation. Taken together, these results implicate membrane domain organization
as an important modulator of signal initiation, motivating the design of novel
experimental approaches to measure these important parameters across a wider range of
receptor systems.
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3.4 INTRODUCTION
The plasma membrane is the initiation site for signaling pathways that govern cell
diﬀerentiation, proliferation and survival (Groves and Kuriyan, 2010; Radhakrishnan et
al., 2012). The membrane provides a platform for the reversible binding of ligands to
receptors, initiating critical processes such as dimerization, activation of catalytic activity
and recruitment of binding partners (Groves and Kuriyan, 2010). Given its importance in
cell signaling, the structure and composition of membranes have been probed by many
diﬀerent groups. Singer and Nicholson, in their landmark paper of the fluid mosaic
model, proposed membranes to be largely homogenous with randomly distributed
mixtures of integral membrane proteins and lipids (Singer and Nicolson, 1972). However,
the authors also showed electron microscopy images of major histocompatibility antigen
“patches,” providing early evidence for membrane organization. Since then, considerable
evidence has accumulated showing that membrane proteins and lipids can be transiently
confined in specific domains (Kaizuka et al., 2007; Chung et al., 2010; Treanor et al.,
2010; Radhakrishnan et al., 2012; Goñi, 2014). The anomalous diﬀusion of membrane
constituents, observed through single molecule tracking methods (Fujiwara et al., 2002),
is likely due, at least in part, to their transient entrapments within heterogeneous domains
(Marguet et al., 2006). Multiple theories exist to explain the richness of the plasma
membrane topography, including lipid rafts which are enriched in unsaturated fatty acids
and cholesterol (Pike, 2003), corrals formed by the actin cortical cytoskeleton network
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(Jaqaman et al., 2011; Kalay, 2012; Cambi and Lidke, 2015) and protein islands
(Lillemeier et al., 2006). Even very short periods of confinement within domains give rise
to lateral heterogeneity and an uneven distribution of proteins on the membrane surface
that can be captured in “snap-shot” images by electron microscopy of membrane rip-flips
(Wilson et al., 2000; Prior et al., 2001; Andrews et al., 2009). More recently, superresolution microscopy methods have also been employed to document the clustering of
membrane proteins (van den Dries et al., 2013; Itano et al., 2014). The exchange of
proteins between domains is highly variable, ranging from very low exchange rates
observed in yeast membranes (Spira et al., 2012) to very rapid exchanges described for
the EGFR in mammalian cell membranes (Low-Nam et al., 2011).
Many important receptors exhibit varying degrees of clustering prior to ligand
engagement, including members of the EGFR/ErbB family (Nagy et al., 2002; Yang et
al., 2007) and the ITAM-bearing immunoreceptors (FcεRI, BCR, TCR) (Pike, 2003;
Lillemeier et al., 2006; Andrews et al., 2009; Tolar et al., 2009; Treanor et al., 2010;
Dinic et al., 2015). Experimental evidence has suggested that membrane domains can
both enhance and inhibit signaling in diﬀerent settings (Marmor and Julius, 2001; Miura
et al., 2001; Douglass and Vale, 2005; Allen et al., 2007; Bénéteau et al., 2008; Ganguly
et al., 2008). Computational studies have also supported the concept that membrane
organization has cell and receptor-specific outcomes (Lim and Yin, 2005; Hsieh et al.,
2008; Costa et al., 2011; Abel et al., 2012; Kalay et al., 2012). For example, the
formation of diﬀerent signaling clusters has been proposed to support distinct TCR
signaling patterns (Singleton et al., 2009). Vale and colleagues recently demonstrated in
model membranes that phase separation of signaling partners can create distinct signaling
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compartments (Su et al., 2016). Members of the ErbB family of receptor tyrosine kinases
have been shown to have distinct distribution patterns on cancer cell membranes (Yang et
al., 2007; Steinkamp et al., 2014), leading to computational studies from our group that
predict the impact of critical variables such as receptor co-expression, density and dimer
oﬀ-rates (Hsieh et al., 2008; Pryor et al., 2013, 2015).
Deterministic models based upon Ordinary Diﬀerential Equations (ODEs) are not
well suited to explore spatial aspects of signaling, since they assume molecules in a
system are well mixed. Stochastic modeling approaches oﬀer greater flexibility to
consider eﬀects of membrane topography, receptor clustering and diﬀusion dynamics on
signaling events (Mayawala et al., 2006; Nicolau et al., 2006; Hsieh et al., 2008; Costa et
al., 2009; Chaudhuri et al., 2011). These versatile mathematical models provide a
platform for rapid exploration of key factors that are diﬃcult to vary (and measure)
experimentally. In this study, we take advantage of this powerful approach to consider
the eﬀect of two parameters, membrane domain overlap and domain retention, on ErbB3
and ErbB2 homo-and heterodimerization. Our group previously evaluated the domain
occupancy and distribution of ErbB2 and ErbB3 stably expressed as recombinant proteins
in Chinese Hamster Ovary (CHO) cells (Steinkamp et al., 2014; Pryor et al., 2015).
Analysis of dual-color single particle tracking data, which permitted independent
observations of each species, indicated that domains confining the two ErbB receptors
were only partially overlapping in the CHO cell membrane (Pryor et al., 2015). We then
built a spatial stochastic model based upon this distribution, as well as experimentally
measured values for dimer oﬀ-rates, kinase/phosphatase activity and receptor diﬀusion
(Pryor et al., 2015). However, we speculate that the degree to which there is diﬀerential
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segregation of these two closely related receptors will vary widely as a property of cell
type, because of dissimilar receptor ratios, density, cytoskeletal features, membrane
composition and on-going signal transduction from other cell surface receptors triggered
by circulating or local ligands. In this paper, we focus on two specific parameters that
aﬀect the degree to which ErbB2 and ErbB3 experience periods of co-confinement:
domain overlap and retention, where the latter is expressed as a function of escape
probability.

3.5 MATERIALS AND METHODS

3.5.1 Spatial stochastic model for ErbB2 and ErbB3 homo- and heterodimerization

3.5.1.1 Reactions
The spatial stochastic model of ErbB2 and ErbB3 interactions was described
previously (Pryor et al., 2015). Briefly, the model includes two members of the EGFR
family, ErbB2 and ErbB3, which diﬀuse within the simulation space and interact with
each other.
The following reactions are accounted for in the model:
(i)

Dimerization: Homo- and heterodimerization of ErbB2 and ErbB3 receptors.

(ii)

Phosphorylation: Receptors are phosphorylated through intrinsic phosphorylation

rates.
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(iii)

Dephosphorylation: Receptors are dephosphorylated through experimentally

determined dephosphorylation rates.
(iv)

Dissociation: Dimer dissociation occurs through experimentally determined dimer

oﬀ rates.
We assume that the dimerization of receptors occurs through the interaction of the
dimerization arms on the extracellular domain of receptors. In the absence of ligand, the
ErbB3 extracellular domain fluxes from a closed (tethered) to an open (dimer-competent)
conformation. The open conformation of ErbB3 is stabilized by ligand binding (Pryor et
al., 2015). Unliganded ErbB3 is assumed to be predominately closed (99.99% closed). At
any given time step, there is a 10−4 probability for unoccupied ErbB3 receptors to assume
the upright dimer-competent state while all ligand-bound ErbB3 monomers are dimercompetent (Hsieh et al., 2008). ErbB3 ligand concentrations vary in the simulations as
described in the legends. ErbB2 receptors are assumed to be in open conformation and
dimerization competent (Cho et al., 2003; Garrett et al., 2003). In the model, ErbB2 has a
single representative tyrosine phosphorylation site based on uniform dephosphorylation
kinetics over two tested phosphorylation sites (Pryor et al., 2015). ErbB3 has two
representative phosphorylation sites based upon (Y1289; Y1197). Table 1 lists the
reaction

parameters

used

in

our

model

including

receptor

dimerization,

phosphorylation/dephosphorylation, and receptor dissociation as previously described
(Pryor et al., 2015). For receptor phosphorylation events, the model takes into
consideration the asymmetric orientation of kinase domains which occurs during ErbB
receptor activation (Ward and Leahy, 2015). Reactions are governed by binding radii
estimated using SMOLDYN, a software application that takes into consideration receptor

51
on-rates, diﬀusion coeﬃcients and simulation time steps to construct a binding radius
(Andrews and Bray, 2004). An unbinding radius of 5 times the binding radius was used
to decrease rebinding events.

TABLE 1: Model parameters of receptor monomers and dimers

a

Pryor et al. (2015).
Steinkamp et al. (2014).
c
Pryor et al. (2013).
d
Kleiman et al. (2011).
e
Shi et al. (2010).
b
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3.5.1.2 Simulation landscape
The simulation landscape contains receptor specific domains (Figure 3.1A) and
receptors can diﬀuse across domains and domain-free areas. An exit penalty limits
receptor escape from the domains. Figure 3.1A depicts domains that were identified in
previous work (Pryor et al., 2015). Represented by a rectangular box measuring 0.1995
µm2 in area (Figure 3.1A), the space contains 5 ErbB2 and 9 ErbB3 receptor domains.
These domains were derived from domain analysis of two-color single particle tracking
data where ErbB3 was labeled with HRG-conjugated quantum dot (QD) and HA-tagged
ErbB2 was labeled with anti-HA Fab conjugated QD (Pryor et al., 2015). The total ErbB2
domain area is 0.0502 µm2; the total ErbB3 domain area is 0.0274 µm2.The free area
outside the domains is 0.1219 µm2. We then created three distinct domain overlap
conditions for comparison:
(i)

100% overlap: 100% of the ErbB3 domain area is overlapping with the ErbB2

domain area. This resulted in complete mixing of ErbB3 and ErbB2 domains (Figure
3.1D).
(ii)

50% overlap: 50% of the ErbB3 domain area is overlapping with ErbB2 domain

area. This resulted in partial overlapping of ErbB3 and ErbB2 domains (Figure 3.1C).
(iii)

0% overlap: 0% of the ErbB3 domain area is overlapping with the ErbB2 domain

area. This resulted in complete separation of ErbB3 and ErbB2 domains (Figure 3.1B).
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Figure 3.1: Four domain configurations of the simulation space. Simulation space was partitioned
into receptor-specific domains with defined domain overlaps. (A) A simulation space that mimics the
domain properties of CHO cells overexpressing ErbB2 and ErbB3 based on domain analysis of SPT
data. ErbB2 (light gray, shaded) and ErbB3 (dark gray, shaded) membrane domains overlap by
42.4%. ErbB2 receptors (light gray, circled) and ErbB3 receptors (dark gray, circled) are randomly
distributed within their own domains as well as outside the domains (white region). (B–D) Domains
were rearranged to create a simulation space where the ErbB2 and ErbB3 domains are completely
non-overlapping (0% overlap, B), partially overlapping (50% overlap, C) or completely overlapping
(100% overlap, D). In the initial configuration, ErbB2 and ErbB3 receptors were positioned to
randomly occupy their respective domains.
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3.5.1.3 Number and density of receptors
The model was populated with 50,000 ErbB2 and 50,000 ErbB3 receptors/cell.
Since the total area of a cell is 314.16 µm2 (with a diameter of 10 µm), this translates into
a receptor density of ∼159 receptors/µm2 for each receptor. Adjusted for a simulation
area of 0.1995 µm2, the total number of receptors is 31 of each receptor species.

3.5.1.4 Receptor diffusion
Receptor diﬀusion occurs in the two dimensional membrane simulation space (x
and y direction) through Brownian motion. Receptor jumps in these two directions are
calculated using diﬀusion coeﬃcients generated from SPT data and normally distributed
random numbers.

3.5.1.5 Boundary conditions
As in Pryor et al. (2015) and Pryor et al. (2013), the periodic boundary condition
is applied to the edges of the simulation space. If a receptor jump takes the receptor
across the edge of the simulation space, the jump distance is divided between the
distances covered before and after the boundary is crossed. The receptor then traverses
the distance to the boundary and the remaining distance is calculated from the opposite
edge of the simulation space. Hence, the receptor “re-enters” the simulation space from
the opposite boundary. Reflective boundary conditions are applied when a receptor
reaches the edge of a membrane domain. Like the periodic boundary conditions, the jump
distance is divided between the distances covered before and after reaching the boundary.
A probability for crossing/escaping from the membrane boundary is calculated and if the
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probability of escaping is not met, then the receptor hits the boundary and is deflected
back into the domain. If the probability of escape is met, then the receptor continues
across the boundary. Escape rates in Pryor et al. (2015) were estimated by parameter
fitting to the ratio of domain-confined receptors experimentally measured in CHO cell
membranes; this rate is a key variable of the present study (Table 2).

TABLE 2: Escape rates of receptor monomers and dimers

a

Pryor et al. (2015).
Simulation data in this paper.

b

3.5.1.6 Simulation code
Input files containing the initial simulation space, receptor locations and ligand
concentrations are generated in Matlab. These files are then accessed by a program
written in Fortran, which simulates brownian diﬀusion and molecular interactions
between the two receptors. At the end of the simulations, all output files are processed in
Matlab for analysis of results. Code is available upon request.
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3.6 RESULTS

3.6.1 Domain overlap affects the frequency of hetero-interactions and receptor
phosphorylation events
It is unknown to what extent diﬀerent receptors share the same membrane
domains, how fluid these domains are over time, and whether activation of receptors alter
domain overlap. Therefore, we explored these possibilities through simulations, reporting
results as changes in homo- and hetero-dimerization and phosphorylation status. Unlike
prior work fit to cells overexpressing ErbB family members (Pryor et al., 2013, 2015), we
used receptor densities within the range of expression values expected for normal cells
(50,000 receptors/cell). The simulation landscape included either no domains or ErbB2
and ErbB3-specific domains with partial, full or no overlap (Figure 3.1).
The rapid cycling of ErbB3 receptors through diﬀerent states is illustrated in
Figure 3.2, where simulations were initially performed in a landscape lacking domains.
Here, ligand-bound ErbB3 freely diﬀuse, encountering other ErbB3 or ErbB2 monomers
with no barriers imposed. They constantly cycle through homodimer (red), heterodimer
(orange) and monomer (white) states by binding and unbinding to other receptors as they
diﬀuse through the simulation space (Figure 3.2A). Oﬀ-rates for hetero- and homodimers
are assigned probabilities based upon experimental measures for unoccupied and ligand
bound dimers (Steinkamp et al., 2014). The catalytic activity of each monomer in a dimer
is tracked throughout the simulation. Activity is dependent on the stochastically-governed
orientation of the monomer in the asymmetric model, where one of the monomers is the
“activator” and the other monomer is the “receiver.” Further, ErbB3 monomers are
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assumed to require phosphorylation by a “receiver” ErbB2 in a prior hetero-dimerization
event. A phosphorylated ErbB3 monomer remains a competent “receiver” during
subsequent encounters only until it is dephosphorylated. Simulation time steps are 1 ×
10−6 s and observations are recorded every 0.05 s. Plots in Figure 3.2B show that
dimerization is already occurring by the earliest observation interval and continues to rise
over the first 10 s of the simulation. Phosphorylation kinetics are delayed, observable
within 0.5 s of the simulation and rising to steady state values by 50 s.
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Figure 3.2: Kinetics of ErbB3 dimerization and phosphorylation. (A) Representative plot of
individual ErbB3 receptors showing changes in receptor state over time. ErbB3 receptors cycle
between homodimer, heterodimer and monomer states. (B) Plot showing the kinetics of dimer
formation and phosphorylation of ErbB2 and ErbB3. ErbB2/3 heterodimer and ErbB3/3 homodimer
formation are plotted with total ErbB2 and ErbB3phosphorylation over time for 100% ligand in the
absence of domains. Data in B are the averages of 4 runs.
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In Figure 3.3, we report the eﬀect of adding domains to these simulations. The
extreme cases of completely overlapping vs. non-overlapping ErbB2 and ErbB3 domains
are shown in Figures 3.3A–H. Color keys in these plots indicate shifting profiles of
monomers and dimers, as well as report phosphorylation states. Clearly, confinement in
shared domains favors heterodimer interactions with a corresponding decrease in ErbB3
homodimers and ErbB2 monomers (Figures 3.3A,B). Phosphorylation kinetics is aﬀected
by co-confinement with a delayed but steep rise in phosphorylation (Figures 3.3C,D).
Therefore, the overall signaling response is likely increased with shared domains.
Results in Figure 3.4 report dimers at steady state (240 s) using the three distinct
domain configurations shown in Figures 3.1B–D as well as no domain configuration.
Simulations with completely overlapping domains produced the greatest number of
heterodimers regardless of ligand concentration, although the greatest diﬀerence can be
seen with 100% ligand (Figure 3.4A). At lower ligand concentrations, the eﬀect of
overlapping domains on dimer formations was diminished. This phenomenon is best
explained by segregation of the few ligand bound receptors. ErbB3 homodimers
displayed the opposite trend to that of heterodimers, where the highest number of
homodimers were seen when ErbB3 domains did not overlap with ErbB2 (Figure 3.4B).
This was notable for conditions of 100% and 50% liganded ErbB3.
Steady state phosphorylation levels are also aﬀected by the configuration of
domains (Figures 3.4C,D). Phosphorylation levels of both ErbB2 and ErbB3 decreased as
domain overlap decreased, highlighting the importance of heterointeractions for maximal
signaling. ErbB2 phosphorylation was most aﬀected by domain overlap, particularly in
simulations with 100% liganded ErbB3 (Figure 3.4D). Note that ErbB3 phosphorylation,
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which is heavily dependent on interactions with ErbB2 is not favored under conditions
where ErbB2 homodimers are predominant.
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Figure 3.3: The effect of overlapping domains on ErbB2/ErbB3 dimerization and phosphorylation
kinetics with 100% ligand-bound ErbB3. Plots for the completely overlapping domain configuration
(A–D): The kinetics of dimer formation (A), representative plots of dimerization state for individual
receptors over the simulation time (B), the kinetics of receptor phosphorylation (C), and a
representative plot of phosphorylation state for receptors over time (D). (E–H): Plots for the nonoverlapping domain configuration. Plots are arrayed as in (A–D).
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Figure 3.4: Overlapping domains influence dimer formation and phosphorylation. (A,B): Dimer
counts across different ligand concentrations with 4 different membrane configurations- 100% (blue
bars), 50% (orange bars), and 0% overlap (gray bars) as well as no domain simulations (yellow bars)
for ErbB2/ErbB3 heterodimers (A) and ErbB3 homodimers (B). (C,D): Total receptor
phosphorylation across different ligand concentrations and all four domain configurations for ErbB3
(C) And ErbB2 (D). All bars are the averages of 4 runs ± standard deviation.
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3.6.2 Stronger

domain

retention

affects

receptor

dimerization

and

phosphorylation events only when the domains partially overlap or non-overlap
Although the clustering of receptors in domains is important for signaling, little is
known about the movement of receptors into and out of membrane domains or the extent
to which this movement is altered with receptor activation. Since it is diﬃcult to measure
experimentally receptor residency times within domains, Pryor et al., estimated an escape
rate based on the ratio of domain-confined to free receptors in CHO cells under low
ligand conditions (Pryor et al., 2015). To examine the eﬀect of this parameter on
signaling outcome, we ran simulations where we varied the escape rate to model changes
in domain retention. The aﬃnity of receptors for their domains was increased by reducing
the escape rate of both monomers and dimers. We compared simulations run with the
original nominal escape rate, or with the escape rate reduced by ½ or ¼. The eﬀect of
these escape rates were examined with diﬀerent ligand concentrations in the four domain
overlap configurations (Figure 3.5). Reducing the escape rates had no eﬀect on
heterodimer formation for domains that were completely overlapping. However, when
the domains were partially overlapping or non-overlapping, heterodimer formation was
significantly reduced as the escape rate decreased. For instance, in the case of 100%
liganded ErbB3, when the escape rate was reduced to ¼ and the domains were partially
overlapping, the number of heterodimers at steady state was 35% lower than with the
original escape rate. With non-overlapping domains, heterodimers were reduced by 70%
(Figure 3.5A). Similar trends were seen in 50% and 20% ligand conditions (Figures
3.5B,C). With unliganded ErbB3, heterodimerization was rare (Figure 3.5D). With
completely overlapping domains, reducing the escape rates did not aﬀect erbB3
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homodimer formation either (Figures 3.5A–D). With overlapping domains, reducing the
escape rate increased ErbB3 homodimers for partially and non-overlapping domains
(Figures 3.5E–G). Escape rates ¼ of the original rate yielded maximum increase of 63%,
which occurred with non-overlapping domains and 100% ligand (Figure 3.5E). Similar
trends were seen with lower ligand concentrations (Figures 3.5F,G). Unliganded ErbB3 is
not shown since there were no homodimers in this condition.
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Figure 3.5: The effect of changes in domain retention on ErbB2/3 heterodimer and ErbB3/3
homodimer counts across different ligand concentration and domains. Dimer counts across different
membrane configurations, ligand concentration and three different escape rates- nominal escape rate
(blue bars), escape rate reduced by ½ (orange bars), and escape rate reduced by ¼ (gray bars) as well
as no domain simulations (yellow bars). (A) ErbB2/3 heterodimer for 100% liganded ErbB3. (B)
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ErbB2/3 heterodimer for 50% liganded ErbB3. (C) ErbB2/3 heterodimer for 20% liganded ErbB3.
(D) ErbB2/3 heterodimer for 0% liganded ErbB3. (E) ErbB3/3 homodimer for 100% liganded
ErbB3. (F) ErbB3/3 homodimer for 50% liganded ErbB3. (G) ErbB3/3 homodimer for 20% liganded
ErbB3. The ErbB3/3 homodimer count was 0 for 0% liganded ErbB3. All bars are the averages of 4
runs ± standard deviation.
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The significant changes in dimerization with increased domain retention had
variable eﬀects on downstream signaling as assessed by steady state phosphorylation
levels of ErbB3 and ErbB2 (Figure 3.6). For ErbB3, phosphorylation levels are relatively
stable with increased domain retention (Figures 3.6A–D). The greatest eﬀect on
phosphorylation levels occurred in the case of no domain overlap, where the ErbB3
monomers were more restricted from encounters with ErbB2. In the case of fullyliganded ErbB3, a four-fold reduction in escape rate led to a 28% reduction in
phosphorylation (Figure 3.6A, gray bar for 0% overlap). For lower ligand concentrations,
varying domain overlap had a greater eﬀect on phosphorylation than domain retention
(Figures 3.6C,D).
ErbB2 phosphorylation was markedly sensitive to increases in domain retention.
Reduced ErbB2 phosphorylation corresponded to decreases in heterodimer formation
(Figures 3.6E–G). Once again, little change was seen with completely overlapping
domains. However, increasing domain retention lowered ErbB2 phosphorylation with
either partially or non-overlapping domains. Results were striking for simulations run
with a four-fold lower escape rate and 100% liganded ErbB3. Here, ErbB2
phosphorylation was reduced by 39% (partially overlapping domains) or 74% (nonoverlapping domains).
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Figure 3.6: The effect of changes in domain retention on ErbB3 and ErbB2 phosphorylation across
different ligand concentration and domains. Total receptor phosphorylation across different
membrane configurations, ligand concentration and three different escape rates- nominal escape rate
(blue bars), escape rate reduced by ½ (orange bars), and escape rate reduced by ½ (gray bars) as well
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as no domain simulations (yellow bars). (A) Total ErbB3 phosphorylation for 100% liganded ErbB3.
(B) Total ErbB3 phosphorylation for 50% liganded ErbB3. (C) Total ErbB3 phosphorylation for
20% liganded ErbB3. (D) Total ErbB3 phosphorylation for 0% liganded ErbB3. (E) Total ErbB2
phosphorylation for 100% liganded ErbB3. (F) Total ErbB2 phosphorylation for 50% liganded
ErbB3. (G) Total ErbB2 phosphorylation for 20% liganded ErbB3. (H) Total ErbB2
phosphorylation for 0% liganded ErbB3. All bars are the averages of 4 runs ± standard deviation.
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3.7 DISCUSSION
ErbB2 and ErbB3 are members of the ErbB family of receptor tyrosine kinases
that are often co-expressed in cells. Under physiological conditions, neither receptor is
active on its own. However, through heterointeractions these receptors activate two key
pro-survival pathways. ErbB3 primarily activates the PI3K/Akt pathway and ErbB2
favors the MAP kinase pathway (Yarden and Sliwkowski, 2001). Activation of the
ErbB2/ErbB3 signaling unit via overexpression of the receptors, gain-of-function
oncogenic mutations, or autocrine release of the ErbB3 ligand, heregulin, have been
identified in many types of cancer (Holbro et al., 2003; Wolf-Yadlin et al., 2006; Sheng
et al., 2010; Jaiswal et al., 2013; Capparelli et al., 2015). Given the potency of this
interaction, normal cells must maintain tight control over ErbB2/ErbB3 interactions. In
the absence of ligand, dimerization is limited by the constant fluxing of the ErbB3
extracellular domain from a tethered, inactive conformation to an upright, active
conformation with the active conformation stabilized by ligand binding (Dawson et al.,
2007). Another way to control ErbB2/ErbB3 interactions may be through dynamic
reorganization of membrane domains. Sequestration of ErbB2 and ErbB3 in separate
domains could prevent spurious signaling in the absence of ligand, while reorganization
into overlapping domains upon ligand binding could encourage the formation of
signaling clusters (Vámosi et al., 2006). Evidence for reorganization can be seen in
electron microscopy studies of SKBR3 breast cancer cell membranes. ErbB2 and ErbB3
are dispersed in the absence of ligand, but in the presence of ligand, ErbB3 forms large
clusters with areas of co-localized ErbB2 and ErbB3 (Yang et al., 2007). It has also been
shown that ErbB2 clusters within lipid rafts and that disruption of these rafts reduces both
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ErbB2 clustering and the association of ErbB2 and ErbB3 (Nagy et al., 2002). The
remodeling of domains during active signaling has not yet been explored by simulation,
in part due to diﬃculties in accurately measuring the dynamics of these changes. Here,
we have examined how domain remodeling, represented in our model by varying domain
overlap and domain retention, will eﬀect heterodimer formation and signaling.
Our spatial stochastic model of ErbB2/ErbB3 interactions provides a useful
system in which to explore how changes in domain configuration might aﬀect receptor
activation. We began with a model parameterized based on single particle tracking data
acquired under low (nanomolar) ligand conditions. We then explored how changes in
domain characteristics, as well as ligand occupancy, influences dimerization and
phosphorylation in this system. The sensitivity of the model to these parameters
illustrates that variations in domain characteristics amongst diﬀerent cell and tissue types
are likely unappreciated modulators of signaling by these (and other) receptors.
Previous spatial stochastic models have shed insight on the eﬀect of domains on
signaling (Hsieh et al., 2008; Costa et al.,2009, 2011; Chaudhuri et al., 2011; Kalay et al.,
2012). Kalay et al. evaluated movement of tracer molecules within lattice-based domains
and found that confinement increased reaction rates (Kalay et al., 2012). Addressing
ErbB receptor family interactions with rectangular subdomains, Hsieh et al., found that
domains created local densities that favored EGFR interactions on the membrane surfaces
(Hsieh et al., 2008). Our model increases the complexity by introducing two interacting
receptor types with unique behaviors and overlapping, experimentally-defined domains.
Thus, the model provides a mechanistic understanding of the interplay between domain
overlaps and domain retention on the complex interactions of ErbB2 and ErbB3. The
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model relies on previously described characteristics of these receptors. For example,
ErbB2 homodimers are not favored due to evidence for electrostatic repulsion (Garrett et
al., 2003); this translates in the model to a low probability for ErbB2 homointeractions. In
addition, ErbB3 has very low kinase activity unless activated by ErbB2 (Steinkamp et al.,
2014). Thus, in cells where these are the two predominant ErbB species, they are
predicted to be mutually dependent on each other for activation. It follows that
diﬀerential preference of the two species for unique confinement zones or membrane
domains should have a strong influence.
Accordingly, we found that phosphorylation of the two ErbB species was
diﬀerentially aﬀected by domain overlap. This was particularly evident in the case of
100% liganded ErbB3, where ErbB2 phosphorylation dropped by 50% between
completely overlapping to non-overlapping domains (Figure 3.4D). At these
physiological receptor levels, ErbB2 homo-encounters are largely unproductive due to
the low on-rate. Simulations with more domain overlap had a larger number of
heterodimer interactions than those with partial or no domain overlap. This was most
notable when all ErbB3 were occupied with ligand (Figure 3.4). ErbB3 relies heavily on
heterodimerization for activation. However, once ErbB3 receptors are activated by
ErbB2, they can go on to homodimerize and activate other ErbB3 receptors. Therefore,
steady state ErbB3 phosphorylation was less dependent on domain overlap.
It should be noted that the amount of hetero- and homodimers and
phosphorylation levels were nearly the same between no domain spatial stochastic
simulations and 100% domain overlapping conditions. This finding diﬀers from our
previous work with EGFR which showed that domains greatly improved phosphorylation
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of EGFR receptors, indicating that the introduction of multiple receptor types to these
simulations further complicates outcome (Pryor et al., 2013). True domain overlaps are
likely to fall somewhere between non-overlapping and completely overlapping
configurations, indicating the need for spatial simulations that take this into account.
Ligand binding to ErbB3 in SKBR3 breast cancer cell membranes leads to formation of
large ErbB3 clusters with modest levels of co-localized ErbB2; this indicates that domain
reorganization can occur during signaling (Yang et al., 2007). The remodeling of
domains during active signaling has not yet been explored by simulation, in part due to
diﬃculties in accurately measuring the dynamics of these changes.
SPT has revealed a range of non-brownian motion for proteins on the membrane
plane. Anomalous diﬀusion is a term often used to explain the characteristic restricted
movements of proteins that “hop” between membrane domains. There are also reports of
specific membrane proteins that undergo directed (motor-driven) motion (Kusumi and
Sako, 1996; Saxton and Jacobson, 1997; Schütz et al., 1997; Kusumi et al., 2005). These
diﬀerent modes of motion can have a profound impact on reaction kinetics on the
membrane surface by perturbing reaction rates (Saxton and Jacobson, 1997; Melo and
Martins, 2006). Thus, it is important to continue evaluating factors, such as diﬀusion
coeﬃcients, corral sizes and escape probability of proteins from their confined domains
(Saxton and Jacobson, 1997), that are expected to impact signal initiation and
propagation. In this work, we used a simulation approach to study the eﬀect of escape
probabilities on the reaction kinetics of the ErbB2/3 signaling pathway. We show that
membrane segregation can influence signaling in non-intuitive ways that are linked to the
individual characteristics of receptors. Given the technical challenges associated with
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measuring the dynamics of domain confinement, extent of mixing and escape rates in live
cell membranes, simulation oﬀers a powerful tool to explore these variables.
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4.1 ABSTRACT
Progenitors of B cells express the pre-B cell receptor (pre-BCR) early in the B
lymphocyte development pathway. Expression of this receptor is critical for survival and
proliferation of B cells. The pre-BCR undergoes ligand independent tonic signaling
through frequent, but short lived, homodimer interactions. To investigate tonic signaling
emanating from this receptor, we developed a rule-based spatial stochastic model of preBCR aggregation and downstream signaling events. The model was populated with data
from single particle methods from two different pre-BCR cell lines (697 and Nalm6),
which exhibit characteristic differences in their diffusion coefficients and dimer off rates.
We found that these differences affected pre-BCR aggregation and consequent signaling
events in the pre-B cells. The Nalm6 cell line, which had a lower off rate and lower
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diffusion coefficient, formed higher order oligomers than the 697 cell line. There was
also an increase in the steady-state levels of receptor phosphorylation in the Nalm6 cell
line. Thus, the spatial stochastic model of pre-BCR presented here was able to estimate
aggregate sizes and predict the receptor phosphorylation landscape during tonic
signaling.

4.2 INTRODUCTION
The precursor B cell receptor (pre-BCR) appears early in the developmental
pathway of B lymphocytes and serves as a checkpoint for the progression of B cell
progenitors into mature B lymphocytes (Rickert, 2013) . The pre-BCR is expressed on
the surface of progenitor B cells and it is composed of a rearranged Immunoglobulin
heavy chain (IgH) and non-polymorphic surrogate light chain (SLC) consisting of l5 and
VpreB (Rickert, 2013). The pre-BCR is also non-covalently attached to Iga (CD79a) and
Igb (CD79b), two heterodimeric subunits containing the immunoreceptor tyrosine-based
activation motif (ITAM) that help to propagate signaling downstream of the pre-BCR
(Monroe, 2006). Signaling from the pre-BCR entails phosphorylation of the ITAMs on
tyrosine residues by Src family kinases (SFK) such as Lyn; the phosphotyrosines then
serve as docking sites for the spleen tyrosine kinase (Syk) (Gauld and Cambier, 2004).
Syk docks to the pre-BCR using its pair of Src homology 2 (SH2) domains and generates
signaling responses that lead to remodeling of the cytoskeleton, intracellular calcium
response and differential gene expression patterns necessary for B cell maturation
(Cornall et al., 2000; Guo et al., 2000; Monroe, 2006).
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The SLCs of the pre-BCR do not undergo gene rearrangements (Monroe, 2006).
Since the SLC are non-polymorphic, the pre-BCR lack the ability to bind to conventional
antigens of the BCR, hence, one of the major challenges in the field has been to identify
the exact mechanism with which the pre-BCRs interact and activate signaling cascades
that promote progenitor B cell differentiation and survival. There is limited evidence for
ligand dependent pre-BCR signaling, that is mediated through reactivity to self-antigens;
crosslinking can also be induced when l5 components of the SLC bind to the dimeric
stromal ligand galectin-1 (Gauthier et al., 2002; Kohler et al., 2008; Erasmus et al.,
2016). Basal signals may emanate from Iga and Igb on unaggregated receptors (FuentesPanana et al., 2004).

Ubelhart and colleagues propose that pre-BCR signaling is

dependent on a conserved asparagine (N)-linked glycosylation site on IgH (Ubelhart et
al., 2010). However, there is growing evidence that ligand-independent pre-BCR homointeractions lead to induction of weak or ‘tonic’ signaling on progenitor B cells (Ohnishi
and Melchers, 2003; Monroe, 2006; Bankovich et al., 2007; Erasmus et al., 2016b).
Erasmus et al., used single particle tracking (SPT) methods to track the diffusional
dynamics as we all as homodimer events between ligand independent pre-BCR on B-cell
precursor acute lymphoblastic leukemia (BCP-ALL) cell lines. The pre-BCR on these
cell lines undergo frequent but short lived dimerization events which lead to tonic
signaling comprising of induction of pro-survival B cell lymphoma 6 protein (BCL6), a
transcription repressor, necessary for pre-BCR to transition into the next developmental
stage (Duy et al., 2010; Erasmus et al., 2016).
Acute lymphoblastic leukemia (ALL) constitutes one of the most common
childhood cancers and a majority of these neoplasms have been found to lack a functional
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pre-BCR (~85%) (Müschen, 2015). However, there is a subset of ALL cases (13.5%),
where the neoplasms express a functional pre-BCR and exploit the tonic signaling
generated foirom this receptor to survive and proliferate (Geng et al., 2015; Müschen,
2015). Inhibitors of Lyn and Syk tyrosine kinases, which are active participants in the
pre-BCR pathway, have been shown to negatively affect survival of pre-BCR+ ALL
cells, thus highlighting the therapeutic potential of these small molecules in combating
BCP-ALL (Geng et al., 2015; Erasmus et al., 2016). Erasmus et al also observed that
monovalent anti-VrepB antibody fragments could inhibit pre-BCR dimerization and
interrupt survival signals from this receptor (Erasmus et al., 2016).
Key parameters in our model are derived from Erasmus et al., This includes
distinct values for pre-BCR diffusion coefficients, as well as homodimer off rates, for
two BCP-ALL cell lines: 697 and Nalm6 (Erasmus et al., 2016). The pre-BCR on the
surface of 697 cells dimers diffused considerably faster and had higher dimer off rates as
compared to the Nalm6 cells. These data led us to hypothesize the difference in dimer
off rate could lead to existence of higher order oligomers in Nalm6 cell lines; the
tendency to form slightly larger aggregates would explain the overall slower diffusion
rate. In support of this theory, some of the apparent dimer pairs observed through SPT of
pre-BCR in the Nalm6 cell line were also more than 100nm apart, which was the
theoretical distance between a single pair of dimerized receptors labeled with quantum
dots. One interpretation of these data is that the SPT captured cases of Nalm6 oligomers
where the two quantum dots were bound to receptors located at the ends of a chain of a
trimer or tetramer.
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Since receptors are sparsely labeled in SPT experiments, aggregation beyond
dimers is difficult to quantify. To investigate the existence of these higher order
oligomers and the impact of the apparent diffusion coefficients and dimer off rates, we
developed a spatial, stochastic model of pre-BCR aggregation and tonic signaling. We
parameterized the model with coefficients directly measured from single particle tracking
as well as from the available literature. Our motivation for creating a spatial model of
tonic pre-BCR signaling pathway evolved from observing electron micrographs of
labeled pre-BCR which were confined in domains formed by the actin cytoskeletons
(Figure A.1). Using the spatial stochastic model, we found that receptor dimer off rates
and domains affected aggregate sizes and consequent signaling events.

4.3 MATERIALS AND METHODS
We developed a rule-based spatial stochastic model of pre-BCR to investigate
tonic signaling occurring downstream of receptor aggregation events. The two pre-BCR
cell lines that were used for experimental measurements were Nalm6 and 697, each with
specific pre-BCR diffusion coefficients as well as dimer off rates (Table 3). This model
has been parameterized with data from SPT measurements and morphometric analysis of
pre-B cell lines, as well as from the literature. The earliest tyrosine kinases in the signal
transduction pathway, Lyn and Syk, are explicitly represented in the model. Details of
reaction kinetics and rules specifying the interaction of molecules are given below.
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4.3.1 The signal transduction pathway
Although the pre-BCR and BCR occur at distinct time points in the lymphocyte
development and contain structurally different light chains, both the receptors enlist the
same set of Src and Syk family kinases to initiate signaling (Benschop and Cambier,
1999; Meffre et al., 2000). The Pre-BCR propagates signaling through the noncovalently attached Iga and Igb units which each contain ITAMs (Monroe, 2006). The
ITAMs contain tyrosine residues (Y182 and Y193 on Iga and Y195 and Y206 on Igb)
that are substrates for phosphorylation by the kinases (Pao et al., 1998; Storch et al.,
2007).
In the model, the pre-BCR receptors form linear dimers which may bind further to
form higher order oligomers through their free receptor binding domains (Table 3).
Receptor aggregation are triggered through molecule collision events and receptor
unbinding is intrinsically triggered whose probability is determined by the experimentally
measured dimer off-rate and the time step.
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Table 3: Pre-B cell receptor cell line characteristics in the
model
697

a

No of receptors
No of Lyn available to receptorb
No of Syka
Binding radius (µm)c
Dimer off rate (/s)c
Diffusion coefficient Receptors (µm2/s)d
Diffusion coefficient Lyn (µm2/s)e
2

Diffusion coefficient Syk (µm /s)
a

f

17

Estimated from Wofsy et al. 1997, Faeder et al. 2003

Estimated from Erasmus et al. 2016

d
e

0.4

Experimental data in this paper

b
c

f

Nalm 6
10000
10% of receptor
48,290
274,302
0.000215
0.772
0.164
0.16

Erasmus et al. 2016

Stone et al. 2015

Brock et al. 1999

Ligand independent receptor aggregation in pre-BCR is followed by binding of
Lyn to the ITAMs (Monroe, 2006; Erasmus et al., 2016). Lyn has four structurally
distinct domains through which it interacts with the ITAMs (Boggon and Eck, 2004;
Parsons and Parsons, 2004). The unique domain of Lyn is known to constitutively
associate with receptors and bind to non-phosphorylated Iga whereas the SH2 domain
binds to phosphorylated ITAMs on both Iga and Igb (Pleiman et al., 1994; Vonakis et al.,
1997). Although Lyn has been reported to bind ITAMs in both signaling subunits, it
preferentially binds to Iga at least twice more likely than to Igb (Johnson et al., 1995).
In the model, Lyn can bind to a free ITAM site on a receptor (Table 4). The
receptor maybe a part of an aggregate or be a single receptor by itself. Lyn can bind to an
unphosphorylated Iga through its unique domain and bind to a phosphorylated Iga or
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phosphorylated Igb through its SH2 domain. Only one Lyn molecule is allowed to bind
per Iga or Igb. Just as receptor-receptor binding events occur, Lyn-receptor binding
events are collision triggered and unbinding is based on a probability calculated through
off rates and the time step. The two phosphorylation sites on Iga have been lumped
together into one site and can have the phosphorylation status- 0, 1 or 2. The
phosphorylation sites on Igb are treated similarly.

Table 4: Lyn and Syk molecule binding radii and dimer off
rate
Molecules
Lyn

ITA
M
Ig⍺

Syk

Igβ
Ig⍺
Igβ

a

Phos. Status
0
≥1
≥1
1
2
1
2

Binding radius
(µm)
2.29E-04a
2.29E-04a
1.14E-04c
1.31E-04d
1.57E-03d
4.37E-05f
5.25E-04f

Dimer off rate (/s)
20b
0.12b
0.12b
2.6e
0.3e
2.6e
0.3e

Estimated from Faeder et al. (2003) and Smoldyn- Andrews et al. (2004)

b

Faeder et al. (2003)

c

Estimated according to observed experimental data (Lyn binding to Igb is approximately 1/2 of the
binding observed to Ig⍺) in Johnson et al. (1995).
d
Estimated from Schwartz et al. (2017), Tsang et al. (2008) and Smoldyn- Andrews et al. (2004)
e

Schwartz et el. (2017)

f

Estimated from Schwartz et al. (2017), Tsang et al. (2008), Kurosaki et al. 1995 (Binding of Syk to Ig⍺
is 3x more than binding observed to Igb) and Smoldyn- Andrews et al. (2004)

Lyn association with the receptors is followed by receptor phosphorylation and
one Lyn in an aggregate is sufficient for initiating phosphorylation of other receptors in
an aggregate (Wofsy et al., 1999). Lyn itself can also become transphosphorylated
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(Y397) by other Lyn molecules, which results in an increase of Lyn kinase activity
(Yamashita et al., 1994; Sotirellis et al., 1995; Wofsy et al., 1999; Ingley, 2012).
In the model, Lyn on a receptor can phosphorylate Lyn on a nearby receptor, i.e.
the two receptors must be bound to immediate neighbors in the same receptor complex
(Table 5). Phosphorylation rates depend on the phosphorylation state of Lyn. Similar to
Lyn-Lyn phosphorylation, Lyn must be on an immediately adjacent receptor in the same
complex in order to phosphorylate the ITAMs. Phosphorylated Lyns are assumed to be
activated and have a stronger kinase activity. The Lyn phosphorylation site can have the
phosphorylation status- 0 or 1.

Table 5: Kinase and substrate phosphorylation status and rates
Kinase Phos. Status
Lyn
0
0
1
1
0
1
0
1
Syk
0
1
a

Substrate
Ig⍺(Y182/Y19
3)
Igβ(Y195/206)
Lyn(Y397)

Phos. Status
0
1
0
1
0

Syk(Y342/Y34
6)

0

Syk(Y519/Y52
0)

0

Rate (/s)
30a
15b
100a
50b
30a
100a
30a
100a
100a
200a

Faeder et al. (2003)

b

Estimated from Barua et al. (2012). Phosphorylation of 2nd site on the
ITAM occurs at half the rate from first.

The phosphorylated ITAMs form docking sites for the Syk (Kurosaki et al.,
1995). While Syk can bind to both mono-phosphorylated and doubly-phosphorylated
ITAMS through its SH2 domains, the binding affinity is significantly higher for doubly
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phosphorylated ITAMS; this is reflected by high dimer on-rate and lower off-rate (Tsang
et al., 2008). Binding of Syk to Iga is three times more than the binding seen to Igb
(Kurosaki et al., 1995).
In the model, free Syk can bind to any one of the two ITAM (Iga and Igb) sites
on each receptor upon collision (Table 4). Each ITAM in an ITAM pair is regarded as a
Syk binding site, and can bind Syk independently of each other. However, since Lyn
binding is also possible on the same sites, Syk molecules cannot bind the ITAMs if they
are occupied and the same rule is applied for Lyn molecules. Syk dissociation from the
receptor also occurs through an intrinsically triggered unbinding probability which is
determined through the Syk off rate and the time step. The Syk off-rate is higher for
doubly phosphorylated ITAMS versus singly phosphorylated.
Syk can undergo phosphorylation on specific tyrosine residues in its catalytic
domain (Y519 and Y520) by another Syk docked on adjacent ITAMS in the same BCR
or pre-BCR aggregate (Keshvara et al., 1998; Zhang et al., 2000). Syk can also undergo
phosphorylation by a Lyn docked on adjacent ITAMs in the same BCR or pre-BCR
aggregate molecule in its linker regions (Y342 and Y346) (Keshvara et al., 1998).
In the model, Syk or Lyn molecules must be on an immediately adjacent receptor
in the same complex in order to phosphorylate other Syk molecules (Table 5). Syk
molecules can phosphorylate other Syk molecules in their catalytic domain and Lyn
molecules can phosphorylate other Syk molecules in their linker regions. Syk molecules
that have been phosphorylated in their catalytic domain are assumed to have stronger
kinase activity. The two phosphorylation sites on the catalytic domain have been lumped
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together and can have the phosphorylation status- 0 or 1. The two phosphorylation sites
on the linker region have been treated similarly
Receptor, Lyn and Syk dephosphorylations in the model are all intrinsically
triggered from a dephosphorylating probability which takes into account the molecule
dephosphorylations rate and the time step (Table 6).

Table 6: Dephosphorylation rates
Substrate
Ig⍺(Y182/Y193)
Igβ(Y195/206)
Lyn(Y397)
Syk(Y342/Y346)
Syk(Y519/Y520)
a

Phos. Status
2
1
2
1

Rate (/s)
40a
20b
40a
20b

1

20b

Estimated from Faeder et al. (2003) and Barua et al.
(2012)(Dephosphorylation of doubly phosphorylated ITAMs
occur at 2x the rate of singly phosphorylated ITAM)
b
Faeder et al. (2003)
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4.3.2 Simulation Landscape

Figure 4.1: 3-D simulation space containing pre-BCR, pre-BCR domains, Lyn and Syk molecules
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We created a 3-D simulation landscape in MATLAB to track interactions between
the pre-BCR and Lyn, which are both plasma membrane residents, and Syk in the
cytosol. Thus, the 2-D membrane is populated with transmembrane pre-BCR and inner
leaflet-bound Lyn molecules, while the 3-D cytosol is populated with Syk molecules
(Figure 4.1). The membrane contains pre-BCR receptor specific domains and receptors
can diﬀuse across domains and domain-free areas. Figure 4.1 depicts domains that were
identified through analysis of two-color SPT. For SPT measurements, monovalent AntiIgb Fabs’ against the Igb subunit were generated using hybridomas and labeled with
streptavidin-conjugated QD585 and QD655. The monovalent QD probes were then
allowed to tag Pre-BCR and their movement was tracked on a live membrane using SPT
imaging (Erasmus et al., 2016). In order to extract the receptor domain sizes and contours
from SPT, data sets containing the particle trajectories were subjected to the domain
reconstruction algorithm (DRA), which was previously developed and used in Pryor et
al., 2015 (Pryor et al., 2015). Briefly, the DRA reads in the SPT trajectories and ranks
them into slow moving (confined) or fast moving points (free) using their jump sizes over
different time intervals. The confined points are postulated to be in a domain (such as
lipid rafts, protein domains or corrals) that impede the movement of the particles. We
then cluster the slow moving points into groups based on whether their distance from
each other is less than the reference distance, L. After cluster identification, we build
contours around them that represent vertices of receptor domains.
From morphometric measurements, pre-B cell was estimated to have a total cell
surface area of 315.7 µm2 and a cytosolic volume of 321.8 µm3. The pre-B cell radius
was 5 µm and nuclear radius was 3.7 µm. In our simulations, the pre-B cell membrane
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landscape is represented by a rectangular cuboid with an area of 2.25 µm2 (1.5 µm x 1.5
µm) and volume of 1.25 µm3 (depth of 0.5 µm). The total number of receptors is
equivalent in both the cell lines (10,000 receptors) for a density of ~ 32 receptors/µm2.
For our simulation area, this resulted in 71 receptors occupying the membrane landscape.
The amount of Syk varied between the cell lines. Based upon calibrated western
blotting experiments, we estimate that 697 cell line has ~ 48,000 Syk molecules while the
Nalm6 cell line has 274,000. For our simulation volume, this resulted in 169 Syk
molecules for the 697 cell line and 959 Syk molecules for the Nalm6 cell line. The
amount of Lyn available to the receptors is estimated to vary between 5% and 10% of the
total receptors present in the cell (Yamashita et al., 1994; Wofsy et al., 1997). Faeder et
al., in their investigation of signals emanating from FceRI, modeled the pool of Lyn
available to the receptors as 7% of the total receptor concentration and assumed that all of
the available Lyn is in a form, which when bound to the receptors, is capable of initiating
phosphorylation events (Faeder et al., 2003). We apply the same principles in our model,
where we assume that the total amount of Lyn available to the receptors would be at most
10%. This would mean that at any given time in the pre-B cell, only 1000 Lyn molecules
are available for interaction with the 10,000 pre-BCRs. For our simulation area, this
amounts to 7 Lyn molecules available for interaction with a total number of 71 receptors.

4.3.3 Molecule diffusion
In our simulation molecules can undergo Brownian motion in the x, y and z plane.
Lyn and pre-BCR undergo diffusion in the x and y plane only, whereas Syk molecules
can also diffuse in the z plane.
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Receptor jumps are generated by choosing a random number from a normal
distribution and processing it with the root mean square (RMS) of the molecule to
generate the new coordinates with the time increment of Δt. The RMS is given by:
𝑅𝑀𝑆 =

2 ∗ 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ∗ Δt. Following rules are applied for calculation

of the new spatial coordinates (Andrews and Bray, 2004; Erban, 2014; Pryor et al., 2015):
x(t+ Δt) = x(t) + RMS * ξx
y(t+ Δt) = y(t) + RMS * ξy
z(t+ Δt) = z(t) + RMS * ξz

ξx, ξy, ξz are random numbers chosen from a normal distribution. x, y and z represent
the molecule’s Cartesian coordinates.
Since pre-BCRs form higher order oligomers, in the model we assume that the
diffusion of a pre-BCR complex is inversely proportional to the size of the complex. The
size of the complex reflects the number of receptors in an aggregate.

4.3.4 Boundary conditions and probability of escape
For any simulation space, boundary conditions need to be specified so that
particles remain in the simulation area or volume. For the pre-BCR, we apply periodic
boundary conditions at the edges of the simulation space. When a receptor reaches the
edge of the simulation space (in x or y plane) and the receptor jump calculated displaces
the receptor outside the simulation space, we divide the jump into two segments. The first
segment displaces the receptor to the edge and the second segment is calculated from the
opposite edge of the simulation space, such that the receptor re-enters the simulation

90
space from the opposite boundary. For receptors in domain we apply the reflective
boundary conditions. As before, the receptor jump is divided into two segments: one
segment displaces the receptor to the edge of the domain and the second displaces it
outside of the domain. When the receptor reaches the edge of the domain, a probability
for escape from the domain is calculated and if the probability of escape is not met, then
the receptor is reflected back into the domain with the remaining segment. If the
probability of escape is met, then the receptor continues across the domain. An exit
penalty limits receptor escape from the domains. The exit penalty was obtained by
calculating the ratio of the membrane area explored by the slow moving points versus the
membrane area explored by fast moving points. The exit probability for receptors in the
pre-B cells was found to be 0.2. We apply the same periodic boundary conditions to Lyn
and Syk molecules in the x and y plane. For Syk, we also apply reflective boundary
condition in its z plane, such that when the receptor reaches edge of the simulation space,
it is reflected back into the cytosol.

4.3.5 Reaction kinetics
For molecule reactions, we chose reaction kinetics similar to those used in the
spatial stochastic simulator Smoldyn, which uses Smoluchowski dynamics with revisions
to implement reaction events. In essence, there are two different ways to simulate
reaction events depending on whether they are first or second order reactions. First order
reactions

include

molecule

phosphorylation,

dephosphorylation

and

molecule

dissociation. The probability of any of these first order reaction events occurring at time
step Δt is given by (Andrews and Bray, 2004; Pryor et al., 2015):
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P(First order reaction) =1− exp (−First order reaction rate *Δt)
However, due to the very small time step, this probability has been reduced to the
following:
P(First order reaction) =First order reaction rate *Δt
Second order reactions include molecule association events such as receptor
dimerization or aggregation into higher order oligomers and molecules such such as Lyn
and Syk binding to the receptor. For these reactions, a parameter called the binding radius
is used to determine the outcome of a collision event. If two molecules are within the
binding radius of each other, then a binding event will take place. The binding radius for
Lyn and Syk molecules were calculated using Smoldyn, which takes into account the on
rate of the reaction, diffusion coefficients and the time step to determine a binding radius
for molecular association events. The binding radius for a pair of receptors was
determined using SPT data from Erasmus et al., well mixed Matlab simulations and
spatial stochastic simulations with no domains. Briefly, we ran well mixed Matlab
simulations with an estimated on rate and estimated dimer off rate for pre-BCR
aggregation in the 697 cell line. This produced a ratio of monomers, dimers and higher
order oligomers. We then used the estimated dimer off rate with varying binding radii in
a spatial stochastic simulation (coded in Fortran) with no domains to obtain the same
ratio of monomers, dimers and higher order oligomers as observed in the well mixed
Matlab simulations. The binding radius which correctly reproduced the ratio of the
oligomers in the spatial simulations was used in the simulations as the pre-BCR binding
radius (Table 3).
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4.4 RESULTS

4.4.1 Impact of varying dimer off rate and domains on receptor aggregation
From SPT measurements, Erasmus et al., had observed that the 697 cell line had a
higher dimer off rate as compared to the Nalm6 cell line. This led to the speculation that
Nalm6 was forming higher sized oligomers, supported by observed cases of SPT that
captured apparent “dimers” of pre-BCR tagged quantum dots that exceeded the
theoretical distance of 100 nm for a minimal pre-BCR dimer. We populated our spatial
stochastic model with the estimated off rates in order to observe whether the two cell
lines formed different sized aggregates. Figure 4.2A represents the aggregate sizes
formed in the 697 cell line and Figure 4.2C represents the aggregate sizes formed in the
Nalm 6 cell line. As observed from the Figures 4.2A and C, the Nalm6 cell line forms
much higher order oligomers when compared to the 697 cell line. The number of
monomers was also higher in the 697 cell line as compared to the Nalm6. Thus, the
spatial stochastic models provides evidence for the existence of much higher order
oligomers in Nalm6 cell line as compared to 697.
From electron microscopy images of immune-gold labeled plasma membrane
“rip-flips” (Figure A.1), we observed corral-like cortical cytoskeletal structures on the
membrane of pre-B cells indicating that the receptors might be confined in domains. In
order to investigate the effect of domains on receptor aggregation, we used data gathered
from SPT measurements to re-create pre-BCR domains in our in silico membrane
landscape. We found that the presence of domains increased the size of pre-BCR
aggregates in both the cell lines (Figure 4.2A-D). Figure 4.2A displays the ratio of

93
aggregates in the 697 cell line with domains while Figure 4.2B displays the ratio of
aggregates formed in the same cell line without domains. Clearly there is an increase in
the oligomer size in simulations where domains were present. Figure 4.2C and Figure
4.2D compare the aggregate sizes in the Nalm6 cell line, with and without domains
respectively. A similar trend is seen where the simulations with domains had an impact
on the aggregate sizes. Hence, as seen in our earlier studies (Kerketta et al., 2016),
domains again prove to be important regulators of receptor aggregation and consequent
signaling pathways.
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Figure 4.2: Receptor aggregation on 697 and Nalm6 cell line. (A) 697, Domain. (B) 697, No Domain.
(C) Nalm6, Domain. (D) Nalm6, No Domain.
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4.4.2 Impact of varying dimer off rate and domains on ITAM phosphorylation
It is known that receptor aggregation leads to phosphorylation of tyrosine residues
on the ITAMs of pre-BCR by Lyn as well as Lyn transphosphorylation by other Lyn
molecules (Wofsy et al., 1999; Ingley, 2012). In our model, Lyn can phosphorylate other
receptors on the same aggregate and also be trans-phosphorylated by other Lyn
molecules, provided they all reside on the same aggregate. We simulate this relationship
by providing a receptor bound Lyn access to receptors for phosphorylation that are one
bond over on each side on an aggregate. This would indicate that as the size of an
aggregate increases, we expect more Lyn to be associated with that aggregate, followed
by more phosphorylation events. Since the sizes of the oligomers formed in the two
different cell lines differed, we wanted to investigate the effect of aggregate sizes on
ITAM phosphorylation. Figure 4.3 (A-D) display the amount of Iga and Igb
phosphorylation observed in the 697 and Nalm6 cell lines. We found that the presence of
domains had an impact on the amount of receptor phosphorylation in both the cell lines
(Figure 4.3 and Figure. 4.4). There were overall more phosphorylated ITAMS in 697 cell
line with domains as compared to no domains (Figure 4.3 A,B and Figure 4.4). Similar
trends were seen when comparing Nalm6 cell line with domains and without domains
(Figure 4.3 C, D and Figure 4.4).
It was also interesting to note that the amount of single phosphorylated Iga and
Igb were at similar levels in both the cell lines, however, there were differences in the
amount of doubly phosphorylated ITAMs (Figure 4.4). The amount of doubly
phosphorylated Iga ITAMS were considerably higher in the Nalm6 cell line with
domains as compared to 697 (Figure 4.4).
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Figure 4.3: Receptor Iga and Igb phosphorylation on 697 and Nalm6 cell line. (A) 697, Domain. (B)
697, No Domain. (C) Nalm6, Domain. (D) Nalm6, No Domain. Iga-1: once phosphorylated, Iga-2:
twice phosphorylated, Igb-1: once phosphorylated, Igb-2: twice phosphorylated.

97

Ig⍺ and Igβ Phosphorylation status
2.5

1P

2P

2

Counts

1.5

1

0.5

0

Ig⍺

Igβ
Nalm6 D

Ig⍺

Igβ

Nalm6 ND

Ig⍺

Igβ
697 D

Ig⍺

Igβ

697 ND

Figure 4.4: ITAM (Iga and Igb) phosphorylation status of 697 and Nalm6 cell lines (with and without
domains). All stacked bars are averages of 2 runs (± standard deviation) between 10 and 600 seconds.
Nalm6D: Nalm6 with domains; Nalm6 ND: Nalm6 with no domain; 697 D: 697 with domains; 697
ND: 697 no domains.
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4.4.3 Impact of varying dimer off rate and domains on Lyn binding and
phosphorylation
Lyn molecules can bind to receptors through their unique or SH2 domains
(Boggon and Eck, 2004). Receptor bound Lyn can trans-phosphorylate other Lyn
molecules and thus, activate other Lyn kinases (Barua et al., 2012). This causes an
increase in the catalytic activity of Lyn when the Lyn gets phosphorylated in its
activation loop (Ingley, 2012). In the model, Lyn can bind to the ITAMS on the pre-BCR
depending on the phosphorylation status of the ITAMs. Lyn can bind to
unphosphorylated Iga through its unique domain or phosphorylated Iga through its SH2
domain. Lyn can also bind to Igb through its SH2 domain. Once bound, Lyn molecules
can phosphorylate the ITAMS as well as other Lyn molecules, one receptor over, on the
aggregate. Once Lyn molecules are phosphorylated in their activation loop tyrosine site,
they are assumed to be activated kinases. We wanted to investigate whether the different
dimer off rates between the cell lines and the presence of domains have an effect on the
amount of Lyn recruited to the receptors as well as their phosphorylation/activation
status. From our simulations, we observed that the average amount of Lyn molecules
recruited to the receptors were the same in three of the simulation conditions- Nalm6 with
domains, Nalm6 without domains and 697 with domains (Figure 4.5 and Figure 4.6A).
However, the amount of Lyn activation was considerably higher in Nalm6 with domains,
followed by Nalm6 without domains, 697 with domains and 697 without domains (Figure
4.6B). Clearly, the different dimer off rate and the presence of domains were affecting the
phosphorylation status of the Lyn molecules.
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Figure 4.5: Receptor bound Lyn and activated on 697 and Nalm6 cell line. (A) 697, Domain. (B) 697,
No Domain. (C) Nalm6, Domain. (D) Nalm6, No Domain.
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Figure 4.6. Lyn bound and Lyn phosphorylation counts. (A) Amount of receptor bound Lyn. (B)
Amount of Lyn phosphorylated. All bars are the averages of 2 runs (± standard deviation) between
10 and 600 seconds.
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4.4.4 Impact of varying dimer off rate and domains on Syk binding
The phosphorylation of ITAMs by Lyn molecules leads to creation of docking
sites for SH2 domain containing Syk molecules (Kurosaki et al., 1995). Syk can bind to
both singly or doubly phosphorylated Iga and Igb, as they have two SH2 domains.
Binding to doubly phosphorylated ITAMs is stronger than binding to singly
phosphorylated ITAMs (Tsang et al., 2008). Binding is also affected by the preference of
Syk molecules for Iga over Igb (Kurosaki et al., 1995). Once receptor bound, Syk
molecules can be phosphorylated by other Lyn molecules in its linker regions or it can be
phosphorylated by other Syk molecules in its catalytic domain (Keshvara et al., 1998).
Syk is assumed to be an activated kinase upon phosphorylation of its catalytic
domain(Keshvara et al., 1998). We wanted to investigate the effect of different dimer off
rates and presence of domain on Syk associations with the receptor as well as Syk
phosphorylation status. Apart from the differences in the dimer off rate between the two
cell lines we also know from SPT and experimental measurements that the amount of Syk
molecules varies markedly in the two different cell lines with Nalm6 having a much
higher amount of Syk molecules. Our simulations accordingly predict higher levels of
receptor bound Syk in the Nalm6 line, as compared to 697 cell line (Figure 4.7A,D and
Figure 4.8A). Cell lines with domains also had higher levels of Syk bound to the receptor
(Figure 4.7 and Figure 4.8A).
We did not observe phosphorylation in the catalytic domain of Syk by other Syk
molecules (Figure 4.7) in our simulations. We did ,however, find Syk phosphorylated in
its linker regions by Lyn (Figure 4.7 and Figure 4.8B). The amount of Syk
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phosphorylation was the highest in Nalm6 cell line with domains, followed by Nalm6
without domains, 697 with domains and 697 without domains (Figure 4.8B).
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Figure 4.7: Receptor bound Syk on 697 and Nalm6 cell line. (A) 697, Domain. (B) 697, No Domain.
(C) Nalm6, Domain. (D) Nalm6, No Domain. Syk phosphorylation (site 1): Syk phosphorylated by
other Syk molecules in the catalytic domain. Syk phosphorylation (site 2): Syk phosphorylated by
other Lyn molecules in the linker region.
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Fig 4.8. Syk bound and Syk phosphorylation counts. (A) Amount of receptor bound Syk. (B)
Amount of Syk phosphorylated by Lyn. All bars are the averages of 2 runs (± standard deviation)
between 10 and 600 seconds
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4.5 DISCUSSION
In this study, we developed a spatial stochastic model to explore tonic signaling
between the two different cell lines (697 and Nalm6) of leukemic pre-BCR. We found
differences in sizes of the aggregates and molecule phosphorylation levels based on the
different dimer off rates and presence of domains. The presence of domains impacted the
pre-BCR chain lengths with domains favoring formation of higher order oligomers
(Figure 4.2). The different dimer off rates between the two cell lines also had a major
impact on the size of the aggregates formed (Figure 4.2). The Nalm6 cell line with the
lower dimer off rate increased receptor aggregate sizes. From SPT measurements, we had
speculated that Nalm6 was forming larger aggregates as dimer pairs that were more than
100 nm were often observed. Here, we provide strong evidence that the lower dimer off
rate as measured in Nalm6 impacts the aggregate sizes in the pre-BCR leukemic cell line.
We also investigated receptor phosphorylation levels in these receptors. The
overall phosphorylation level of receptors was found to be very low with the highest
amount of phosphorylation seen in Nalm6 with domains. About 2.6% of Iga and 2.1% of
Igb were found to be phosphorylated in these simulations. In the 697 cell line, we found
about 1.8% of Iga and 1.6% of Igb phosphorylated. Thus, these numbers indicate that
tonic signaling entails very low level of receptor phosphorylation. Low levels of receptor
phosphorylation mean that the amount of important downstream signaling molecules
such as Syk recruited to the receptor would also be very low since Syk docks to
phosphorylated ITAMs. The amount of receptor phosphorylated might set up an upper
limit for signaling activation of this pathway.
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We also investigated the amount of Lyn molecules recruited to the pre-BCRs
from the pool of available Lyns. The amount of receptor bound Lyn was seen to be at
similar levels in Nalm6 with and without domains and 697 with domains. This amount
varied between 25% and 23% in these three conditions. The lowest amount of receptor
bound Lyns was seen in simulations of 697 with no domains. Here, the amount of Lyn
bound was found to be about 18%. Thus, in tonic signaling, about a quarter percent of the
pool of available Lyns seem to be receptor bound at steady state in both the cell lines.
The total Lyn phosphorylation levels were also very low with about 2% of Lyn
phosphorylated in Nalm6 with domains and 0.56% of Lyn phosphorylated in 697 with
domains. Thus, activated Lyn was also present at a very low percentage during
simulation of tonic signaling. This indicates that tight control of Lyn recruitment is
implemented in these cells to keep subsequent receptor and Lyn phosphorylations at low
levels.
The total amount of receptor bound Syk in Nalm6 with domains was 0.05% and it
was 0.02% in 697 with domains. Syk receptor phosphorylation in the linker region by
Lyn was also very low. About 0.02% of Syk molecules were phosphorylated on this site
in Nalm6 with domains and 0.006% were phosphorylated in 697 with domains. We did
not observe phosphorylation of Syk in its catalytic domain by Syk. Thus, recruitment
along with phosphorylation of Syk molecules appears to be at very low levels in these
cells.
Thus, from the simulations conducted in this study, it has become apparent that
during tonic signaling, even though a large number of receptors might be involved in
forming higher order aggregates, the total amount of Lyn and Syk molecules bound to
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these receptors remain low. The receptor, Lyn and Syk phosphorylation were also
observed to be at very low levels. A reason for such low level of signaling could be that
pre-BCRs have to judiciously regulate their signaling during their early development as
too little or too much signaling could lead to apoptosis and impediment of their
development pathway (Erasmus et al., 2016).
Erasmus et al., also obtained B cell progenitor cells from two BCP-ALL patients
(patient# 238 and patient# 280) that were positive for the pre-BCR. Remarkably, preBCR on the surfaces of cells from the two patient samples displayed diffusion
characteristics that were similar either to 697 cells (patient# 238) or to Nalm6 cells
(patient# 280). Cells from patient# 280 were found to have slightly higher levels of BCL6
than from patient# 238 and were also more sensitive to antibodies against the VrepB
region of the SLC which blocked pre-BCR dimerization. From experimental
measurements, we know that Nalm6 has a higher number of Syk molecules. From the
spatial stochastic model, we can observe that the Nalm6 cell line also forms higher order
oligomers as well as more Lyn and Syk recruitment and phosphorylation. Thus, this
could provide an explanation for the presence of higher amount of BCL6 in the patient
pre-BCR cell line that behaved like Nalm6. The higher order oligomers in Nalm6,
combined with an increased density of Syk molecules in the cell, led to increased BCL6
production.
This model can be used to further test knockouts of different protein for observing
their effect on this signaling pathway. Obtaining the parameters for this pathway had
proven to be very challenging. More experimental measurements are needed, so that the
model can be fully biologically validated. We present here a model of basic tonic pre-
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BCR aggregation and signaling. Other acting proteins in this pathway can be added in the
future as more parameters become available.
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CHAPTER 5: DISCUSSION
5.1 SUMMARY
In this dissertation, we explored the heterogeneity that exists across different
biological scales using a variety of mathematical and computational methods. We used
both deterministic (differential equations based) and stochastic methods to build models
that were populated with both patient and experimental data in order to make biologically
relevant predictions. In this first section of the discussion, a summary of the biological
insights gained through the use of these models is presented.
In chapter 2 of this dissertation, we explored the heterogeneity that exists in the
tumor microenvironment and its impact on patient therapeutic outcomes using a
mathematical model of drug transport. This model considered patient specific parameters
such as the blood vessel perfusion and radius of blood vessels, which tends to vary
between patients, for predicting the effect of chemotherapy on patient tumors. We used
H&E stained histological cross sections from patients as well as data from their CT scans
to populate our model for making patient specific predictions. We found that patients
who exhibited higher blood vessel perfusion in their tumors, also displayed a better
prognosis in their treatment outcomes. This was because in well perfused tumors, drugs
could easily reach the cancer cells whereas in tumors, where the blood vessel perfusion
was low, cancer cells had a higher chance of escaping the toxic drugs. This study
highlighted that even in patients who have the same type of cancer, treatment outcomes
can very because each patient’s tumor microenvironment is differently shaped and
formed. Not only are genetic and cellular markers necessary for making decisions
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regarding patient treatment, but a patient’s overall tumor microenvironment also needs to
be taken into consideration before any therapy is administered.
In chapter 3 of this dissertation, we investigated the role of membrane domains in
regulating cell signaling emanating from the ErbB2/ErbB3 receptor dimer. ErbB2 and
ErbB3 receptors have been found to be overexpressed in many cancers and together form
a very potent signaling unit. Since, unnecessary signaling from this receptor could be
highly deleterious for a cell, we wanted to investigate how these receptors might be
regulated by the membrane domains on the cell’s surface. We found that the amount of
signaling from these receptors was dependent on the degree of overlap between their
domains. Additionally, we also found that increasing the strength of the confinement of
receptors in domains only affected signaling when the receptors were completely
segregated. In essence, the domains tightly regulated the receptors’ proximity with each
other to control cell signaling events.
The pre-BCR appears at a critical junction in the development of B lymphocytes.
This is where the progenitor B cells decide whether to undergo apoptosis or to continue
to develop into a mature B cell. A subset of patients with B-cell acute lymphoblastic
leukemia also show expression of this receptor. In these patients, the leukemic cells
exploit the tonic signaling pathway to survive and proliferate indefinitely. Therefore,
understanding the regulation of this receptor is essential to devise strategies to combat
this cancer. We investigated tonic signaling emanating from this receptor using two
different BCP-ALL cell lines. In chapter 4, we created a spatial stochastic model of preBCR aggregation and populated the model with data acquired through SPT. We found
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differences in receptor aggregation and downstream signaling events based on the
characteristic difference between the two cell lines.

5.2 SIGNIFICANCE
Our group has been involved in building lattice based and lattice free models of
receptor signaling pathways with a focus on investigating the impact of spatial
heterogeneity on membrane surfaces (Mayawala et al., 2005b; a; 2006; Hsieh et al., 2008;
Costa et al., 2009; Hsieh et al., 2010; Costa et al., 2011; Pryor et al., 2013; Pryor et al.,
2015). In chapter 3 of this dissertation, we used and extended the 2-D spatial stochastic
model developed by Pryor et al., to investigate varying domain overlaps and receptor
confinement on ErbB2/ErbB3 signaling pathways (Pryor et al., 2015; Kerketta et al.,
2016). In the previous study, static spatial data gathered from SPT was used to create
confinement zones for receptors which represented membrane domains in which
receptors were “trapped” and had to pay a penalty for escape. This gave rise to spatial
inhomogeneity on the membrane surface by creating dense or sparse areas of receptor
population. We used the same principles in chapter 4 to build receptor domains from
static spatial data of pre-BCR that were specific for this cell type. These receptor domains
were used in conjunction with a 3-D spatial stochastic model of pre-BCR that simulated
receptor diffusion, aggregation and phosphorylation, thus shedding insight on tonic
signaling associated with this receptor.
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5.2.1 Lattice free model of immunoreceptor signaling
Lattice based stochastic simulations, which take into account the spatial effect of
receptor diffusion by displacing the molecules on a grid like membrane, have been used
to investigate signaling in the mature B cell receptor (BCR) (Tsourkas et al., 2012;
Mukherjee et al., 2013). However, spatial inhomogeneity existing on a biological
membrane cannot be accurately represented by grid like confinement domains as these
domains are dynamic with respect to time and are highly irregular in their shape and size.
Hence, a more accurate representation of these domains can be built through
reconstruction of some of the membrane domains observed during SPT. The pre-BCR
spatial stochastic model presented in chapter 4 is a lattice free model, with receptor
confinement zones recreated directly from experimental data, and hence might more
accurately represent the spatial inhomogeneity present on the membrane surface of the
immunoreceptors. Thus, this model can be used as a platform to simulate spatial
inhomogeneity in other immunoreceptors including the BCR and T cell receptor (TCR).

5.2.2 The 3-D spatial stochastic model
The need for developing a 3-D model arose from the need to investigate the effect
of spatial inhomogeneity on important cytoplasmic signaling molecules such as Syk in
the pre-BCR pathway. Syk diffuses in the cytoplasm and transduces signal downstream
of the pre-BCR. Thus, in order to capture the diffusion and reaction kinetics of Syk and
its impact on the pre-BCR signaling, a 3-D spatial stochastic model had to be developed.
This model holds the potential to simulate different cytoplasmic molecules important in
either the pre-BCR pathway or other receptor signaling pathways. Therefore, this model
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provides a platform for developing 3-D spatial stochastic models of other important
receptor pathways.

5.2.3 Aggregate sizes of immunoreceptor chains are directly obtained from the
model
Although SPT of receptors is extremely useful in generating data on the
diffusional and reaction dynamics of receptors on a live cell membrane, the low level of
receptor labeling renders some of the information such as sizes of higher order oligomers
inaccessible. In order to gain access to such information, computational models, that
simulate receptor reactions using basic parameters obtained through experimental
measurements, can be used to extrapolate the aggregate sizes formed in such receptor
systems. The pre-BCR spatial stochastic model presented here, uses basic parameters
obtained from SPT and experimental data to model formation of different sized
aggregates and present the oligomer size as a key output of the model. This is in contrast
to recent modeling efforts investigating the B cell receptor (BCR), where aggregation of
receptors was modeled implicitly and the actual oligomer sizes were unreported (Barua et
al., 2012; Mukherjee et al., 2013). Hence, this model can be used to simulate receptors
which undergo aggregation and where reporting of the distinct oligomer sizes is a key
requirement of the model simulations.

5.3 FUTURE INVESTIGATIONS
As mentioned in the above sections the 3-D spatial stochastic model of pre-BCR
can be used to explore other immunoreceptors that undergo aggregation. Moreover, other
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cytoplasmic molecules can be added to further refine the model. Below is a description of
potential future explorations in the pre-BCR signaling pathway.

5.3.1 Addition of Lyn specific domains on the membrane
One of the avenues that can be investigated is the effect of Lyn domains on the
pre-BCR signaling pathway. Since Lyn is a membrane bound molecule, there is likely to
be existence of Lyn rich domains on the membrane. It would be interesting to explore the
effect of both Lyn and receptor specific domains on the signaling pathway. However, in
order to reproduce Lyn specific domains on the in silico membrane, SPT with quantum
dots tagged to the membrane bound Lyn molecule will have to be utilized. This might be
experimentally challenging, however, if this objective is achieved then it would further
shed light on the recruitment of Lyn molecules from Lyn specific domains to pre-BCR
specific domains upon receptor aggregation.

5.3.2 Model parameter calibration with further experimental measurements
For the pre-BCR model, we relied heavily on data present in the literature for
parameters such as phosphorylation and dephosphorylation rates for the receptors, Lyn
and Syk molecules. To enable more accurate representation of tonic signaling, these
model parameters need to be measured directly in the pre-BCR cell lines used in the
experimental study. The model then needs to be recalibrated with the updated rates for
more precise estimations of tonic signaling events.
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APPENDICES
APPENDIX A: CHAPTER 3 SUPPLEMENT

Figure A.1: Electronmicroscopy image of pre-b cell
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APPENDIX B: RANDOM 3-D SIMULATION SPACE GENERATOR
close all; clear all; clc
datafilename = '08_25_17_Nalm6Run8' % save the simulation file with this
name'03_07_17b
%Receptor information
%[pBCR Lyn Syk] % Lyn
NP_rec = [71 7 959]; % [697 Nalm6] % if z is 1[syk338 #syk1918] % if z is 0.5[syk169
% syk959]
numdomain= [0] % domains,
%For 2-D
%NP_rec = [795]
NP = sum(NP_rec)
%Membrane information (in micrometer)
xlimmin = 0
xlimmax = 1.5
ylimmin = 0
ylimmax = 1.5
zlimmax = 0
zlimmin = -0.5
Membranevolume = xlimmax*ylimmax*abs(zlimmax)
% For 2_D
%MembraneArea = xlimmax*ylimmax
point_x = xlimmin + (xlimmax-xlimmin)*rand(NP,1)
point_y = ylimmin + (ylimmax-ylimmin)*rand(NP,1)
point_z = zlimmax + (zlimmin-zlimmax)*rand(NP_rec(3),1)
pBCR = [point_x(1:NP_rec(1)) point_y(1:NP_rec(1)) zeros(NP_rec(1),1)
zeros(NP_rec(1),1) ones(NP_rec(1),1)]
Boss = (ones*(1:NP_rec(1)))'
r_pBCR = [pBCR Boss zeros(NP_rec(1),1) zeros(NP_rec(1),1)]
np = NP_rec(1)+NP_rec(2)
Lyn = [point_x(NP_rec(1)+1:np) point_y(NP_rec(1)+1:np) zeros(NP_rec(2),1)
zeros(NP_rec(2),1) ]
Syk = [point_x(np+1:NP(end)) point_y(np+1:NP(end)) point_z zeros(NP_rec(3),1)]
pBCRdomainRec = 0
%r_Lyn = [Lyn 2*ones(NP_rec(2),1)]
%r_Syk = [Syk 3*ones(NP_rec(3),1)]
figure(1)
%plot(pBCR(:,1),pBCR(:,2),'or')
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plot3(pBCR(:,1),pBCR(:,2), pBCR(:,3),'ro', Lyn(:,1),Lyn(:,2),Lyn(:,3),'b*',
Syk(:,1),Syk(:,2),Syk(:,3),'go')
box on
xlabel('\mum, x','FontSize',20)
ylabel('\mum, y','FontSize',20)
zlabel('\mum, z','FontSize',20)
title('Simulation space','FontSize',18)
set(gca,'FontSize',10)
hold on
% set(gca,'xtick',linspace(xlimmin,xlimmax,3))
% set(gca,'XTickLabel',linspace(xlimmin,xlimmax,3))
% set(gca,'ytick',linspace(ylimmin,ylimmax,3))
% set(gca,'YTickLabel',linspace(ylimmin,ylimmax,3))
% set(gca,'ztick',linspace(zlimmin,zlimmax,3))
% set(gca,'ZTickLabel',linspace(zlimmin,zlimmax,3))
%set(gcf,'Position',[967 573 527 773])
%axis([xlimmin xlimmax ylimmin ylimmax zlimmin zlimmax])
save (datafilename)
%DIFFUSION
% read the domains
FIN=fopen('ContourInfo.txt','r');
NContour = fscanf(FIN,'%d',1);
Contour = cell(NContour,1);
CSize = fscanf(FIN,'%d',NContour);
for iContour=1:NContour
Contour{iContour} =fscanf(FIN,'%f',[CSize(iContour), 2]);
Contour{iContour} = Contour{iContour} - repmat([15, 27.5],CSize(iContour),1);
end
fclose(FIN);
%figure(1);
%clf
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MyColors = rand(5,3);
for iContour=1:5
plot(Contour{iContour}([1:end 1],1),Contour{iContour}([1:end 1],2),...
'Color',MyColors(iContour,:));
end
xlim([-0.2 1.7]);
ylim([-0.2 1.7]);
axis equal
legend('Pre-BCR','Lyn','Syk','Domain 1','2','3','4','5');
plot([0 1 1 0 0]*1.5,[0 0 1 1 0]*1.5,'k-');
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APPENDIX C: SCRIPT TO GENERATE INPUT FILES
%%
% Load data file
load 08_25_17_Nalm6Run8
%%
% Number of runs desired
q=8
StartFileNum=q;
EndFileNum=q;
%%
% Simulation Length [=] s
t=600;
%%
% Simulation time step
dt=0.00001;
% Print Frequency
printfreq=20;
N=t/dt;
%%
time=clock;
if time(2) < 10
savedir=strcat('',['0' num2str(time(2))],'_',num2str(time(3)),'_',num2str(time(1)2000),'/')
elseif time(3) < 10
savedir=strcat('',num2str(time(2)),'_',['0' num2str(time(3))],'_',num2str(time(1)2000),'/')
elseif time(2) < 10 && time(3) <10
savedir=strcat('',['0' num2str(time(2))],['0' num2str(time(3))],'_',num2str(time(1)2000),'/')
else
savedir=strcat('',num2str(time(2)),'_',num2str(time(3)),'_',num2str(time(1)-2000),'/')
end
mkdir(savedir)
%%
for jj = StartFileNum:EndFileNum
numrun=strcat('Run_',num2str(jj),'/');
if exist(strcat(savedir,numrun),'dir') == 0
mkdir(strcat(savedir,numrun))
end
fid = fopen(strcat(savedir,numrun,'BMIP'), 'wt');
fprintf(fid,'.\n');
fprintf(fid,'%10.0f%10.0f%10.0f # of
Particles\n',NP_rec(1),NP_rec(2),NP_rec(3));
fprintf(fid,'%10.7f Time Step [s]\n',dt);
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fprintf(fid,'%7.4f%7.4f%7.4f%7.4f%7.4f%7.4f Membrane
Boundaries\n',xlimmax,ylimmax,xlimmin,ylimmin,zlimmin,zlimmax);
fprintf(fid,'%10.0f Data Print Frequency\n',printfreq);
fprintf(fid,'%6.2f%3.0f Length of Simulation [s], # of Domains\n',t,numdomain);
fclose(fid);
fid2 = fopen(strcat(savedir,numrun,'InitialParticleLoc'),'wt');
for j = 1:size(pBCR,1)
fprintf(fid2,'%18.16f%18.16f%18.16f%2.0f%2.0f%3.0f%2.0f%2.0f\n',(r_pBCR(j,
1)),(r_pBCR(j,2)),(r_pBCR(j,3)),(r_pBCR(j,4)),(r_pBCR(j,5)),(r_pBCR(j,6)),(r_pBCR(j,
7)),(r_pBCR(j,8)))
end
fid3 = fopen(strcat(savedir,numrun,'InitialParticleLoc_lyn'),'wt');
for j = 1:size(Lyn,1)
fprintf(fid3,'%18.16f%18.16f%18.16f%2.0f\n',(Lyn(j,1)),(Lyn(j,2)),(Lyn(j,3)),(Ly
n(j,4)))
end
fid4 = fopen(strcat(savedir,numrun,'InitialParticleLoc_Syk'),'wt');
for j = 1:size(Syk,1)
fprintf(fid4,'%18.16f%18.16f%18.16f%2.0f\n',(Syk(j,1)),(Syk(j,2)),(Syk(j,3)),(Sy
k(j,4)))
end
mkdir(strcat(savedir,numrun,'Data_Files'))
end
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APPENDIX D: PRE-BCER SPATIAL STOCHASTIC SIMULATION PROGRAM
MODULE ModelConstants
! Variables defined in a module are accessible to any unit that uses the module
! General Constants
DOUBLE PRECISION, PARAMETER :: Pi = 3.14159265
!*Diffusion-Reaction Model Parameters*!
! NOTE base units are:
! length -- um (micrometer 1 um = 10^-6 m)
! time -- s (second)
! ** Diffusion **
DOUBLE PRECISION, PARAMETER :: DiffCoeff_Monomer = 0.16 ! receptor
DOUBLE PRECISION, PARAMETER :: EscapeProb = 0.2 !0.1; ! 0.0941 ! receptor
escape prob
DOUBLE PRECISION, PARAMETER :: Syk_DiffCoeff_Monomer = 17 ! um^2/s ??
DOUBLE PRECISION, PARAMETER :: Lyn_DiffCoeff_Monomer = 0.4 ! um^2/s
Stone et al. Nature Comm 2015
! ** Binding (dimerization)
! NOTE UnbindRad_<...> are the Smoldyn-style unbinding radii used to separate the
products of dissociation; they are normally set to 5x the BR
! Rec-Rec
DOUBLE PRECISION, PARAMETER :: BindRad_Dimer = 0.000215 ! (rec-rec) (use
0.000313 from e2/e3) and use sim area 25 nanometer square for 10. or 75 by 75 for 100
DOUBLE PRECISION, PARAMETER :: UnbindRad_RestDimer = BindRad_Dimer *
5 ! UBR
! Lyn-Rec
DOUBLE PRECISION, PARAMETER :: Lyn_BindRad_Dimer = 0.000228519!2.25e-4
! unique domain binding to iga for sh2 binding BR^2 is scaled up by [100 (iga) 20 (igb)]
! (2D Smoldyn: 1.4e-2 /um^2)
! value of BR=1.34e-5 um (dt=1e-5) obtained by trial and error from Smoldyn to
match the on-rate of 4.6e-5 /(s#/um^2)
double precision, dimension(3), parameter :: LynBindScaleFactor = [1.0, 1.0, 0.5] ![1.0,
1.0, 0.5]! rel. rates [unique dom, Igalpha(Ph>0), Igbeta(Ph>0)]
DOUBLE PRECISION, PARAMETER :: Lyn_UnbindRad_RestDimer =
Lyn_BindRad_Dimer * 5 ! the * 10 is for activated Ig sites; use it for all Lyn unbinding
double precision, parameter :: Lyn_available_fraction = 1 ! 1! only 3.5% of (unactivated) Lyn is in a state where it is able to bind receptor
! Syk-Rec
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DOUBLE PRECISION, PARAMETER :: Syk_BindRad_Dimer =0.00157424 !
represents Syk to Igb binding; others scaled in the code (see next line)
! double precision, dimension(2), parameter :: SykBindScaleFactor = [1.0, 3.0] ! relative
binding rates [Igalpha(Ph>0), Igbeta(Ph>0)]
! TODO change to this
double precision, dimension(4), parameter :: SykBindScaleFactor = [1.0/12.0, 1.0,
1.0/36.0, 1.0/3.0] ! relative binding rates [Igalpha(Ph=1,2), Igbeta(Ph=1,2)]
DOUBLE PRECISION, PARAMETER :: Syk_UnbindRad_RestDimer =
Syk_BindRad_Dimer * 5 ! UBR 0.0000111
! ** Dissociation (unbinding)
DOUBLE PRECISION, PARAMETER :: Dimer_off_rate= 0.164! Rec-Rec ! "true
dimer lifetime" based rate from Adam - 0.772 /s (697) , 0.164 /s (Nalm6)
DOUBLE PRECISION, dimension(2), PARAMETER :: Lyn_dimer_off_rate = [20.0,
0.12 ]! Lyn-Rec ! if Lyn_Site = 1, then first off rate, if Lyn_Site = 2, then second off rate
DOUBLE PRECISION, dimension(2), PARAMETER :: Syk_dimer_off_rate = [ 2.6,
0.63]! Syk-Rec ! if Syk_Site = 1, then first off rate, if Syk_Site = 2, then second off rate
! ** Phosphorylation **
! (Receptor)
! Lyn mediated phos rates depend on (Lyn phos state (InActive,Active) x substrate
ITAM state (P0,P1) )
! !! CAUTION !! The rates below have a factor of 10x or 100x for the inactive Lyn case
over the rate we estimated from Barua et al (4.93e-4 /s - 0.296 /s)
!
a factor of ~3-10 is justified by the inverse (Rec-Rec bond count):(total Rec
count) ratio (i.e. only 10-30% of receptors are bound at all)
!
the rate is much higher in another paper (0.5 /s in Weiss and 100 /s in
Tsourkas )
double precision, dimension(4), parameter :: Phos_rate = [ 30,15,100,50 ] ! /s Lyn
mediated phos rates by substrate and Lyn state: [IA(P0), IA(P1), A(P0), A(P1)]
double precision, dimension(2), parameter :: Phos_off_rate = [ 20, 40 ] ! receptor
dephos rate (/s) depends on initial state [P1,P2]
!double precision, dimension(4), parameter :: Phos_rate = [
100*0.000985,100*0.000493,0.296,0.148 ] ! /s Lyn mediated phos rates by substrate and
Lyn state: [IA(P0), IA(P1), A(P0), A(P1)]
!double precision, dimension(2), parameter :: Phos_off_rate = [ 1.0, 2.0 ] ! receptor
dephos rate (/s) depends on initial state [P1,P2]
! (Syk)
DOUBLE PRECISION, dimension(2), PARAMETER :: Syk_Phos_Rate = [100, 200] !
[IA,A] Syk-mediated for Unactivated syk & activated syk
! DOUBLE PRECISION, dimension(3), PARAMETER :: Syk_Phos_Rate = [0.0148,
1.48, 0.5]! [IA,A,self] Syk-mediated for Unactivated syk & activated syk + syk phos by
itself
! TODO (?) eliminate the self entry from Syk_Phos_Rate
! TODO (?) introduce separate Syk phos by Lyn rate
DOUBLE PRECISION, PARAMETER :: Syk_DePhos_Rate = 20.0 ! /s
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! (Lyn)
! !! CAUTION !! The rates below have a factor of 10x or 100x for the inactive Lyn case
DOUBLE PRECISION, dimension(2), PARAMETER :: Lyn_Phos_Rate = [30,100] !
[100*0.000493, 0.148] ! Lyn mediated [IA,A]
DOUBLE PRECISION, PARAMETER :: Lyn_Dephos_Rate = 20.0 ! /s
END MODULE ModelConstants
MODULE ParticleInfo
INTEGER, PARAMETER :: MaxAgg = 50; ! Largest expected aggregate (chain) length
integer, parameter :: MaxContour = 500; ! largest expected number of points defining a
contour
integer, parameter :: MaxDom = 20 ! maximum expected number of domains
! Put generally relevant variables here instead of in the Sytem_Information struct
! variables at-large relevant to the state of the system
integer :: NumDomains,DomainParticleCount(MaxDom) ! number of domains and
particles in each of them
!
double precision, dimension(2) :: XBox, YBox, ZBox ! to replace
System_Info%SimSpace_Boundary
integer :: Syk_Pick_Count=0, Syk_Intrinsic_Count=0, &
Syk_PickNoReaction=0, Syk_FreePick=0, Syk_BoundPick=0,
Syk_BoundPick_Unbound=0, &
Syk_DiffCall_Count=0, Syk_Diff_Reaction=0, Syk_Diff_NoReaction=0, &
Syk_BindCall_Count=0, Syk_Bind_Reaction=0, Syk_Bind_NoReaction=0, &
Enc_EligAggCount=0, Enc_BossCount=0
integer, dimension(2) :: Enc_SysPhosCount
double precision :: SysMinDist = 100
double precision, parameter :: SykLayerDepth = 1.0e-1 ! thickness of layer close to the
membrane where Syk could possibly interact with membrane bound species
! Variable types specific to the simulation : domains, molecule types (receptor, lyn, syk)
type Domain ! part of MODULE ParticleInfo
integer :: ContourLength ; ! number of points in the contour (last point is the same as
the first)
double precision :: Contour(MaxContour,2) ;! contour defining the domain
! double precision :: EscapeProb ! future; for now use a universal value
double precision :: Xlim(2) ! max and min x coordinates for quick checking
double precision :: Ylim(2) !
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end type Domain
TYPE Lyn ! part of MODULE ParticleInfo
DOUBLE PRECISION :: Position(3) ! (x1,y1)
INTEGER :: Receptor_ID !This will be zero if the Lyn is free;
INTEGER :: Phos ! 0= unactive, 1 = active
INTEGER :: Itam_site ! 0 = unbound, 1 = Igalpha, 2 = Ig beta
INTEGER :: Lyn_site ! 0 = unbound, 1 = Unique, 2 = SH2
END TYPE Lyn ! part of MODULE ParticleInfo
TYPE Syk ! part of MODULE ParticleInfo
DOUBLE PRECISION :: Position(3) ! (x1,y1)
INTEGER :: Receptor_ID ! !This will be zero if the Lyn is free
INTEGER :: Phos ! 0 = unactive, 1 = active (catalytic site is activated by adjacent
Syk)
INTEGER :: Phos_2 ! 0 = unactive, 1 = active (other phos site activated by adjacent
Lyn)
INTEGER :: Itam_site ! 0 = unbound, 1 = Igalpha, 2 = Igbeta
INTEGER :: Syk_site ! 0 = unbound, 1 = bound through 1 SH2 only, 2 = bound
through 2 SH2s (tandem SH2s)
! TODO: check that Syk_site correctly reflects underlying SH2 state
!
also check what happens if the ITAM site is phoshporylated AFTER Syk was
bound
! TODO? Syk type could be merged with the Lyn type
END TYPE Syk ! part of MODULE ParticleInfo
TYPE Molecule ! = Receptors ! part of MODULE ParticleInfo
! position - current
DOUBLE PRECISION :: Position(3) ! (x1,y1,z1)
DOUBLE PRECISION :: r_Squared ! r^2 of receptor calculated each pdt step
DOUBLE PRECISION :: LastOnOffTime ! the time this particle got into the current
aggregate configuration
integer :: RecID ! same as the index, useful for array manipulation
integer :: Domain ! domain ID consistent with current position
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! binding configuration
INTEGER :: Bond
! 0 = No bond, 1 = 1 bonds, 2 = 2 bonds
INTEGER :: BoundRec_1 ! ID of receptor bound on site 1
INTEGER :: BoundRec_2 ! ---------------------------- 2
! containing aggregate
INTEGER :: Boss
! ID of the boss receptor of the containing aggregate
INTEGER :: Agg_Size
! size (number of receptors) of the containing aggregate
! itam state
INTEGER :: Iga_Phos ! 0= unphosphorylated, 1 = singly phosphorylated, 2 = double
phosphorylated
INTEGER :: Iga_Lyn ! 0= no Lyn, some number is Lyn ID
INTEGER :: Iga_Syk ! 0= no Syk, some number is Syk ID
INTEGER :: Igb_Phos ! 0= unphosphorylated, 1 = singly phosphorylated, 2 = double
phosphorylated
INTEGER :: Igb_Lyn ! 0= no Lyn, some number is Lyn ID
INTEGER :: Igb_Syk ! 0= no Syk, some number is Syk ID
END TYPE Molecule ! part of MODULE ParticleInfo
TYPE SystemInformation ! part of MODULE ParticleInfo
! holds the current state of the system for handy access
!
! TODO -- these global variables could simply be declared as such
!
within the ParticleInfo module, I am not sure there is
!
a need to keep them bundled like this
CHARACTER(80) :: Save_Directory ! Parameter
INTEGER :: Num_Particles ! Parameter , number of receptors -- **duplicated** by
Total_Rec_Count
integer :: Num_Aggregates ! Variable, number aggregates of receptors
INTEGER :: AggSizeCount(MaxAgg) ! Variable, keeps track of aggregate size
distribution
DOUBLE PRECISION :: Time_Step ! Parameter
DOUBLE PRECISION :: SimSpace_Boundary(6) ! Parameter
INTEGER :: Print_Frequency ! Parameter,
DOUBLE PRECISION :: Simulation_Time ! Parameter (?)
INTEGER :: Number_Domains ! Parameter
DOUBLE PRECISION :: Current_Simulation_Time ! variable, system time
LOGICAL :: Reaction ! flag, indicates whether a reaction occurred in the latest
update
INTEGER :: Total_Rec_Count, Total_Lyn_Count, Total_Syk_Count ! parameter
(number of spatial particles, bound or not)
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INTEGER :: Free_Lyn_Count, Free_Syk_Count ! global state variable
INTEGER :: OutputLevel ! Parameter, switch
END TYPE SystemInformation ! part of MODULE ParticleInfo
! the state of the system is represented by instances of the above defined types
! part of MODULE ParticleInfo
TYPE(Molecule), POINTER :: RecMolecule(:), RecMoleculeInitial(:),
RecMoleculePrevious(:)
TYPE(Lyn),
POINTER :: LynMolecule(:), LynMoleculeInitial(:),
LynMoleculePrevious(:)
TYPE(SYK), POINTER :: SykMolecule(:), SykMoleculeInitial(:),
SykMoleculePrevious(:)
type(Domain), pointer :: Dom(:)
TYPE(SystemInformation) :: System_Info
contains ! ! part of MODULE ParticleInfo
function InDomain(Coord,DomID) result(Inside)
implicit none
real*8, intent(in) :: Coord(2) ! (x,y) to test
integer, intent(in) :: DomID ! index of domain
logical :: OnBoundary ! rarely this might be true
logical :: Inside ! true if in the domain, false otherwise
integer :: Counter(2) ! counts intersections (left,right)
integer :: i1,i2 ! indices of the contour segment
real*8 :: Xa,Xb,Ya,Yb,XP,YP, Xint
! NOTE: contours are assumed closed "by hand"
!
i.e. we pretend the first point in the list FOLLOWS the last point
!
but they SHOULD NOT be identical
! check if there is a domain by the index specified
if (NumDomains < DomID) then
write(*,*) ' InDomain: requested domain ',DomID,' does not exist'
return
end if
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! algorithm idea:
! loop through the segments (12),(23),...(end-1 end),(end 1)
! for segment (ij) check if
! (a) YP between y(i), y(j)
! (b) if (a), is XP to the left of point where the (ij) segment intersects the horizontal
line y=YP
! --> count the times (a)(b) are true
! (XP,YP) is inside the contour if and only if* the count is odd
!
! * caveat -- if YP equals one or more of the y(k)'s, special procedure
! use these for clarity
XP = Coord(1)
YP = Coord(2)
! count the left (Xint < Xp) and right (xint > Xp) intersections
Counter = 0
! just in case the point is exactly on the boundary
OnBoundary = .false.
! default answer is outside
Inside = .false.
do i1=1,Dom(DomID)%ContourLength
! index of points in the contour segment
i2 = i1+1
if (i2>Dom(DomID)%ContourLength) i2=1
! xy of the two ends of the segment
Xa = Dom(DomID)%Contour(i1,1)
Xb = Dom(DomID)%Contour(i2,1)
Ya = Dom(DomID)%Contour(i1,2)
Yb = Dom(DomID)%Contour(i2,2)
! check for "YP between Ya,Yb
if ( (Yb - YP) * (YP - Ya) > 0 ) then
! x coordinate of the intersection
Xint = Xa + (Xb - Xa) * (YP - Ya) / (Yb - Ya)
if(Xint < XP) then
Counter(1) = Counter(1) + 1
else if (Xint > XP) then
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Counter(2) = Counter(2) + 1
else
write(*,*) 'InDomain warning -- point ',XP,YP,' is on the boundary of domain
',DomID
OnBoundary = .true.
endif
! TODO: also figure out what to do when Ya=Yb or when
! the product (Yb - YP) * (YP - Ya)=0 (i.e. YP = Ya or Yb)
end if
end do
if (modulo(Counter(1),2)==1) Inside = .true.
end function InDomain ! part of MODULE ParticleInfo
END MODULE ParticleInfo
!! NOTE: Moved subroutines to the end of the file, preferably in the order of
dependencies
!!
-- i.e. main program first, then subroutines called by the program, etc.
PROGRAM Pre_BCR
USE mtmod ! used to generate random numbers
USE ParticleInfo
USE ModelConstants
IMPLICIT NONE
! Declare variables local to the main program
double precision :: DiffSTD, DiffSTD_Lyn, LynDiffSTD, DiffSTD_Syk!! diffusion
standard deviation
DOUBLE PRECISION :: UnBindProb, LynBindProb, LynUnBindProb
double precision :: PhosProb(2), DePhosProb(2) ! used for receptors and also for Syk
(two sites, one act.by Lyn, one by Syk)
DOUBLE PRECISION :: SykBindProb, SykUnbindProb ! SykTotalPhosProb
double precision :: ProbVec(5), SumProb, Prob_1, Prob_2 ! used in choosing the
phosphorylation / dephos site
integer :: PhosIndex, chosen_site
! used in choosing the phosphorylation /
dephos site
integer :: PhosLevel
! use to count phosphorylation of ITAMs
!
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DOUBLE PRECISION :: r1, r2, x1, y1, z1, w1, w2, rannum, r3 ! Random Numbers
INTEGER :: k, i, m, ii, w, lifecount, p, seed, seed_random(8), CurrentSpecies, next,size,
ic, d, f ! counters
integer :: iBR, iITAM, BoundRecID, LynRecID, NeighborLynID, NeighborLynState,
NeighborSykState, NeighborSykID,SykRecID !
INTEGER :: iLyn, iSyk, B1_Lyn, B2_Lyn
INTEGER :: Boss, Bond_count_i,Bond_count_k, v, c, NewBoss
INTEGER :: NP, Lyn_num, Syk_num, NPT ! number of particles (receptors only /Lyn,
Syk / total)
INTEGER :: printfreq, nd, domainnum, BoundRec_1, BoundRec_2! data print
frequency, number of frames, number of domains
INTEGER :: Current_bond, Bond_Count! Used for select case switching
DOUBLE PRECISION :: st, dt, t, pdt! time step, time, system time, timestep per particle
DOUBLE PRECISION :: xlimmax, ylimmax,xlimmin,ylimmin, zlimmin, zlimmax !
width of simulation (x axis), length (y axis) of simulation
DOUBLE PRECISION :: MSD ! MSD calculation
CHARACTER*200 fnstring ! Filename string
CHARACTER(80) :: outdir ! extra path info for HPC
LOGICAL :: Reaction
INTEGER*8 :: N, frames, datacut, moves, j,tt,o,y ! Number of moves, number of
frames, cycles until print is needed, total number of moves, move counter
integer :: ParticleDomain(10)
!!!!!!! DO NOT USE FILE # 5 (DEFAULT INPUT FILE NUMBER) OR 6 (DEFAULT
OUTPUT FILE NUMBER) !!!!!!
WRITE(*,*) 'FORTRAN Simulation Started'
! Open input files
OPEN (1,file='BMIP')
OPEN (2,file='InitialParticleLoc')
OPEN (3,file='DomainLimits')
OPEN (112,file = 'InitialParticleLoc_lyn')
OPEN (13,file = 'InitialParticleLoc_Syk')
open(17,file = 'ContourInfo.txt'); ! domain contours
print *, 'Initializing:'
print *, '

reading BMIP file..'

! Read in values from input file
READ(1,107) outdir ! HPC Path info
write(*,*) outdir
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READ(1,100) NP,Lyn_num,Syk_num ! # of particles - for now, receptors only -TODO : input lyn, syk counts in BMIP
write(*,*) NP,Lyn_num,Syk_num
READ(1,101) dt ! Time step [s]
READ(1,102) xlimmax,ylimmax,xlimmin,ylimmin, zlimmin, zlimmax ! simulation
boundaries
! write(*,*) 'Sim boundaries:',xlimmax,ylimmax,xlimmin,ylimmin, zlimmin, zlimmax
READ(1,105) printfreq ! data print frequency
READ(1,106) t, NumDomains ! simulation length [s], # of domains
! write(*,*) t, NumDomains
100 FORMAT(I10,I10,I10)
101 FORMAT(F10.7)
102 FORMAT(F7.4,F7.4,F7.4,F7.4,F7.4,F7.4)
105 FORMAT(I10)
106 FORMAT(F6.2,I3)
107 FORMAT(a)
CLOSE(1)
! Set System Info
System_Info%Save_Directory = outdir
System_Info%Num_Particles = NP ! NP, "Particles" refers to receptors for now
System_Info%Total_Rec_Count = NP
System_Info%Num_Aggregates = NP
System_Info%AggSizeCount = 0
System_Info%AggSizeCount(1) = NP
System_Info%Time_Step = dt
System_Info%SimSpace_Boundary(1) = xlimmax
System_Info%SimSpace_Boundary(2) = ylimmax
System_Info%SimSpace_Boundary(3) = xlimmin
System_Info%SimSpace_Boundary(4) = ylimmin
System_Info%SimSpace_Boundary(5) = zlimmin
System_Info%SimSpace_Boundary(6) = zlimmax
write(*,*) 'Simulation Box boundaries: '
write(*,*) 'x [',xlimmin,xlimmax,']'
write(*,*) 'y [',ylimmin, ylimmax,']'
write(*,*) 'z [',zlimmin, zlimmax,']'
System_Info%Print_Frequency = printfreq
System_Info%Simulation_Time = t
System_Info%Current_Simulation_Time = 0
System_Info%Reaction = .false.
System_Info%Total_Lyn_Count = Lyn_num !1592 !
System_Info%Total_Syk_Count = Syk_num !3844 !
System_Info%Free_Lyn_Count = Lyn_num! 1592 !
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System_Info%Free_Syk_Count = Syk_num! 3844 !
! *** domain stuff ***
allocate(Dom(NumDomains)) ! allocate memory for the required number of domains
read(17,*) nd ! number of domains in the contour file
! make sure there are enough contours
if(nd < NumDomains) then
write(*,*) 'Error: ', NumDomains, ' domains specified, found only ',nd
return
end if
! write(*,*) 'There are ',nd,' contours in the input file.'
! write(*,*) 'We are looking for ',NumDomains,' contours..'
read(17,*) Dom(:)%ContourLength
do i=1,NumDomains
write(*,*) 'Domain ',i,' has ', Dom(i)%ContourLength, ' points.'
read(17,*) Dom(i)%Contour(1:Dom(i)%ContourLength,1)
read(17,*) Dom(i)%Contour(1:Dom(i)%ContourLength,2)
! shift the domains -- TODO take this out and put shited coordinates into a file
Dom(i)%Contour(1:Dom(i)%ContourLength,1) =
Dom(i)%Contour(1:Dom(i)%ContourLength,1) - 15.0
Dom(i)%Contour(1:Dom(i)%ContourLength,2) =
Dom(i)%Contour(1:Dom(i)%ContourLength,2) - 27.5
Dom(i)%Xlim(1) = minval(Dom(i)%Contour(1:Dom(i)%ContourLength,1))
Dom(i)%Xlim(2) = maxval(Dom(i)%Contour(1:Dom(i)%ContourLength,1))
Dom(i)%Ylim(1) = minval(Dom(i)%Contour(1:Dom(i)%ContourLength,2))
Dom(i)%Ylim(2) = maxval(Dom(i)%Contour(1:Dom(i)%ContourLength,2))
write(*,*) '

bounds -- x:',Dom(i)%Xlim(:),' y:',Dom(i)%Ylim

!!$ do ii=1,Dom(i)%ContourLength
!!$
write(*,*) ' Dom ',i,' point
',ii,'x=',Dom(i)%Contour(ii,1),'y=',Dom(i)%Contour(ii,2)
!!$ end do
end do
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close(17)

System_Info%OutputLevel = 1
! Suggestion: 1 - one line per actual reaction, format for reading in matlab etc.
!
2 - details eg. agg membership
!
3 - debug stuff, what particle came in, intermediate steps etc
! *** end of inputs ***
! Create output files
open(4, file=TRIM(outdir)//'/TrueDimerLifeTimes') ! dimer lifetimes from the actual
simulation, not the frame rate
open(7, file=TRIM(outdir)//'/MSDData')
! MSD info written to according to
frame rate, calculated each dt
open(8, file=TRIM(outdir)//'/TimeToPhos')
! time to phosphorylation for each
dimer
open(9, file=TRIM(outdir)//'/PhosLifetimes') ! Phosphorylation time
open(10,file=TRIM(outdir)//'//DomainExitInf') ! Exit rate info
! Output file header lines
WRITE(7,*) 'MSD' !
WRITE(4,*) 'Reac ',' Time Step ', ' i ', ' k ', ' AggSize ',' AggSize ',' AggSize '
! Calculate number of moves
N=t/dt
! we select from among all rec,lyn,syk, so this is what sets the effective time step
NPT = System_Info%Total_Rec_Count + System_Info%Total_Lyn_Count +
System_Info%Total_Syk_Count
! Calculate number of data frames to record and store as an integer
frames = INT(printfreq*t)
! Number of frames to write out
datacut = INT((N*NPT)/(printfreq*t)) ! Iterations (steps) one frame
! Give dimensions for the arrays and matrices
ALLOCATE (RecMolecule(System_Info%Total_Rec_Count))
ALLOCATE (LynMolecule(System_Info%Total_Lyn_Count))
ALLOCATE (SykMolecule(System_Info%Total_Syk_Count))
ALLOCATE (RecMoleculeInitial(System_Info%Total_Rec_Count))
ALLOCATE (LynMoleculeInitial(System_Info%Total_Lyn_Count))
ALLOCATE (SykMoleculeInitial(System_Info%Total_Syk_Count))
ALLOCATE (RecMoleculePrevious(System_Info%Total_Rec_Count))
ALLOCATE (LynMoleculePrevious(System_Info%Total_Lyn_Count))
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ALLOCATE (SykMoleculePrevious(System_Info%Total_Syk_Count))
! Read intial position of Receptor Molecule
WRITE(*,*) ' read initial particle positions..'
DO k = 1,System_Info%Total_Rec_Count
READ(2,103) &
RecMolecule(k)%Position(1),RecMolecule(k)%Position(2), &
RecMolecule(k)%Position(3),RecMolecule(k)%Bond,
RecMolecule(k)%Agg_Size, &
RecMolecule(k)%Boss, RecMolecule(k)%BoundRec_1,
RecMolecule(k)%BoundRec_2
RecMolecule(k)%RecID = k ! restored 02-23-2017
! use modulo to shift all initial positions into the simulation box
! should work if (1) modulo is always non-negative (mod(5,3)=2 and mod(-1,3)=3)
!
(2) xlimmax > xlimmin, same for the y bounds
RecMolecule(k)%Position(1) = xlimmin + mod( RecMolecule(k)%Position(1),
xlimmax-xlimmin)
RecMolecule(k)%Position(2) = ylimmin + mod( RecMolecule(k)%Position(2),
ylimmax-ylimmin)
RecMolecule(k)%Position(3) = 0 !set z position to zero by hand

1103 FORMAT(F18.10,F18.10,F18.10,I2,I2,I6,I6,I6)
if (System_Info%OutputLevel>=1) &
write(*,&
FMT="('RecID ',I3,' Coord ',3(' ',f10.6),' Bond Size Boss Buddies ',5(I3,' '))"),&
k, RecMolecule(k)%Position,&
RecMolecule(k)%Bond, RecMolecule(k)%Agg_Size, RecMolecule(k)%Boss, &
RecMolecule(k)%BoundRec_1, RecMolecule(k)%BoundRec_2

103 FORMAT(F18.16,F18.16,F18.16,I2,I2,I3,I2,I2)
END DO
CLOSE(2)
! Reading of lyn paramters
WRITE (*,*) 'read lyn positions here'
DO iLyn = 1,System_Info%Total_Lyn_Count
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READ (112,1104) &
LynMolecule(iLyn)%Position(1), LynMolecule(iLyn)%Position(2), &
LynMolecule(iLyn)%Position(3), LynMolecule(iLyn)%Receptor_ID
1104 FORMAT(F18.16,F18.16,F18.16,I2)
! use modulo to shift all initial positions into the simulation box
! should work if (1) modulo is always non-negative (mod(5,3)=2 and mod(-1,3)=3)
!
(2) xlimmax > xlimmin, same for the y bounds
LynMolecule(iLyn)%Position(1) = xlimmin + mod(LynMolecule(iLyn)%Position(1),
xlimmax-xlimmin)
LynMolecule(iLyn)%Position(2) = ylimmin + mod(LynMolecule(iLyn)%Position(2),
ylimmax-ylimmin)
LynMolecule(iLyn)%Position(3) = 0
LynMolecule(iLyn)%Phos = 0
LynMolecule(iLyn)%Itam_site = 0
LynMolecule(iLyn)%Lyn_site = 0
! TODO -- really not much info here, this is just to avoid error messages
if (LynMolecule(iLyn)%Receptor_ID > 0) then
LynMolecule(iLyn)%Itam_site = 1
LynMolecule(iLyn)%Lyn_site = 1
endif
if (System_Info%OutputLevel>=1) &
write(*,FMT="('LynID ',I3,' Coord ',3(' ',f18.16),' Rec ',i2)"), iLyn,
LynMolecule(iLyn)%Position,&
LynMolecule(iLyn)%Receptor_ID
END DO
CLOSE(112)
WRITE (*,*) 'read syk positions here'
DO iSyk = 1,System_Info%Total_Syk_Count
READ (13,1105) &
SykMolecule(iSyk)%Position(1), SykMolecule(iSyk)%Position(2), &
SykMolecule(iSyk)%Position(3), SykMolecule(iSyk)%Receptor_ID
! use modulo to shift all initial positions into the simulation box
! should work if (1) modulo is always non-negative (mod(5,3)=2 and mod(-1,3)=3)
!
(2) xlimmax > xlimmin, same for the y bounds
SykMolecule(iSyk)%Position(1) = xlimmin + mod(SykMolecule(iSyk)%Position(1),
xlimmax-xlimmin)
SykMolecule(iSyk)%Position(2) = ylimmin + mod(SykMolecule(iSyk)%Position(2),
ylimmax-ylimmin)
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SykMolecule(iSyk)%Position(3) = - mod(abs(SykMolecule(iSyk)%Position(3)),
abs(zlimmax-zlimmin))
SykMolecule(iSyk)%Itam_site=0;
SykMolecule(iSyk)%Syk_site=0;
if (SykMolecule(iSyk)%Receptor_ID > 0) then
! TODO: this should be updated when the input files are
SykMolecule(iSyk)%Itam_site=1;
SykMolecule(iSyk)%Syk_site=1;
endif
SykMolecule(iSyk)%Phos = 0
1105 FORMAT(F18.16,F18.16,F19.16,I2)
! NOTE -- because the z coordinate is negative, you need 3 extra characters
!
using f18.16 shifts the read and the final decimal is read as the
!
next thing, i.e. the bound receptor
if (System_Info%OutputLevel>=1) &
write(*,FMT="('SykID ',I3,' Coord ',3(' ',f18.16),' Rec ',i2)"), iSyk,
SykMolecule(iSyk)%Position,&
SykMolecule(iSyk)%Receptor_ID
END DO
CLOSE(13)

! TODO: either read the initial positions of Lyn and Syk from a file (eg. two new input
files)
!
or generate random initial positions right here
!
one way or another, positions of Lyn and Syk should be set up here
! Calculate Diffusion Standard Deviation for each species type
DiffSTD = sqrt(2*DiffCoeff_Monomer*dt) ! only one type is wortth pre-calculating
DiffSTD_Lyn = sqrt(2*Lyn_DiffCoeff_Monomer*dt)
DiffSTD_Syk = sqrt(2*Syk_DiffCoeff_Monomer*dt)
!DiffSTD(1) = sqrt(2*DiffCoeff_Monomer*dt) ! Activated receptor: R
!DiffSTD(2) = sqrt(2*(DiffCoeff_Monomer/Agg_Size)*dt) ! Resting Receptor: RR
! Define Initial Positions and states
! .. as copies of the initial large particle structs
RecMoleculeInitial = RecMolecule
LynMoleculeInitial = LynMolecule
SykMoleculeInitial = SykMolecule
! also the "Previous" set for comparing at periodic printouts
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RecMoleculePrevious = RecMolecule
LynMoleculePrevious = LynMolecule
SykMoleculePrevious = SykMolecule
! initial Lyn, Syk and Phos states
! TODO: This only works for the "everything off" initial condition
RecMolecule%Iga_Phos = 0 ! 0= unphosphorylated, 1 = singly phosphorylated, 2 =
double phosphorylated
RecMolecule%Iga_Lyn = 0! 0 no Lyn, some number is Lyn ID
RecMolecule%Iga_Syk = 0 ! 0 no Syk, some number is Syk ID
RecMolecule%Igb_Phos = 0 ! 0= unphosphorylated, 1 = singly phosphorylated, 2 =
double phosphorylated
RecMolecule%Igb_Lyn = 0! ! 0 no Lyn, some number is Lyn ID
RecMolecule%Igb_Syk = 0 ! 0 no Syk, some number is Syk ID
RecMolecule%Domain = 0! assume free
!Define initial boss
RecMolecule%Boss = RecMolecule(:)%Boss ! ??
!Initialize the last on-off time
RecMolecule%LastOnOffTime = 0 !
! *** identify the initial domain for each particle ***
DomainParticleCount = 0 ! set the counte to zero for each domain
do i=1,NP
ParticleDomain=0
do ii=1,NumDomains
if(InDomain(RecMolecule(i)%Position(1:2),ii)) then
ParticleDomain(ii)=1
RecMolecule(i)%Domain = ii
endif
end do
if (RecMolecule(i)%Domain>0) &
DomainParticleCount(RecMolecule(i)%Domain) =
DomainParticleCount(RecMolecule(i)%Domain)+1
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! formatted printout of initial receptor positions and containing domains
write(*,*) 'RecID=',i,' Coord ',RecMolecule(i)%Position(1:2),' Dom ',
RecMolecule(i)%Domain, ' InDom',sum(ParticleDomain(1:5))
!write(*,*) RecMolecule(i)%Position(1:2), RecMolecule(i)%Domain
end do
write(*,*) 'Total receptors: ', System_Info%Total_Rec_Count,' by domain: ',
DomainParticleCount(1:NumDomains),&
' untrapped: ', System_Info%Total_Rec_Count sum(DomainParticleCount(1:NumDomains))
! Initialize Time counter
st=0 ! Time
m=0 ! writing filename counter
lifecount=0 ! lifetime update counter
p=0 ! print counter
! Initialize dephosphorylation event counter
!dephosevent=0
! Generate seed from system clock
CALL SYSTEM_CLOCK(COUNT=seed)
! Seed grnd() ! USE THIS FOR SIMULATIONS
seed=1234 ! fixed seed ensures the same random numers each time, USE FOR
DEVELOPMENT ONLY
if (System_Info%OutputLevel >=1) write(*,*) 'WARNING: Using fixed random
seed:',seed
CALL sgrnd(seed)
! Calculate number of loop steps
moves=N*NPT
! Calculate time step per particle
pdt=dt/NPT
! Main simulation loop
DO j=1,moves
! Update Time
st=j*pdt
System_Info%Current_Simulation_Time = st
! *** Diffusion & Kinetic Portion of Code ***
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! Pick particle to move/react from among ALL particles,
! i.e. receptors, Lyn, Syk free or bound
tt =
System_Info%Total_Rec_Count+System_Info%Total_Lyn_Count+System_Info%Total_
Syk_Count
if (System_Info%OutputLevel >=2) write(*,*) 'Main loop pass.. Particle counts:', &
'Total:',tt,&
'Rec:',System_Info%Total_Rec_Count,&
'Lyn:',System_Info%Total_Lyn_Count,&
'Syk:',System_Info%Total_Syk_Count
i = 1 + int(tt * real(grnd(), 16)) ! grnd() is simple "real", we convert it to double -- this
version is ok on a Mac
!i = 1 + int(tt * real(grnd())) ! grnd() is simple "real", we convert it to double -- need
this for PC ?
if (i>tt) i=tt
if (System_Info%OutputLevel >=2) write(*,*) 'Chosen particle: ', i
! [re]set the reaction indicator to false
System_Info%Reaction=.false.
! *** diffusion, binding, and unbinding (d/b/u) ***
if (i <= System_Info%Total_Rec_Count) then ! this branch for receptors
! ** Receptor Branch (d/b/u) **
if (System_Info%OutputLevel >=2) write(*,*) 'DBU - Receptor no.',i

! diffusion, binding, and unbinding are implemented by aggregate (bosses only)
IF (RecMolecule(i)%Boss == i .AND. RecMolecule(i)%BoundRec_1 == 0) THEN
! diffusion also checks for binding (if it occurs, System_Info%Reaction will be set
to true)
CALL ParticleDiffuse(i, DiffSTD / RecMolecule(i)%Agg_Size )
! unbinding only happens for bosses that have not undergone binding
IF (RecMolecule(i)%Agg_Size > 1 .and. (System_Info%Reaction .eqv. .false.) )
THEN
rannum = grnd()
UnbindProb = Dimer_off_rate * (RecMolecule(i)%Agg_Size - 1) * dt
IF (rannum <= UnbindProb) THEN ! undimerize
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CALL UnbindReaction(i)
System_Info%Reaction=.true.
END IF
END IF
END IF ! if this particle is a boss
! ** end of Receptor branch for diffusion, binding and unbinding (d/b/u) **
else if (i <= (System_Info%Total_Rec_Count + System_Info%Total_Lyn_Count))
then ! Lyn branch
! ** Lyn d/b/u/ branch **
iLyn = i-System_Info%Total_Rec_Count
if (System_Info%OutputLevel >=2) write(*,*) 'DBU - Lyn no.',iLyn
IF (LynMolecule(iLyn)%Receptor_ID == 0) THEN
! if this Lyn is free, then it diffuses and may bind to a receptor
CALL LynDiffuse (iLyn, DiffSTD_Lyn)
ELSE
! if bound to a receptor, it may unbind
rannum = grnd()
! The lyn off-rate depends on how it is bound to the receptor- through it's unique
domain or SH2
UnBindProb=Lyn_dimer_off_rate(LynMolecule(iLyn)%Lyn_site)*dt ! Lyn_site =
1 (unique domain) OR Lyn_site =2 (SH2 domain)
IF (rannum <= UnbindProb) THEN ! unbind
CALL LynUnbindReaction(iLyn)
System_Info%Reaction=.true.
END IF
END IF
! ** end of Lyn d/b/u branch **
else if (i <= (System_Info%Total_Rec_Count + System_Info%Total_Lyn_Count +
System_Info%Total_Syk_Count)) then ! Syk branch
! ** Syk d/b/u branch **
iSyk = i-System_Info%Total_Rec_Count - System_Info%Total_Lyn_Count
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if (System_Info%Reaction .or. System_Info%OutputLevel >=2) write(*,*) 'DBU Syk no.',iSyk
Syk_Pick_Count = Syk_Pick_Count + 1
IF (SykMolecule(iSyk)%Receptor_ID == 0) THEN
! if this Syk is free, then it diffuses and may bind to a receptor
Syk_FreePick = Syk_FreePick+1
CALL SykDiffuse (iSyk, DiffSTD_Syk)
ELSE
! if this Syk is bound to a receptor, it may unbind (diffusion triggered by the
aggregate..)
! TODO : check that probabilities are right
Syk_BoundPick = Syk_BoundPick+1
! Syk dimer off rate will depend on SH2 binding site (1=Iga, 2=Igb)
UnbindProb = Syk_dimer_off_rate(SykMolecule(iSyk)%Syk_site) * dt
rannum = grnd()
IF (rannum <= UnbindProb) THEN ! undimerize
CALL SykUnbindReaction(iSyk)
System_Info%Reaction=.true.
Syk_BoundPick_Unbound = Syk_BoundPick_Unbound + 1
END IF
END IF
if (System_Info%Reaction .eqv. .false.) Syk_PickNoReaction =
Syk_PickNoReaction + 1
! ** end of Syk d/b/u branch **
! ** Rec, Lyn, Syk d/b/u branches meet **
end if
! done with diffusion, binding, unbinding
! may have resulted in aggregate changes (System_Info%Reaction)
! next, implement intrinsically triggered processes, OTHER THAN dissociation
! each process type is visited when the PARTICLE THAT IT AFFECTS is chosen
if (System_Info%Reaction .eqv. .false.) then ! all intrinsic reactions are off if a
binding/unbinding reaction has occurred
! intrinsic reactions next ...
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if (i <= System_Info%Total_Rec_Count) then ! intrinsic branch for receptors only
! Principle: Intrinsic reactions of receptors are triggered via receptors - 05-18-2017
! ALL receptors picked will go through this branch (not only bosses)
! the only reactions we are concerned with here are receptor phos and dephos
! the rates depend on presence of and state of Lyn on an adjacent receptor
! and of the phos state of each site
! ** Compute probabilities for intrinsic reactions **
! they apply to all receptors, but are treated as mutually exclusive
! with binding and unbinding
! NOTE: Lyn and Syk binding are not intrinsic reactions (if Lyn and Syk are
spatial)
! * Phosphorylation / Dephosphorylation probabilities *
! gather some info on the aggregate containing this receptor
! the probabilities below are vectors
! default is zero, will enter nonzero values as needed
DePhosProb=0
PhosProb = 0
! Receptor Phosphorylation (Lyn mediated)
! 05-18-2017 -- requires presence of Lyn on an immediately ADJACENT receptor
!
number of Lyn's found does not matter, only whether
!
(1) there is a Lyn (2) there is an activated Lyn
! * determine the presence and most active state of a Lyn on adjacent receptors *
NeighborLynState=0; ! 0 means no Lyn present
do iBR=1,2 ! loop over neighbor to the left and right
BoundRecID = RecMolecule(i)%BoundRec_1
if (iBR==2) BoundRecID = RecMolecule(i)%BoundRec_2
if (BoundRecID > 0) then ! only go on if there is a receptor there
do iITAM=1,2 ! loop over ig alpha ig beta
NeighborLynID=RecMolecule(BoundRecID)%Iga_Lyn
if (iITAM==2) NeighborLynID=RecMolecule(BoundRecID)%Igb_Lyn
if (NeighborLynID>0) then
NeighborLynState = max(NeighborLynState,1) ! a Lyn is present so raise
state to >=1; Inactive lyn
! check the state of the Lyn
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if (LynMolecule(NeighborLynID)%Phos >0) NeighborLynState =2;
!Active Lyn
endif
enddo ! loop over itams
endif ! if there is a receptor bound
enddo ! loop over neighbors
if (System_Info%OutputLevel >=3) &
write(*,FMT="('RecID ',I3,' Intrinsic -- AggSize ',I3, ' Lyn status ', I2)"),&
i,RecMolecule(i)%Agg_Size,NeighborLynState
! Phos probabilities depend on ITAM state and activity of neighboring Lyn, and
the state of the substrate ITAM
! Phos_rate[IA(0 phos), IA(1Phos), A(0 Phos), A(1 Phos)]; IA = Inactive Lyn, A=
Active Lyn
if (NeighborLynState > 0) then ! Lyn is present (Inactive=1, Active=2)
! Deal with Igalpha
if (RecMolecule(i)%Iga_Phos < 2) PhosProb(1) =
Phos_rate(2*NeighborLynState - 1 + RecMolecule(i)%Iga_Phos) * dt
! Deal with Igbeta
if (RecMolecule(i)%Igb_Phos < 2) PhosProb(2) =
Phos_rate(2*NeighborLynState - 1 + RecMolecule(i)%Igb_Phos) * dt
if (System_Info%OutputLevel >=3) then
write(*,FMT="('A RecID ',I3,' Intrinsic -- AggSize ',I3, ' Lyn status ', I2,'
PhosProb=',2(e10.4,' '))"),&
i,RecMolecule(i)%Agg_Size,NeighborLynState, PhosProb
endif
end if ! if NeighborLynState>0
! Dephosphorylation probs are the same for IgA,IgB; depend on phos state (2->1
or 1->0); docked Lyn or Syk protects
! Dephos probablity [1P, 2P]
! Deal with Igalpha
if (RecMolecule(i)%Iga_Phos >= 1 .AND. RecMolecule(i)%Iga_Lyn == 0 .AND.
RecMolecule(i)%Iga_Syk == 0) &! tyrosines are not protected
DePhosProb(1) = Phos_off_rate(RecMolecule(i)%Iga_Phos) * dt
! Deal with Igbeta
if (RecMolecule(i)%Igb_Phos >= 1 .AND. RecMolecule(i)%Igb_Lyn == 0 .AND.
RecMolecule(i)%Igb_Syk == 0) &! tyrosines are not protected
DePhosProb(2) = Phos_off_rate(RecMolecule(i)%Igb_Phos) * dt
! Put the phos/dephos probs into a vector
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ProbVec(1:2)=PhosProb ! (1 = Iga+, 2 = Igb+
ProbVec(3:4)=DePhosProb !(3 = Iga-, 4 = Igb-)
ProbVec(5)=1-sum(ProbVec(1:4)) ! for the null event included explicitely to have
a normalized probability vector
if (NeighborLynState > 0 .and. System_Info%OutputLevel >=3) then
write(*,FMT="('C RecID ',I3, ' Lyn status ', I2,' PhosProb=[',2(e12.4,' '),']')"),&
i,NeighborLynState, PhosProb
write(*,FMT="(' cont ProbVec = [ ',4(e12.4,' '),']')"), ProbVec
endif
! TODOx -- only do the following if the probabilities are not all zero
! choose exactly one outcome (including non-event)
if(sum(ProbVec)>0) then
rannum = grnd()
! unfortunately this is necessary
do while(rannum > 1.0 .and. rannum < 0.0)
rannum = grnd()
enddo
SumProb=0
PhosIndex=0 !
do while(rannum > SumProb)
PhosIndex=PhosIndex+1
SumProb = SumProb + ProbVec(PhosIndex)
enddo
! TODO - check behavior when rannum=0 or 1
! TODOx perhaps do this for safety -if(rannum<=0) PhosIndex=1
! if(rannum>=1) PhosIndex=4
if (NeighborLynState > 0 .and. System_Info%OutputLevel >=3) then
write(*,FMT="('RecID ',I3,' NLS=',I2,' PV=[',5(e10.4,' '),'] Ind=',I1,'
SP=',e10.4,' ran=',e10.4)"),&
i,NeighborLynState,ProbVec,PhosIndex,SumProb,rannum
endif
! p has the chosen event type
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if(PhosIndex<5) then
if (System_Info%OutputLevel >=3) &
write(*,FMT="('Phos Choice -- PV:',8(f8.6,' '),' r=',f8.6,' p=',i0,' CP=',e10.6
)") &
ProbVec, rannum, PhosIndex, SumProb
System_Info%Reaction = .true.
if

(PhosIndex == 1) then ! Iga Phos
RecMolecule(i)%Iga_Phos = RecMolecule(i)%Iga_Phos + 1
! if Iga reached Ph=2, update the binding mode on any bound Syk
if(RecMolecule(i)%Iga_Phos==2 .AND. RecMolecule(i)%Iga_Syk>0 ) &
SykMolecule( RecMolecule(i)%Iga_Syk )%Syk_site = 2
else if (PhosIndex == 2) then ! Igb Phos
RecMolecule(i)%Igb_Phos = RecMolecule(i)%Igb_Phos + 1
! if Igb reached Ph=2, update the binding mode on any bound Syk
if(RecMolecule(i)%Igb_Phos==2 .AND. RecMolecule(i)%Igb_Syk>0 ) &
SykMolecule( RecMolecule(i)%Igb_Syk )%Syk_site = 2
else if (PhosIndex == 3) then ! Iga Dephos
RecMolecule(i)%Iga_Phos = RecMolecule(i)%Iga_Phos - 1
else if (PhosIndex == 4) then ! Igb Dephos
RecMolecule(i)%Igb_Phos = RecMolecule(i)%Igb_Phos - 1
end if

! log output
if (System_Info%OutputLevel >=1) then
if (PhosIndex<=2) then ! Phos
write(*,FMT="('T=',f14.8,' RecPhos RecID=',i3,' Ig:',i1,'(',(2i1),')
Agg=',i3,' Sz=',i0)") &
System_Info%Current_Simulation_Time,i,PhosIndex,RecMolecule(i)%Iga_Phos,RecMo
lecule(i)%Igb_Phos,&
RecMolecule(i)%Boss,RecMolecule(i)%Agg_Size
else ! Dephos
write(*,FMT="('T=',f14.8,' RecDeph RecID=',i3,' Ig:',i1,'(',(2i1),')
Agg=',i3,' Sz=',i0)") &
System_Info%Current_Simulation_Time,i,PhosIndex2,RecMolecule(i)%Iga_Phos,RecMolecule(i)%Igb_Phos,&
RecMolecule(i)%Boss,RecMolecule(i)%Agg_Size
endif
endif
else ! non-event
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endif ! if PhosIndex < 5
endif ! if sum(ProbVec)>0
! * end intrinsic reactions Rec branch * !
else if (i <= (System_Info%Total_Rec_Count + System_Info%Total_Lyn_Count))
then ! Lyn branch
! ** Lyn phos/dephos branch **
iLyn = i-System_Info%Total_Rec_Count! ID of Lyn particle
IF (LynMolecule(iLyn)%Phos == 0) then ! phos site on lyn is 0 --> check for
phos
! EXPLANATION: Lyn phos must be mediated by another Lyn
!
substrate and activator Lyn's must be *bound to adjacent receptors*
!
the substrate Lyn is the one we are updating
if (LynMolecule(iLyn)%Itam_site> 0) then ! require lyn bound to a receptor
! phos possible only if nearby lyns are present
! id of receptor this Lyn is bound to
LynRecID = LynMolecule(iLyn)%Receptor_ID
! * determine the presence and most active state of a Lyn on adjacent receptors
*
NeighborLynState=0; ! 0 means no Lyn present
do iBR=1,2 ! loop over neighbor to the left and right
BoundRecID = RecMolecule(LynRecID)%BoundRec_1
if (iBR==2) BoundRecID = RecMolecule(LynRecID)%BoundRec_2
if (BoundRecID > 0) then ! only go on if there is a receptor there
do iITAM=1,2 ! loop over ig alpha ig beta
NeighborLynID=RecMolecule(BoundRecID)%Iga_Lyn
if (iITAM==2) NeighborLynID=RecMolecule(BoundRecID)%Igb_Lyn
if (NeighborLynID>0) then
NeighborLynState = max(NeighborLynState,1) ! a Lyn is present so
raise state to >=1; Inactive lyn
! check the state of the Lyn
if (LynMolecule(NeighborLynID)%Phos >0) NeighborLynState =2;
!Active Lyn
endif
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enddo ! loop over itams
endif ! if there is a receptor bound
enddo ! loop over neighbors
if (NeighborLynState > 0) then ! if Lyn is present..
rannum = grnd() ! implement phos with appropriate rate
if (System_Info%OutputLevel >=3) &
write(*,FMT="('LynID ',I3,' RecID ',I3,' NLS=',I2,' Pr=',e10.4,'
ran=',e10.4)"),&
iLyn,LynRecID,NeighborLynState,Lyn_Phos_Rate(NeighborLynState) *
dt,rannum
if (rannum <= Lyn_Phos_Rate(NeighborLynState) * dt) then
LynMolecule(iLyn)%Phos=1 ! phosphorylation
System_Info%Reaction = .true.
if (System_Info%OutputLevel >=1) & ! log output for Lyn
phosphorylation
write(*,FMT="('T=',f14.8,' LynPhos LynID=',i3,' RecID=',i3,' Agg=',i3,'
Sz=',i0)") &
System_Info%Current_Simulation_Time,iLyn,LynRecID,&
RecMolecule(LynRecID)%Boss,RecMolecule(LynRecID)%Agg_Size
endif ! if phos happens
endif ! if activator present
endif ! if this Lyn is receptor bound
ELSE !phos site on lyn is >0 -- dephos possible
rannum = grnd()
if (rannum <= Lyn_Dephos_Rate * dt ) then
LynMolecule(iLyn)%Phos = 0 ! lyn dephosphorylation
System_Info%Reaction = .true.
if (System_Info%OutputLevel >=1) & ! log output for Lyn de-phosphorylation
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write(*,FMT="('T=',f14.8,' LynDeph LynID=',i3,' RecID=',i3,' Agg=',i3,'
Sz=',i0)") &
System_Info%Current_Simulation_Time,iLyn,LynRecID,&
RecMolecule(LynRecID)%Boss,RecMolecule(LynRecID)%Agg_Size
endif
END if ! if Lyn phos state=0
! * end intrinsic reactions Lyn branch *
else if (i <= (System_Info%Total_Rec_Count + System_Info%Total_Lyn_Count +
System_Info%Total_Syk_Count)) then ! Syk branch
! ** intrinsic reactions (phos/dephos) Syk branch **
Syk_Intrinsic_Count = Syk_Intrinsic_Count + 1
! ID of the Syk being updated
iSyk = i-System_Info%Total_Rec_Count - System_Info%Total_Lyn_Count
! SykPhos reactions..
!IF (SykMolecule(iSyk)%Phos == 0 .OR. SykMolecule(iSyk)%Phos_2 == 0 ) then
! phos site on syk is 0 --> check for phos
! EXPLANATION: Syk phos possible only if
! (1) nearby syks are present (on adjacent receptors, similar to Lyn) or
! (2) syk_site = 2 (tandem SH2 domains are engaged with an ITAM)
! both require substrate docked on receptor
! boh lead to the same outcome, so probs will be added up
if (SykMolecule(iSyk)%Itam_site > 0) then ! is syk bound to a receptor ?
! id of receptor this Syk is bound to
SykRecID = SykMolecule(iSyk)%Receptor_ID
else
! Syk is free -- may still dephosphorylate
SykRecID = 0
endif
! Syk has two phosphorylation sites: one is phosphorylated by Syk (phos) and the
other by Lyn (phos_2)
! there is a dephos. rate for each site
!
! Calculate the probability of each [de]phosphorylation
! (1) If site 1 is active --> DePhos1
!
inactive --> Phos1; may happen only if NeighborSykState > 0
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!
! (2) If site 2 is active --> DePhos2
!
inactive --> Phos 2; may happen only if NeighborLynState > 0
!
! NOTE: we avoid implementing two transformations in the same update, so we
!
assign / split the (very small) prob. of both sites changing states back to
!
the prob. of one site changing
! re-use PhosProb(2), DePhosProb(2), ProbVec(5)
PhosProb=0
DePhosProb=0
ProbVec=0
if (SykMolecule(iSyk)%Phos == 1) then
! dephos - prob > 0 only if the site is active
DePhosProb(1) = Syk_DePhos_Rate * dt ! approximates 1 - exp( Syk_DePhos_Rate * dt )
else
! phos 1 - site must be inactive and there must be an adjacent Syk
! * determine the presence and most active state of a Syk on adjacent receptors *
NeighborSykState=0; ! 0 means no adjacent Syk present
if (SykRecID > 0) then
do iBR=1,2 ! loop over neighbor to the left and right
BoundRecID = RecMolecule(SykRecID)%BoundRec_1
if (iBR==2) BoundRecID = RecMolecule(SykRecID)%BoundRec_2
if (BoundRecID > 0) then ! only go on if there is a receptor there
do iITAM=1,2 ! loop over ig alpha ig beta
NeighborLynID=RecMolecule(BoundRecID)%Iga_Syk
if (iITAM==2) NeighborLynID=RecMolecule(BoundRecID)%Igb_Syk
if (NeighborSykID>0) then
NeighborSykState = max(NeighborSykState,1) ! a Syk is present so
raise state to >=1; Inactive Syk
! check the state of the Syk
if (SykMolecule(NeighborSykID)%Phos >0) NeighborSykState =2;
!Active Syk
endif
enddo ! loop over itams
endif ! if there is a receptor bound
enddo ! loop over neighbors
if (NeighborSykState>0) PhosProb(1) = Syk_Phos_Rate(NeighborSykState) *
dt
! end Syk phos site 1 inactive case
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endif ! if SykRecID > 0
endif ! if Syk phos site 1 is active ..
if (SykMolecule(iSyk)%Phos_2 == 1) then
! dephos - prob > 0 only if the site is active
DePhosProb(2) = Syk_DePhos_Rate * dt
else
! phos 2 - site must be inactive and there must be an adjacent Lyn
! * determine the presence and most active state of a Lyn on adjacent receptors *
! LynRecID = LynMolecule(iLyn)%Receptor_ID! TODO change this to
SykRecID
NeighborLynState=0; ! 0 means no Lyn present
if (SykRecID > 0 ) then
do iBR=1,2 ! loop over neighbor to the left and right
BoundRecID = RecMolecule(SykRecID)%BoundRec_1
if (iBR==2) BoundRecID = RecMolecule(SykRecID)%BoundRec_2
if (BoundRecID > 0) then ! only go on if there is a receptor there
do iITAM=1,2 ! loop over ig alpha ig beta
NeighborLynID=RecMolecule(BoundRecID)%Iga_Lyn
if (iITAM==2) NeighborLynID=RecMolecule(BoundRecID)%Igb_Lyn
if (NeighborLynID>0) then
NeighborLynState = max(NeighborLynState,1) ! a Lyn is present so
raise state to >=1; Inactive lyn
! check the state of the Lyn
if (LynMolecule(NeighborLynID)%Phos >0) NeighborLynState =2;
!Active Lyn
endif
enddo ! loop over itams
endif ! if there is a receptor bound
enddo ! loop over neighbors
if (NeighborLynState>0) PhosProb(2) = Lyn_Phos_Rate(NeighborLynState) *
dt
endif ! if SykRecID>0
! end Syk phos site 2 inactive case
endif ! if Syk phos site 2 is inactive ...
! Put the phos/dephos probs into a vector
ProbVec(1:2)=PhosProb ! (1 = Phos1, 2=Phos2
ProbVec(3:4)=DePhosProb !(3 = DePhos1, 4 = DePhos2)
ProbVec(5)=1-sum(ProbVec(1:4)) ! for the null event included explicitely to have
a normalized probability vector
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if(sum(ProbVec(1:4))>0) then ! only go through the random selection if there is at
least one nozero prob 1:4
! Choose the outcome using a random number
rannum = grnd()
! hopefully this is not necessary this time
!do while(rannum > 1.0 .and. rannum < 0.0)
! rannum = grnd()
!enddo
SumProb=0
PhosIndex=0 ! set to zero by default - note that the null event is 5
do while(rannum > SumProb .and. PhosIndex < 5)
PhosIndex=PhosIndex+1
SumProb = SumProb + ProbVec(PhosIndex)
enddo
! TODO - check behavior when rannum=0 or 1
! do this for safety -- strange ran() leads to null event
if(rannum<=0 .or. rannum>=1) PhosIndex=5 ! 5 is the null event here
! endif
!*****
if (PhosIndex==1) then
SykMolecule(iSyk)%Phos = SykMolecule(iSyk)%Phos + 1 ! phos and update
elseif (PhosIndex==2) then
SykMolecule(iSyk)%Phos_2 = SykMolecule(iSyk)%Phos_2 + 1 ! phos and
update
elseif (PhosIndex==3) then
SykMolecule(iSyk)%Phos = SykMolecule(iSyk)%Phos - 1 ! dephos and
update
elseif (PhosIndex==4) then
SykMolecule(iSyk)%Phos_2 = SykMolecule(iSyk)%Phos_2 - 1 ! dephos and
update
endif
System_Info%Reaction = .true.
if (System_Info%OutputLevel >=1) then !phosindex 1 = phos1, !phosindex 2
= phos2,
if (PhosIndex<=2) then ! Phos
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write(*,FMT="('T=',f14.8,' SykPhos SykID=',i3,' RecID=',i3,' Phos',i1,' Phos1:',i1,'
Phos2:',i1,' Agg=',i3,' Sz=',i0)") &
System_Info%Current_Simulation_Time,iSyk,SykRecID,PhosIndex,SykMolecule(iSyk)
%Phos, &
SykMolecule(iSyk)%Phos_2,
RecMolecule(SykRecID)%Boss,RecMolecule(SykRecID)%Agg_Size
else if (PhosIndex<=4) then! Dephos
write(*,FMT="('T=',f14.8,' SykDeph SykID=',i3,' RecID=',i3,' Phos',i1,' Phos1:',i1,'
Phos2:',i1,' Agg=',i3,' Sz=',i0)") &
System_Info%Current_Simulation_Time,iSyk,SykRecID,PhosIndex2,SykMolecule(iSyk)%Phos, &
SykMolecule(iSyk)%Phos_2,RecMolecule(SykRecID)%Boss,RecMolecule(SykRecID)
%Agg_Size
endif
endif
!endif ! if Syk is bound to an ITAM
endif ! if sum(Prob(1:4) > 0 )
! * end intrinsic reactions Syk branch *
end if ! i <= receptor count
end if ! System_Info%Reaction .eqv. .false. (i.e. if no reaction happened)
! ** done with intrinsic reactions for Rec,Lyn,Syk **
! write(*,*) '.. done with intrinsic reactions for all'
! *** Record Keeping Portion of Code ***
p=p+1 ! counts the iterations from the last frame export
! Check if the data should be written to a file
IF (p == datacut) THEN
!
write(*,*) 'T=',System_Info%Current_Simulation_Time,&
!
'Syk Picks:',Syk_Pick_Count, ' P-NoRxn:',Syk_PickNoReaction, &
!
' Bind:', Syk_BindCall_Count, ' B-Rxn:', Syk_Bind_Reaction, ' B-NoRxn:',
Syk_Bind_NoReaction,&
!
' NoRxn-AvBossCt:',Enc_BossCount,float(Enc_BossCount)/float(
Syk_Bind_NoReaction),&
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!
' NoRxnAvEligAggCt:',Enc_EligAggCount,float(Enc_EligAggCount)/float(Syk_Bind_NoReacti
on),&
!
' NoRxn-SysPhosSiteCt:',Enc_SysPhosCount,float(Enc_SysPhosCount)/
float(Syk_Bind_NoReaction),&
!
' MinDist:',sqrt(SysMinDist), sqrt(SysMindist) / Syk_BindRad_Dimer
! ' --free:' , Syk_FreePick, ' Intrinsic:',Syk_Intrinsic_Count
! ' -- bound:', Syk_BoundPick, ' --bound-unbound:',Syk_BoundPick_Unbound, &
! set all the above counters to zero
Syk_Pick_Count=0
Syk_Intrinsic_Count=0
Syk_PickNoReaction=0
Syk_FreePick=0
Syk_BoundPick=0
Syk_BoundPick_Unbound=0
Syk_DiffCall_Count=0
Syk_Diff_Reaction=0
Syk_Diff_NoReaction=0
Syk_BindCall_Count=0
Syk_Bind_Reaction=0
Syk_Bind_NoReaction=0
Enc_EligAggCount=0
Enc_BossCount=0
Enc_SysPhosCount=0
! min distance - set to very large to begin the next pass
SysMinDist=100
if (System_Info%OutputLevel >=2) write(*,*) ' Printout ',m+1,'..'
DO ii=1,NP
RecMolecule(ii)%r_Squared=&
(RecMolecule(ii)%Position(1)-RecMoleculePrevious(ii)%Position(1))**2 + &
(RecMolecule(ii)%Position(2)-RecMoleculePrevious(ii)%Position(2))**2
END DO
! Calculate OVERALL MSD (MSDx and MSDy too?) for specific dt
MSD=SUM(RecMolecule(:)%r_Squared)/NP
! Keep the current state for comparison during the next printout
RecMoleculePrevious = RecMolecule
LynMoleculePrevious = LynMolecule
SykMoleculePrevious = SykMolecule
! Restart dt counter
m=m+1
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! generate filename for data storage
write(fnstring, fmt="(i0)") m
open(77, file=trim(outdir)//'/Data_Files/ParticleData.'//trim(fnstring))
WRITE(77,*) 'Rows: Particle Columns: Particle #, x, y, dx, dy, d, B1, &
& B2, Bond, Agg_size, Boss'
!& PhosEvent, # dephosphorylation events, RR Dimer Attempts, RR Dimmer
Successes'
!WRITE(88,*) 'r^2 (Combined x and y moves), species'
! Write data to file
DO i = 1,NP
write(77,fmt="(&
'RecID=',i4,' XYZ=[',3(f7.4,' '),'] BoundRec:',i3,' ',i3,' BondCt:',i1,'
AggBoss:',i4,&
' AggSz:',i2,' LynBound:',2(I3,' '),' SykBound:',2(I3,' '),' Ph:',i1,' ',i1,'
Dom:',i2)")&
i,RecMolecule(i)%Position,&
RecMolecule(i)%BoundRec_1,RecMolecule(i)%BoundRec_2,RecMolecule(i)%Bond,&
RecMolecule(i)%Boss, RecMolecule(i)%Agg_Size,&
RecMolecule(i)%Iga_Lyn, RecMolecule(i)%Igb_Lyn,
RecMolecule(i)%Iga_Syk, RecMolecule(i)%Igb_Syk, &
RecMolecule(i)%Iga_Phos, RecMolecule(i)%Igb_Phos, &
RecMolecule(i)%Domain
END DO
CLOSE(77)
! also write out Lyn and Syk
! -- in separate files (..?)
! * Lyn output *
open(77, file=trim(outdir)//'/Data_Files/ParticleData_Lyn.'//trim(fnstring))
write(77,*) 'Lyn section: LynID, x, y, z, RecID (if bound), Phos, ITAM site
(Iga/Igb), Lyn site (none/UD/SH2)'
do i=1, Lyn_num
write(77,fmt="('LynID=',i4,' XYZ=[',f8.4,' ',f8.4,' ',f8.4,'] Rec=',i4,' Ph=',i1,' Site
Ig:',i1,' Lyn:',i1)")&
i,LynMolecule(i)%Position,LynMolecule(i)%Receptor_ID,LynMolecule(i)%Phos,&
LynMolecule(i)%Itam_site,LynMolecule(i)%Lyn_site
end do
close(77)
! * Syk output *
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open(77, file=trim(outdir)//'/Data_Files/ParticleData_Syk.'//trim(fnstring))
write(77,*) 'Syk section: SykID, x, y, z, RecID (if bound), Phos, ITAM site
(Iga/Igb), Syk site (none/one SH2/two SH2)'
do i=1, Syk_num
write(77,fmt="('SykID=',i4,' XYZ=[',f8.4,' ',f8.4,' ',f8.4,'] Rec=',i4,' Ph=',i1,' Site
Ig:',i1,' Syk:',i1)")&
i,SykMolecule(i)%Position,SykMolecule(i)%Receptor_ID,SykMolecule(i)%Phos,&
SykMolecule(i)%Itam_site,SykMolecule(i)%Syk_site
end do
close(77)

! dimer lifetimes from the actual simulation, not the frame rate
open(11,file=trim(outdir)//'/AggSizeCounts')
WRITE(11,*)
System_Info%Current_Simulation_Time,System_Info%Num_Aggregates,
System_Info%AggSizeCount
WRITE(7,*) MSD ! This is the mean square displacement from frame to frame
p=0
if (System_Info%OutputLevel >=2) write(*,*) ' done with printouts'
END IF
! END SELECT
! write(*,*) 'Loop'
END DO
CLOSE(4)
CLOSE(7)
CLOSE(8)
CLOSE(9)
CLOSE(10)
CLOSE(11)
WRITE(*,*) 'FORTRAN Simulation Ended'
END PROGRAM Pre_BCR
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!***********************************************************************
************************************************************************
**********
SUBROUTINE LynDiffuse (iLyn, MyDiffSTD)
!
!
USE ParticleInfo
USE ModelConstants
USE mtmod
!
!
IMPLICIT NONE
!
!! Declare variables
INTEGER, INTENT (IN) :: iLyn ! chosen particle
DOUBLE PRECISION, INTENT (IN) :: MyDiffSTD ! diffusion standard deviation
DOUBLE PRECISION :: r1, r2, w1, w2, x1, y1,z1, rannum
integer :: CanReact=0
!
!
!! randomly make a trajectory for particles using mtmod.f90 for random numbers !!!
!! Generate random number & Normally distribute random number !
http://www.taygeta.com/random/gaussian.html
!!* Generate x move
r1=2*grnd()-1
r2=2*grnd()-1
!! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
!! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
!! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
!! Normally distributed random # for distance
x1=r1*w2
!
!! Generate y move
r1=2*grnd()-1
r2=2*grnd()-1
!! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
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!! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
!! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
y1=r2*w2
!
!! Account for diffusion coefficient based on species type
y1=y1*MyDiffSTD
x1=x1*MyDiffSTD
z1=0
! Lyn does not move in the z direction

! call periodic boundary condition
!!$ CALL
PeriodicBC(LynMolecule(iLyn)%Position(1)+x1,LynMolecule(iLyn)%Position(2)+y1,
&
!!$
LynMolecule(iLyn)%Position(3)+z1, LynMolecule(iLyn)%Position(1), &
!!$
LynMolecule(iLyn)%Position(2),LynMolecule(iLyn)%Position(3))
CALL PeriodicBC2(&
LynMolecule(iLyn)%Position(1)+x1,LynMolecule(iLyn)%Position(2)+y1, &
LynMolecule(iLyn)%Position(1), LynMolecule(iLyn)%Position(2))
LynMolecule(iLyn)%Position(3)=0
! activated Lyn is always able to bind
CanReact = LynMolecule(iLyn)%Phos
! un-activated Lyn reacts with a probability
if ( LynMolecule(iLyn)%Phos==0) then
rannum=grnd()
if (rannum <= Lyn_available_fraction) CanReact=1
endif
if(CanReact==1) CALL LynBindReaction(iLyn)
END SUBROUTINE LynDiffuse
!***********************************************************************
************************************************************************
*****************
SUBROUTINE LynBindReaction(iLyn)
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USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
INTEGER, INTENT(IN) :: iLyn ! specific particle
INTEGER :: receptor_ID, num, add_lyn, Free_Lyn_Site_Count, LuckyRec,
LuckyRecIndex
DOUBLE PRECISION :: distsq, rannum
! arrays to hold aggregate info Lyn_Agg is actually a list of receptors
INTEGER,DIMENSION(MaxAgg) :: Lyn_Agg=0 ! list of receptors in a given
aggregate
real, dimension( 5, MaxAgg ) :: array_1=0 ! 5 x NumParticles - probabilities of binding
or similar
real, dimension( 5 * MaxAgg ) :: array_2=0, CumSum=0 ! same as above but vector
integer :: d, CurrentParticle, ip, k, h, j, u,m_lyn,rv,cv, i
integer :: AggRecCount ! number of receptors on the current aggregate
if (System_Info%OutputLevel >=3) write(*,*) 'LynBind begin -- LynID ',iLyn
System_Info%Reaction = .FALSE.
! Check for reaction
do k = 1,System_Info%Num_Particles ! loop over particles (receptor monomers)
! Check if one of available receptors is close enough to react
if (RecMolecule(k)%Boss == k) then
! need to know how many free Lyn binding domains on this aggregate
AggRecCount = RecMolecule(k)%Agg_Size ! number of receptors on this
aggregate
!AggRecCount = count( RecMolecule(:)%Boss==k ) ! this should match %AggSize
Lyn_Agg = pack(RecMolecule(:)%RecID, RecMolecule(:)%Boss==k)! holding the
recs in an aggregate
!count each type of binding- each receptor- whether general lyn binding is possible
through Iga, Igb
if (System_Info%OutputLevel >=3) then
WRITE(*,*) ' Lyn_Agg has size ',size(Lyn_Agg),' AggRecCount=',AggRecCount
do j=1,size(Lyn_Agg)
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write(*,*) 'entry',j,':',Lyn_Agg(j)
end do
endif
!count each type of binding- each receptor- whether general lyn binding is possible
through Iga, Igb
array_1 = 0! sets all the elements to 0
Do j = 1,AggRecCount ! this follows the receptor
! TODO: merge branches (1,2,3) and (4,5) in a()
! This block will check for the Igalpha branch
if (RecMolecule(Lyn_Agg(j))%Iga_Lyn == 0 .and.
RecMolecule(Lyn_Agg(j))%Iga_Syk == 0) then ! This will check if Iga has any Lyn at
all
if (RecMolecule(Lyn_Agg(j))%Iga_Phos == 0) then
array_1(1,j)= LynBindScaleFactor(1)! unique domain on lyn binds to site 1 on
receptors
else if (RecMolecule(Lyn_Agg(j))%Iga_Phos == 1) then !
array_1(2,j)= LynBindScaleFactor(2)
else
array_1(3,j)= LynBindScaleFactor(2)!(RecMolecule(Lyn_Agg(j))%Phos ==
2)the probability of binding to a twice phosphorylated itams sould be twice as much
end if
end if
! This block will check for Igbeta branch
if (RecMolecule(Lyn_Agg(j))%Igb_Lyn == 0 .and.
RecMolecule(Lyn_Agg(j))%Igb_Syk == 0) then !This will check if Igb has any Lyn at all
if (RecMolecule(Lyn_Agg(j))%Igb_Phos == 1) then
array_1(4,j)= LynBindScaleFactor(3)! unique domain on lyn binds to site 1 on
receptors
else if(RecMolecule(Lyn_Agg(j))%Igb_Phos == 2) then
array_1(5,j)= LynBindScaleFactor(3) !if (RecMolecule(Lyn_Agg(j))%Phos
== 2)
end if
end if
End Do
! Decide
distsq=& ! Calculate the distance between lyn and receptor
(RecMolecule(k)%Position(1)-LynMolecule(iLyn)%Position(1))**2+&
(RecMolecule(k)%Position(2)-LynMolecule(iLyn)%Position(2))**2
if (distsq <= SUM(array_1(:,1:AggRecCount))*Lyn_BindRad_Dimer**2) THEN
! Lyn is within binding radius
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! implement the binding ..
array_1 = array_1/SUM(array_1(:,1:AggRecCount))
array_2(1:5*AggRecCount) =
reshape(array_1(:,1:AggRecCount),(/5*AggRecCount/)); !array 3 hold them in one
dimensional vector
CumSum(1)= array_2(1)
Do i= 2,5*AggRecCount
CumSum(i)= array_2(i)+CumSum(i-1)
End do
rannum = grnd()
m_lyn = 0
Do u = 1,5*AggRecCount
if (rannum <= CumSum(u)) then
m_lyn = u ! element in array 2
exit
end if
End do
cv= ceiling(REAL(m_lyn)/5)! this will give receptor number
rv= mod(m_lyn,5) ! this will give row number
if (rv == 0) rv=5! this is to make sure that row vector is never 0
! ** updates for successful binding go here **
! update the Lyn and the receptor
LynMolecule(iLyn)%Receptor_ID = Lyn_Agg(cv)
LynMolecule(iLyn)%Position = RecMolecule(Lyn_Agg(cv))%Position ! may not
need this - set Position to zero instead ?
! identify the ITAM and binding mode
If (rv <= 3) then ! Iga ..
RecMolecule(Lyn_Agg(cv))%Iga_Lyn = iLyn
LynMolecule(iLyn)%Itam_site = 1
! Lyn is bound to Igalpha
If (rv == 1) then
LynMolecule(iLyn)%Lyn_site = 1
! Lyn is bound through it's unique
domain
else
LynMolecule(iLyn)%Lyn_site = 2
end if
! Lyn is bound through it's SH2 domain
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else if (rv >= 4) then ! Igb
RecMolecule(Lyn_Agg(cv))%Igb_Lyn = iLyn
LynMolecule(iLyn)%Itam_site = 2
! Lyn is bound to Igbeta
LynMolecule(iLyn)%Lyn_site = 2
! Lyn is ALWAYS bound to Igbeta
through it's SH2 domain
end if
! log output
if (System_Info%OutputLevel >=1) &
write(*,FMT="('T=',f14.8,' LynBind LynID=',i3,'.',i1,' RecID=',i3,'.',i1,'
Agg=',i3,' Sz=',i0,' Free Lyn ',i0)") &
System_Info%Current_Simulation_Time,iLyn,LynMolecule(iLyn)%Lyn_site,
Lyn_Agg(cv),LynMolecule(iLyn)%Itam_site,&
RecMolecule(Lyn_Agg(cv))%Boss,&
RecMolecule(Lyn_Agg(cv))%Agg_Size,System_Info%Free_Lyn_Count
! free Lyn count
System_Info%Free_Lyn_Count = System_Info%Free_Lyn_Count - 1
! flag to end the update pass
System_Info%Reaction = .true.
end if ! if receptor is within BR
end if ! only if there are free lyn binding domains on the aggregate
if (System_Info%Reaction) exit ! break the loop / so only one binding reaction
end do ! loop over all receptors
if (System_Info%OutputLevel >=3) write(*,*) 'LynBind end'
END SUBROUTINE LynBindReaction
!***********************************************************************
************************************************************************
*****************
SUBROUTINE LynUnbindReaction(iLyn)
USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
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INTEGER, INTENT (IN) :: iLyn
DOUBLE PRECISION :: placeangle, x1, y1, z1, rannum
INTEGER :: Receptor_bound_lyn
! receptor lyn is bound to
Receptor_bound_lyn = LynMolecule(iLyn)%Receptor_ID
! make sure the current position is set to that of the [boss of] the binding receptor
LynMolecule(iLyn)%Position =
RecMolecule(RecMolecule(Receptor_bound_lyn)%Boss)%Position
placeangle = 2*Pi*grnd()
x1 = cos(placeangle)*Lyn_UnbindRad_RestDimer
y1 = sin(placeangle)*Lyn_UnbindRad_RestDimer
z1 = 0
!this will update lyn position
!!$ CALL
PeriodicBC(LynMolecule(iLyn)%Position(1)+x1,LynMolecule(iLyn)%Position(2)+y1,
&
!!$
LynMolecule(iLyn)%Position(3)+z1, LynMolecule(iLyn)%Position(1), &
!!$
LynMolecule(iLyn)%Position(2),LynMolecule(iLyn)%Position(3))
CALL
PeriodicBC2(LynMolecule(iLyn)%Position(1)+x1,LynMolecule(iLyn)%Position(2)+y1,
&
LynMolecule(iLyn)%Position(1), LynMolecule(iLyn)%Position(2))
! Update Receptor first
If (LynMolecule(iLyn)%Itam_site==1) then ! if lyn was on Igalpha
RecMolecule(Receptor_bound_lyn)%Iga_Lyn = 0 ! update Igalpha on receptor
else if (LynMolecule(iLyn)%Itam_site==2) then ! if lyn was on Igbeta
RecMolecule(Receptor_bound_lyn)%Igb_Lyn = 0 ! update Igbeta on receptor
End if
! update lyn now
LynMolecule(iLyn)%Receptor_ID = 0
System_Info%Free_Lyn_Count = System_Info%Free_Lyn_Count + 1
LynMolecule(iLyn)%Itam_site = 0 ! 0 = unbound, 1 = Igalpha, 2 = Igebta
LynMolecule(iLyn)%Lyn_site = 0 ! 0 = unbound, 1 = Unique domain, 2 = SH2
!!$ if (System_Info%OutputLevel >=1) &
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!!$
write(*,*) 'LynUnBi: LynID=',iLyn,
'RecID=',Receptor_bound_lyn,'Boss=',RecMolecule(Receptor_bound_lyn)%Boss
if (System_Info%OutputLevel >=1) &
write(*,FMT="('T=',f14.8,' LynUnBi LynID=',i3,' RecID=',i3,' Agg=',i3,' Sz=',i0 '
Free Lyn ',i0)") &
System_Info%Current_Simulation_Time,iLyn,
Receptor_bound_lyn,RecMolecule(Receptor_bound_lyn)%Boss,&
RecMolecule(Receptor_bound_lyn)%Agg_Size,System_Info%Free_Lyn_Count
END SUBROUTINE LynUnbindReaction
!***********************************************************************
************************************************************************
*****************
SUBROUTINE ParticleDiffuse(i, DiffSTD)
! box boundaries are in ParticleInfo, no need to give them again
! the particle number (NP) is also in ParticleInfo, under System_Info%Num_Particles
USE ParticleInfo
USE ModelConstants
USE mtmod
! TODO: (optional) update the position of Lyn and Syk bound to receptors being
updated
IMPLICIT NONE
! Declare variables
INTEGER, INTENT (IN) :: i ! chosen particle
DOUBLE PRECISION, INTENT (IN) :: DiffSTD ! diffusion standard deviation
!double precision, intent (in) :: xlimmax,ylimmax,xlimmin,ylimmin, st
!double precision, intent (in) :: st
INTEGER :: ParticleSpecies, BoundBud, domainnum,
Initial_domain_check,Suspected_domain,k
DOUBLE PRECISION :: r1, r2, w1, w2, x1, y1, rannum, escape_probability
double precision :: NewCoord(3) ! tentative new position of the particle (replaces
MoveDistance)
integer :: DomainEscape ! will be true (+1) if a comain escape occurs
integer :: NewDomain, EscapeAttempt,DomainChange
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!!! randomly make a trajectory for particles using mtmod.f90 for random numbers !!!
!! Generate random number & Normally distribute random number !
http://www.taygeta.com/random/gaussian.html
!* Generate x move
r1=2*grnd()-1
r2=2*grnd()-1
! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
! Normally distributed random # for distance
x1=r1*w2
! Generate y move
r1=2*grnd()-1
r2=2*grnd()-1
! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
y1=r2*w2
! Account for diffusion coefficient based on species type
y1=y1*DiffSTD
x1=x1*DiffSTD

! New position (tentative for now)
! Before dealing with the domains, we need to satisfy the periodic BC
call PeriodicBC2(&
RecMolecule(i)%Position(1)+x1,RecMolecule(i)%Position(2)+y1,&
NewCoord(1),NewCoord(2));
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NewCoord(3)=0 ! no move off the membrane for a receptor
! Check if receptor is in free space and whether it is anticipated to move ---> into a
domain OR another free space
Initial_domain_check = RecMolecule(i)%Domain ! Could be domains --> 0, 1, 2 ,3, 4,
5
DomainEscape = 0; ! assume no domain change
EscapeAttempt = 0; !
DomainChange = 0; ! zero if domain ID does not change in the end
! 4 possibilities:
! 1. domain -> free space
! 2. domain -> domain
! 3. free space -> domain
! 4. free space -> free space

: Reflective BC, if escaped then periodic BC
: No BC
: No boundary check required
: Periodic BC

if (RecMolecule(i)%Domain>0) then
! Case 1+2 .. particle is in a domain before the move
if (InDomain(NewCoord(1:2),Initial_domain_check)) then
! Case 2: stays in the domain, all is well
else
! wants to leave the domain
! used to call DomainEscape() here
EscapeAttempt = 1
if(grnd()<=EscapeProb) then
! Case 1: move will be accepted - escape success
DomainEscape = 1
else
! move is rejected, particle should be reflected off the boundary
NewCoord(1:2) = NewCoord(1:2) - 2*[x1,y1];
! paranoid check on whether the reflected move would constitute an escape
if(InDomain(NewCoord(1:2),Initial_domain_check)) then
! the reflected move is in the domain, hence accepted
else
! the particle is stuck in a narrow section
NewCoord = RecMolecule(i)%Position
endif
endif
! at this point, we have a definite new position (NewCoord)
! which is verified within the simulation box (did BC first thing)
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! the particle may have escaped its initial domain in which case it is
! assumed in free space ; we need to take care of the case when this
! new position immediately puts it into another domain
endif! new position in domain or not
! at this point:
! NewCoord has the accepted new position
! DomainEscape = 1 if and only if the particle was allowed to leave its initial domain
! EscapeAttempt = 1 iff the proposed move was to leave (accepted or not)
if(DomainEscape==1) then
DomainChange=1
! update domain info to free
where(RecMolecule(:)%Boss==i)
RecMolecule(:)%Domain = 0
end where
endif
! all of the above was for when the particle was initially in a domain
endif
! NewCoord is valid now whether the particle was free or not and escaped or not
! time to update the position for this receptor and its subordinates
where(RecMolecule(:)%Boss==i)
RecMolecule(:)%Position(1)=NewCoord(1)
RecMolecule(:)%Position(2)=NewCoord(2);
end where
RecMolecule(:)%Position(3)=0 ! receptors never leave the membrane
! still need to check if the new position puts the particle in a NEW domain
if(Initial_domain_check == 0 .or. DomainEscape > 0 ) then
NewDomain=0;
do k=1,NumDomains
if ((NewCoord(1) >= Dom(k)%Xlim(1)) .AND. (NewCoord(1)<=
Dom(k)%Xlim(2)) &
.AND.(NewCoord(2) >= Dom(k)%Ylim(1)) .AND.
(NewCoord(2)<=Dom(k)%Ylim(2))) then
if(InDomain(NewCoord(1:2),k)) NewDomain=k
endif
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end do
if (NewDomain>0) then
if (Initial_domain_check > 0 .and. NewDomain == Initial_domain_check) then
write(*,*) 'Error - domain escape and not'
else
! legit trapping in NewDomain
DomainChange = 1
! update domain info to free
where(RecMolecule(:)%Boss==i)
RecMolecule(:)%Domain = NewDomain
end where
endif
endif
endif ! if initially free or escaped
! now
! DomainEscape=1 if escape from a domain
! DomainChange=1 if escaped and/or entered a new domain
! NewDomain is correct in both cases above
if (DomainChange==1) then
DomainParticleCount(Initial_domain_check) =
DomainParticleCount(Initial_domain_check) - RecMolecule(i)%Agg_Size
DomainParticleCount(NewDomain) = DomainParticleCount(NewDomain) +
RecMolecule(i)%Agg_Size
if (System_Info%OutputLevel >=1) &
write(*,FMT="(&
'T=',f14.8,' DomChg Rec1 =',i3,&
' Dom ',I1,' --> ',I1,&
' Boss ',i3,' AggSize ',i2,' DomCounts:', 5(i3,' '))") &
System_Info%Current_Simulation_Time,i,Initial_domain_check,NewDomain,&
RecMolecule(i)%Boss,RecMolecule(i)%Agg_Size,&
DomainParticleCount(1:NumDomains)
endif
CALL BindReaction(i)
END SUBROUTINE ParticleDiffuse
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!***********************************************************************
************************************************************************
************
SUBROUTINE ReflectiveBC (i,x1,y1)
USE ParticleInfo
USE mtmod
USE ModelConstants
IMPLICIT NONE
DOUBLE PRECISION, INTENT(IN) :: x1, y1
INTEGER, INTENT(IN) :: i ! Current receptor
DOUBLE PRECISION :: x, y ! Proposed move
x=RecMolecule(i)%Position(1)-x1
y=RecMolecule(i)%Position(2)-y1
RecMolecule(i)%Position(1) = x
RecMolecule(i)%Position(2) = y
END SUBROUTINE ReflectiveBC
!***********************************************************************
************************************************************************
************
SUBROUTINE PeriodicBC2(x,y,xnew,ynew)
USE ParticleInfo
! 2-d verions ot be used for membrane bound species (Rec, Lyn)
IMPLICIT NONE
DOUBLE PRECISION, INTENT(IN) :: x, y ! Proposed new x, Proposed new y
DOUBLE PRECISION, INTENT(OUT) :: xnew, ynew ! New BC satisfied coordinates
DOUBLE PRECISION :: xmax, ymax, ymin, xmin
! Limits on x and y coordinates defined by system boundaries
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xmin=System_Info%SimSpace_Boundary(3)
xmax=System_Info%SimSpace_Boundary(1)
ymin=System_Info%SimSpace_Boundary(4)
ymax=System_Info%SimSpace_Boundary(2)
! Check & Apply Periodic Boundary Condition
! Check x move
IF (x < xmin) THEN ! Add width of box
xnew=x+(xmax-xmin)
ELSE IF (x > xmax) THEN ! Subtract width of box
xnew=x-(xmax-xmin)
ELSE ! remains unchanged
xnew=x
END IF
! Check y move
IF (y < ymin) THEN ! Add length of box
! Define Y New Coordinate
ynew=y+(ymax-ymin)
ELSE IF (y > ymax) THEN ! Subtract length of box
! Define Y New Coordinate
ynew=y-(ymax-ymin)
ELSE ! remains unchanged
! Define Y New Coordinate
ynew=y
END IF
END SUBROUTINE PeriodicBC2
SUBROUTINE PeriodicBC3(x,y,z,xnew,ynew,znew)
! to be used for 3d species (Syk)
! NOTE: (1) BC in the z-direction are REFLECTIVE
!
(2) the simulation boundaries in z are 0 (top) and -Depth (bottom)
USE ParticleInfo
IMPLICIT NONE
DOUBLE PRECISION, INTENT(IN) :: x, y, z ! Proposed new x, Proposed new y
DOUBLE PRECISION, INTENT(OUT) :: xnew, ynew, znew ! New BC satisfied
coordinates
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DOUBLE PRECISION :: xmax, ymax, ymin, xmin, zmin, zmax
! Limits on x and y coordinates defined by system boundaries
xmin=System_Info%SimSpace_Boundary(3)
xmax=System_Info%SimSpace_Boundary(1)
ymin=System_Info%SimSpace_Boundary(4)
ymax=System_Info%SimSpace_Boundary(2)
zmin = System_Info%SimSpace_Boundary(5)
zmax = System_Info%SimSpace_Boundary(6)
! Check & Apply Periodic Boundary Condition
! Check x move
IF (x < xmin) THEN ! Add width of box
xnew=x+(xmax-xmin)
ELSE IF (x > xmax) THEN ! Subtract width of box
xnew=x-(xmax-xmin)
ELSE ! remains unchanged
xnew=x
END IF
! Check y move
IF (y < ymin) THEN ! Add length of box
! Define Y New Coordinate
ynew=y+(ymax-ymin)
ELSE IF (y > ymax) THEN ! Subtract length of box
! Define Y New Coordinate
ynew=y-(ymax-ymin)
ELSE ! remains unchanged
! Define Y New Coordinate
ynew=y
END IF
! Check z move only if z > 0
! the z (vertical) direction must have REFLECTIVE BC
if (z/=0) then
! reflect by zmin
if (z<zmin) then
znew=zmin + (zmin - z)
end if
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if (z>zmax) then
znew=zmax - (z-zmax)
end if
endif
END SUBROUTINE PeriodicBC3
!***********************************************************************
************************************************************************
************
SUBROUTINE BindReaction(i)
! TODO : add collision check and binding with Lyn and Syk
! the particle number (NP) and system time (st) are available in ParticleInfo,
! under System_Info%Current_Simulation_Time and System_Info%Num_Particles
USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
INTEGER, INTENT(IN) :: i ! specific particle
! LOGICAL :: Reaction -- using System_Info%Reaction
INTEGER :: Bond_Count, Bond_Count_i, k, Bond_count_k
INTEGER :: Agg1(System_Info%Num_Particles),
Agg2(System_Info%Num_Particles),&
AggT(System_Info%Num_Particles), size, next, d, f
INTEGER :: NewBoss, NewAggSize, CurrentParticle, ip, c
INTEGER :: OldAggSize_i, OldAggSize_k
DOUBLE PRECISION :: distsq
double precision :: BeginTime_i, BeginTime_k ! begin times of the merging aggregates

if (System_Info%OutputLevel >= 3) write(*,*) &
'BindReaction begin: st:',System_Info%Current_Simulation_Time,&
' NP:', System_Info%Num_Particles,' i=',i, &
' size:', RecMolecule(i)%Agg_Size
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System_Info%Reaction = .FALSE.
!Reaction = .FALSE.
! Check for reaction
DO k = 1,System_Info%Num_Particles ! loop over particles (receptor monomers)
! Check if one of available monomers is close enough to react
IF (k /= i .AND. RecMolecule(k)%Boss == k ) THEN
! Calculate distance between particle of interest and compared particle
distsq=sqrt((RecMolecule(k)%Position(1)-RecMolecule(i)%Position(1))**2+&
(RecMolecule(k)%Position(2)-RecMolecule(i)%Position(2))**2)
Bond_count_i = RecMolecule(i)%Bond
Bond_count_k = RecMolecule(k)%Bond
IF (distsq <= BindRad_Dimer) THEN !LR-RL
System_Info%Reaction = .TRUE.
OldAggSize_k = RecMolecule(k)%Agg_Size
OldAggSize_i = RecMolecule(i)%Agg_Size
NewAggSize = RecMolecule(i)%Agg_Size + RecMolecule(k)%Agg_Size
BeginTime_k = RecMolecule(k)%LastOnOffTime
BeginTime_i = RecMolecule(i)%LastOnOffTime

System_Info%Num_Aggregates = System_Info%Num_Aggregates - 1
System_Info%AggSizeCount( OldAggSize_k) =
System_Info%AggSizeCount(OldAggSize_k) - 1
System_Info%AggSizeCount( OldAggSize_i) =
System_Info%AggSizeCount(OldAggSize_i) - 1
System_Info%AggSizeCount(NewAggSize) =
System_Info%AggSizeCount(NewAggSize) + 1
if (System_Info%OutputLevel >=3) &
write(*,*) 'BindReaction - success ',i,k
END IF
f = RecMolecule(i)%Agg_Size ! same as OldAggSize_i
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if(System_Info%Reaction)then
! Go down chain k
CurrentParticle=k ! k is the binding partner we just found
AggT(1)=CurrentParticle
d = RecMolecule(k)%Agg_Size ! same as OldAggSize_k
DO ip=2,OldAggSize_k
CurrentParticle=RecMolecule(CurrentParticle)%BoundRec_2
AggT(ip) = CurrentParticle
END DO
! Go down chain i
CurrentParticle=i ! i is the originally chosen particle
Agg1(1)=CurrentParticle
DO ip=2,OldAggSize_i
CurrentParticle=RecMolecule(CurrentParticle)%BoundRec_2
Agg1(ip) = CurrentParticle
END DO
next=CurrentParticle
! Make the bond:
! head of partner chain (k)
! connected to tail of incoming chain (next)
RecMolecule(k)%BoundRec_1 = next ! head of partner chain front link
RecMolecule(next)%BoundRec_2 = k ! tail of incoming chain back link
! increment bond counts
RecMolecule(k)%Bond = RecMolecule(k)%Bond + 1
RecMolecule(next)%Bond = RecMolecule(next)%Bond + 1
! Particle(k)%Position(:)=Particle(i)%Position(:) ! position of partner particle -why only this one ???
!Particle(i)%Agg_Size = Particle(i)%Agg_Size+Particle(k)%Agg_Size ! agg size
update -- why only this one ???
! update the entire merged aggregate
WHERE (RecMolecule(:)%Boss == i .OR. RecMolecule(:)%Boss == k)
RecMolecule(:)%Position(1) = RecMolecule(i)%Position(1)
RecMolecule(:)%Position(2) = RecMolecule(i)%Position(2)
RecMolecule(:)%Position(3) = RecMolecule(i)%Position(3)
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RecMolecule(:)%Agg_Size = NewAggSize
RecMolecule(:)%Boss = i
RecMolecule(:)%LastOnOffTime = System_Info%Current_Simulation_Time
END WHERE
!!$
!!$
!!$
!!$
!!$

if (System_Info%OutputLevel>=1) then
write(*,*) 'Time',System_Info%Current_Simulation_Time,&
'RecBind ','RecID ',i,k,&
'OldAggSizes ', OldAggSize_i, OldAggSize_k, &
'NewAggSize ',NewAggSize

if (System_Info%OutputLevel >=1) &
write(*,FMT="(&
'T=',f14.8,' RecBind Rec1 =',i3,' Rec2 =',i3,&
' Aggs [',I3,',',I3,'] --> [',I3,']',&
' Size ',i2,'+',i2,'=',i2,' AggCount ',i3,' Dom ',i1,' ',i1)") &
System_Info%Current_Simulation_Time,k,next,i,k,i,&
OldAggSize_i,OldAggSize_k,NewAggSize,
System_Info%Num_Aggregates,&
RecMolecule(i)%Domain,RecMolecule(k)%Domain
endif ! if a reaction occurs
end if ! if k is a boss
if (System_Info%Reaction) exit ! break the loop / so only one reaction per mini update
end do ! loop over possible reaction partners (k)
if(System_Info%Reaction) then
! check the aggregate by walking down the list
CurrentParticle=i;
do
if (System_Info%OutputLevel >= 2) write(*,1003) CurrentParticle, &
RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2,&
RecMolecule(CurrentParticle)%Bond,&
RecMolecule(CurrentParticle)%Agg_Size,
RecMolecule(CurrentParticle)%Boss,&
RecMolecule(CurrentParticle)%Position(1:2)
1003 format(' ',6I5,2F8.3)
if( RecMolecule(CurrentParticle)%BoundRec_2==0) exit
CurrentParticle = RecMolecule(CurrentParticle)%BoundRec_2
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end do
else
if (System_Info%OutputLevel >=3) write(*,*) 'BindReaction -- no reaction this time'
endif
if (System_Info%OutputLevel >= 3) WRITE(*,*) 'BindReaction end'
! output for "dimer lifetime" record
if(System_Info%Reaction)then
! we need to output enough information to completely define the aggregates that
! are ending with this reaction
! Metadata (for each ending aggregate): Length, Begin and end times, Boss ID
! List of member receptors beginning with the Boss, on a single line
WRITE(4,*) 'Bind', System_Info%Current_Simulation_Time,&
'Ksize',OldAggSize_k,'kagg', AggT(1:OldAggSize_k),&
'Isize',OldAggSize_i,'oldiagg', Agg1(1:OldAggSize_i)
! post mortem aggregate entry: Length, Boss, DescendantBoss1, DescendantBoss2,
BeginTime, EndTime, <Receptor list>
write(4,*), OldAggSize_i,i,k,0, BeginTime_i,
System_Info%Current_Simulation_Time, Agg1(1:OldAggSize_i)
write(4,*), OldAggSize_k,i,k,0, BeginTime_k,
System_Info%Current_Simulation_Time, AggT(1:OldAggSize_k)
!WRITE(4,*) 'Bind', System_Info%Current_Simulation_Time, i, k, OldAggSize1,
OldAggSize2, NewAggSize
end if
END SUBROUTINE BindReaction
!***********************************************************************
************************************************************************
************
SUBROUTINE UnbindReaction(i)
! i identifies the aggregate the breaks (the boss of it is receptor i)
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USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
integer, intent(in) :: i
DOUBLE PRECISION :: placeangle, x1, y1, z1, rannum
INTEGER :: LigandCount, domainnum, BoundBuddy
INTEGER :: BondToBreak, BondToBreakPlusOne, Break_Particle_1,
Break_Particle_2, CurrentParticle, ip
INTEGER :: Agg2(System_Info%Num_Particles),
Agg3(System_Info%Num_Particles),ic
integer :: OldAggSize,NewAggSize1,NewAggSize2, NewBoss
integer :: OldDomain,NewDomain,iDom
double precision :: BeginTime
double precision :: OldPosition(3),NewPosition(3)
! INTEGER, PARAMETER :: OutputLevel = 0
if (System_Info%OutputLevel >= 2) write(*,1002) i,RecMolecule(i)%Agg_Size
1002 format('UnBindReaction Input: Agg:',I3,' size ',I3);
BeginTime = RecMolecule(i)%LastOnOffTime
! check the aggregate by walking down the list
CurrentParticle=i;
do
if (System_Info%OutputLevel >= 2) write(*,1003) CurrentParticle, &
RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2,&
RecMolecule(CurrentParticle)%Bond,&
RecMolecule(CurrentParticle)%Agg_Size, RecMolecule(CurrentParticle)%Boss,&
RecMolecule(CurrentParticle)%Position
1003 format(' ',6I5,2F8.3)
if(RecMolecule(CurrentParticle)%BoundRec_2==0) exit
CurrentParticle = RecMolecule(CurrentParticle)%BoundRec_2
end do
!Break_bond = floor(rannum*(Agg_Size-1))
!k = Break_bond
! This will give me bond to break
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rannum = grnd()
BondToBreak = ceiling(rannum*(RecMolecule(i)%Agg_Size-1))
if (System_Info%OutputLevel >= 2) write(*,*) 'UnBindReaction: Agg ',i,' size
',RecMolecule(i)%Agg_Size, ' break at ', BondToBreak
!write(*,*) 'Breaking bond',BondToBreak,' of ', RecMolecule(i)%Agg_Size-1
! walk down the chain k steps
CurrentParticle=i
Agg2(1)=CurrentParticle
if (System_Info%OutputLevel >= 2) write(*,*) ' Chain start ',CurrentParticle,&
' bonds: ',RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2
DO ip=2,RecMolecule(i)%Agg_Size
CurrentParticle=RecMolecule(CurrentParticle)%BoundRec_2
Agg2(ip) = CurrentParticle
if (System_Info%OutputLevel >= 2) write(*,*) '
next ',CurrentParticle,&
' bonds: ',RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2
!WRITE(*,*) 'LOOP'
END DO
! identifiers of the particles where the chain breaks
Break_Particle_1 = Agg2(BondToBreak)
BondToBreakPlusOne = BondToBreak + 1
Break_Particle_2 = Agg2(BondToBreakPlusOne)
OldAggSize = RecMolecule(i)%Agg_Size
NewAggSize1 = BondToBreak
NewAggSize2 = OldAggSize - BondToBreak
NewBoss = Agg2(BondToBreakPlusOne)
!first chain is Agg2(1:NewAggSize1)
!second chain is Agg2(NewAggSize1+1 : OldAggSize) or
Agg2(BondToBreakPlusOne:OldAggSize)
! Deal with chain 1
! Update BoundRec_2
RecMolecule(Break_Particle_1)%BoundRec_2 = 0
! Update Bond (0 or 1)
IF (RecMolecule(Break_Particle_1)%BoundRec_1 == 0) THEN
RecMolecule(Break_Particle_1)%Bond= 0
ELSE
RecMolecule(Break_Particle_1)%Bond= 1
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END IF
! first piece
!Particle(Agg2(1:NewAggSize1))%Boss=i ! unnecessary
!Update Aggsize of first aggregate
RecMolecule(Agg2(1:NewAggSize1))%Agg_Size=NewAggSize1

!Deal with chain 2
RecMolecule(Break_Particle_2)%BoundRec_1 = 0 !update boundrec_1
IF (RecMolecule(Break_Particle_2)%BoundRec_2 == 0) THEN ! update bond
RecMolecule(Break_Particle_2)%Bond = 0
ELSE
RecMolecule(Break_Particle_2)%Bond = 1
END IF

! second piece
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Boss = NewBoss ! update
Boss
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Agg_Size = NewAggSize2
!update agg size
! figure out the ejected piece's position
OldPosition = RecMolecule(Break_Particle_2)%Position
OldDomain = RecMolecule(Break_Particle_2)%Domain
NewDomain = OldDomain ! not really necessary, it may change only if OldDomain=0
! Add new x and y coordinates
placeangle=2*Pi*grnd() ! Pick a number between 0 and 2*Pi
x1=cos(placeangle)*UnbindRad_RestDimer
y1=sin(placeangle)*UnbindRad_RestDimer
z1= 0
! impose periodic BC on the ejected particle's proposed position
! call
PeriodicBC(OldPosition(1)+x1,OldPosition(2)+y1,OldPosition(3),NewPosition(1),NewP
osition(2),NewPosition(3))
call
PeriodicBC2(OldPosition(1)+x1,OldPosition(2)+y1,NewPosition(1),NewPosition(2))
! now check if there is a domain escape involved
if(OldDomain > 0) then
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! if this move goes outside the domain, try the opposite direction
if(.not. InDomain(NewPosition(1:2),OldDomain)) &
call PeriodicBC2(OldPosition(1)-x1,OldPosition(2)y1,NewPosition(1),NewPosition(2))
! if this move goes out, try the perpendicular direction
if(.not.InDomain(NewPosition(1:2),OldDomain)) &
call PeriodicBC2(OldPosition(1)y1,OldPosition(2)+x1,NewPosition(1),NewPosition(2))
! if this move goes out, try the opposite perpendicular direction
if(.not.InDomain(NewPosition(1:2),OldDomain)) &
call PeriodicBC2(OldPosition(1)+y1,OldPosition(2)x1,NewPosition(1),NewPosition(2))
! if this move still goes out, give up
if(.not.InDomain(NewPosition(1:2),OldDomain)) &
NewPosition = OldPosition
else
! if particle was initially free, it may end up in a domain
NewDomain = 0
do iDom=1,NumDomains
if(InDomain(NewPosition(1:2),iDom)) NewDomain=iDom
end do
endif
! record the ejected position
RecMolecule(Break_Particle_2)%Position = NewPosition
! if trapping occurred
if(OldDomain==0 .and. NewDomain>0) then
RecMolecule(Break_Particle_2)%Domain = NewDomain
DomainParticleCount(NewDomain) = DomainParticleCount(NewDomain) +
NewAggSize2
endif
! update Position in 2nd chain
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Position(1) =
RecMolecule(Break_Particle_2)%Position(1)
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Position(2) =
RecMolecule(Break_Particle_2)%Position(2)
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Position(3) =
RecMolecule(Break_Particle_2)%Position(3)
RecMolecule(Agg2(BondToBreakPlusOne:OldAggSize))%Domain =
RecMolecule(Break_Particle_2)%Domain
! update the last reaction time for all receptors in the original aggregate
RecMolecule(Agg2(1:OldAggSize))%LastOnOffTime =
System_Info%Current_Simulation_Time
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System_Info%Num_Aggregates = System_Info%Num_Aggregates + 1
System_Info%AggSizeCount(OldAggSize) =
System_Info%AggSizeCount(OldAggSize) - 1
System_Info%AggSizeCount(NewAggSize1) =
System_Info%AggSizeCount(NewAggSize1) + 1
System_Info%AggSizeCount(NewAggSize2) =
System_Info%AggSizeCount(NewAggSize2) + 1
WRITE(4,*) 'UnBi', System_Info%Current_Simulation_Time,&
i,NewBoss,OldAggSize,NewAggSize1,NewAggSize2
! post mortem aggregate entry: Length, Boss, DescendantBoss1, DescendantBoss2,
BeginTime, EndTime, <Receptor list>
write(4,*) OldAggSize, i, i, NewBoss,&
BeginTime, System_Info%Current_Simulation_Time, Agg2(1:OldAggSize)
if (System_Info%OutputLevel >= 1) &
write(*,1004) System_Info%Current_Simulation_Time,&
Break_Particle_1, Break_Particle_2,&
i,i,NewBoss,OldAggSize,NewAggSize1,NewAggSize2,
System_Info%Num_Aggregates, &
OldDomain, NewDomain
1004 format('T=',F14.8,' RecUnBi Rec1 =',i3,' Rec2 =',i3,&
' Aggs [',I3,'] --> [',I3,',',I3,']',&
' Size ',I2,'=',I2,'+',I2,' AggCount ',I3,' Dom ',i1,' ',i1)
if (System_Info%OutputLevel >= 2) write(*,*) ' One '
! check the aggregate by walking down the list
CurrentParticle=i;
do
if (System_Info%OutputLevel >= 2) write(*,1003) CurrentParticle, &
RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2,&
RecMolecule(CurrentParticle)%Bond,&
RecMolecule(CurrentParticle)%Agg_Size, RecMolecule(CurrentParticle)%Boss,&
RecMolecule(CurrentParticle)%Position
if( RecMolecule(CurrentParticle)%BoundRec_2==0) exit
CurrentParticle = RecMolecule(CurrentParticle)%BoundRec_2
end do
if (System_Info%OutputLevel >= 2) write(*,*) '
! check the aggregate by walking down the list

Two '
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CurrentParticle=Break_Particle_2;
do
if (System_Info%OutputLevel >= 2) write(*,1003) CurrentParticle, &
RecMolecule(CurrentParticle)%BoundRec_1,
RecMolecule(CurrentParticle)%BoundRec_2,&
RecMolecule(CurrentParticle)%Bond,&
RecMolecule(CurrentParticle)%Agg_Size, RecMolecule(CurrentParticle)%Boss,&
RecMolecule(CurrentParticle)%Position
if( RecMolecule(CurrentParticle)%BoundRec_2==0) exit
CurrentParticle = RecMolecule(CurrentParticle)%BoundRec_2
end do
if (System_Info%OutputLevel >= 2) write(*,*) ' done with this unbinding '
! Record time of undimerization
!RecMolecule(i)%DimOffTime=st
!Particle(BoundBuddy)%DimOffTime=st
! Record who was in the dimer
!Particle(i)%PrevBuddy=BoundBuddy
!Particle(BoundBuddy)%PrevBuddy=i
! Record dimer lifetime and type
!WRITE(4,*) Particle(i)%Lifetime, LigandCount, Particle(i)%DimerOnTime, &
!
&Particle(i)%DimOffTime, i, boundbuddy ! Dimer_liftime
Ligands/Dimer, dimer on time, dimer off time, receptor, bound receptor
! Reset dimer lifetime
!Particle(i)%Lifetime=0
!Particle(BoundBuddy)%Lifetime=0
! Reset time of undimerization
!Particle(i)%DimOffTime=0
!Particle(BoundBuddy)%DimOffTime=0
! Reset time of dimerization
!Particle(i)%DimerOnTime=0
!Particle(BoundBuddy)%DimerOnTime=0
! Reset Time to Phosphorylation
!Particle(i)%PhosTime=0
!Particle(BoundBuddy)%PhosTime=0
! Reset Phosphorylation Event
!Particle(i)%PhosEvent=0
!Particle(BoundBuddy)%PhosEvent=0
! Seperate dimer in to orignal monomer species
!Particle(i)%Species=Particle(i)%OriginalSpecies
!Particle(BoundBuddy)%Species=Particle(BoundBuddy)%OriginalSpecies
! Update species back to monomers and erase partners
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!Particle(i)%DomPartner = 0
!Particle(BoundBuddy)%DomPartner = 0
!
Particle(BoundBuddy)%BoundBuddy = 0
!
Particle(i)%BoundBuddy = 0
!
BoundBuddy=0
if (System_Info%OutputLevel >= 2) write(*,*) 'UnBindReaction end'
END SUBROUTINE UnbindReaction
!***********************************************************************
************************************************************************
************
SUBROUTINE SykDiffuse (iSyk, SykDiffuse_std)
USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
! Declare variables
INTEGER, INTENT (IN) :: iSyk ! chosen particle
DOUBLE PRECISION, INTENT (IN) :: SykDiffuse_std ! diffusion standard deviation
DOUBLE PRECISION :: r1, r2, r3, w1, w2, w3, x1, y1, z1, rannum
if (System_Info%Reaction .or. System_Info%OutputLevel >=2) write(*,*) 'SykDiffuse
begin -- SykID ',iSyk, 'Coords: ',&
SykMolecule(iSyk)%Position
Syk_DiffCall_Count = Syk_DiffCall_Count + 1
!!! randomly make a trajectory for particles using mtmod.f90 for random numbers !!!
!! Generate random number & Normally distribute random number !
http://www.taygeta.com/random/gaussian.html
!* Generate x move
r1=2*grnd()-1
r2=2*grnd()-1
! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
! Generate random number again
r1=2*grnd()-1
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r2=2*grnd()-1
! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
! Normally distributed random # for distance
x1=r1*w2
! Generate y move
r1=2*grnd()-1
r2=2*grnd()-1
! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
y1=r2*w2
!Generate z move
r1=2*grnd()-1
r2=2*grnd()-1
! Check unit circle, if not in reject and try again
w1=r1*r1+r2*r2
DO WHILE (w1 > 1)
! Generate random number again
r1=2*grnd()-1
r2=2*grnd()-1
! Unit circle check
w1=r1*r1+r2*r2
END DO
w2=sqrt((-2*log(w1))/w1)
z1=r2*w2
! Account for diffusion coefficient based on species type
y1=y1*SykDiffuse_std
x1=x1*SykDiffuse_std
z1=z1*SykDiffuse_std

183
if (System_Info%Reaction .or. System_Info%OutputLevel >=2) write(*,*) 'SykDiffuse
- call PBC'
! call periodic boundary condition
CALL PeriodicBC3( &
SykMolecule(iSyk)%Position(1)+x1,SykMolecule(iSyk)%Position(2)+y1,
SykMolecule(iSyk)%Position(3)+z1, &
SykMolecule(iSyk)%Position(1),
SykMolecule(iSyk)%Position(2),SykMolecule(iSyk)%Position(3))
if (System_Info%Reaction .or. System_Info%OutputLevel >=2) write(*,*) 'SykDiffuse
SykID ',iSyk, 'New Coords: ',&
SykMolecule(iSyk)%Position(1:3)
! Check for (dimerization) reactions
if(abs(SykMolecule(iSyk)%Position(3))<SykLayerDepth) &
CALL SykBind(iSyk)
if (System_Info%Reaction .or. System_Info%OutputLevel >=2) write(*,*) 'SykDiffuse
end ',iSyk
if (System_Info%Reaction) then
Syk_Diff_Reaction = Syk_Diff_Reaction + 1
else
Syk_Diff_NoReaction = Syk_Diff_NoReaction + 1
end if
END SUBROUTINE SykDiffuse
!***********************************************************************
************************************************************************
************
SUBROUTINE SykBind (iSyk)
USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
INTEGER, INTENT(IN)::iSyk
INTEGER, DIMENSION(MaxAgg) :: Syk_Agg=0 ! list of receptors in a given
aggregate
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real, dimension(MaxAgg) :: IgABindProb, IgBBindProb
real, dimension(2*MaxAgg) :: SykBindProbVec
real :: CumSum=0
DOUBLE PRECISION :: distsq, rannum
INTEGER :: j, u, m_syk, k, i, rv_syk,cv_syk,ip,h, i_syk
integer, dimension(System_Info%Num_Particles) :: BossList
integer :: BossCount2
integer :: AggRecCount ! number of receptors on the current aggregate
! counters for partners (eligible aggregates), docking sites (one- and two-SH2)
integer :: BossCount, EligibleAggCount=0 ! count per each sub call
integer :: ThisAggEligible=0 ! by agg
integer, dimension(2) :: AggPhosCount=0, SysPhosCount=0 ! count per agg then add up
double precision :: MinDistNow ! closest square dist to an eligible aggregate
if (System_Info%OutputLevel >=2) write(*,*) 'SykBind begin -- SykID ',iSyk
! counters..
Syk_BindCall_Count = Syk_BindCall_Count + 1 ! counts each call to this sub
BossCount = 0 ! count bosses in this sub call
EligibleAggCount=0
SysPhosCount=0
MinDistNow=100
! TODO: try to identify the receptors that have docking sites, and their bosses
!
those are the only receptors that should be checked in the main loop below
!
!!$ BossCount2 = count(RecMolecule(:)%Iga_Phos > 0 .and.
RecMolecule(:)%Iga_Lyn==0 .and. RecMolecule(:)%Iga_Syk==0)
!!$ BossList = pack(RecMolecule(:)%Boss, RecMolecule(:)%Iga_Phos > 0 .and.
RecMolecule(:)%Iga_Lyn==0 .and. RecMolecule(:)%Iga_Syk==0)
!!$
!!$ if(BossCount2==10) then
!!$ do j=1,10
!!$
write(*,*) 'BOSSLIST!! ', j,BossList(j),RecMolecule(BossList(j))%Agg_Size
!!$ end do
!!$ stop
!!$ end if
!!$
!!$
!!$
! Check for reaction (collision)
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do k = 1,System_Info%Num_Particles ! loop over particles (receptor monomers)
if (RecMolecule(k)%Boss == k) then ! this will only check for the bosses
BossCount = BossCount+1 ! count bosses in this sub call
AggRecCount = RecMolecule(k)%Agg_Size ! number of receptors on the aggregate
Syk_Agg = pack(RecMolecule(:)%RecID, RecMolecule(:)%Boss==k)! holding the
recs in an aggregate
!count each type of binding- each receptor- whether general syk binding is possible
through Iga, Igb
if (System_Info%OutputLevel >=3) then
WRITE(*,*) 'ending -- Syk_Agg has size ',size(Syk_Agg),'
AggRecCount=',AggRecCount
do j=1,size(Syk_Agg)
write(*,*) 'entry',j,':',Syk_Agg(j)
end do
endif
! initialize the prob vectors
IgABindProb=0;
IgBBindProb=0;
! to count eligible (at least one site unoccupied and phos>0) aggs
ThisAggEligible=0
! count open (un-occupied) phos sites by phos level 1 or 2
AggPhosCount=0
do j = 1,AggRecCount ! this follows the receptors down the aggregate
! Iga binding requires three conditions.. no Lyn or Syk bound anf phos>0
if (RecMolecule(Syk_Agg(j))%Iga_Syk == 0 .and.
RecMolecule(Syk_Agg(j))%Iga_Lyn == 0 .and. &
RecMolecule(Syk_Agg(j))%Iga_Phos>0) then
IgABindProb(j)=SykBindScaleFactor(RecMolecule(Syk_Agg(j))%Iga_Phos)
! count available sites by phos level (1 or 2)
AggPhosCount(RecMolecule(Syk_Agg(j))%Iga_Phos)=AggPhosCount(RecMolecule(Sy
k_Agg(j))%Iga_Phos)+1
ThisAggEligible=1
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endif
! same for Igb
if (RecMolecule(Syk_Agg(j))%Igb_Syk == 0 .and.
RecMolecule(Syk_Agg(j))%Igb_Lyn == 0 .and. &
RecMolecule(Syk_Agg(j))%Igb_Phos>0) then
IgBBindProb(j)=SykBindScaleFactor(2+RecMolecule(Syk_Agg(j))%Igb_Phos)
! count available sites by phos level (1 or 2)
AggPhosCount(RecMolecule(Syk_Agg(j))%Igb_Phos)=AggPhosCount(RecMolecule(Sy
k_Agg(j))%Igb_Phos)+1
ThisAggEligible=1
endif
end do ! loop through recs in this agg
! counting eligible aggs in the system
EligibleAggCount = EligibleAggCount + ThisAggEligible
SysPhosCount = SysPhosCount + AggPhosCount
distsq=&
(RecMolecule(k)%Position(1)-SykMolecule(iSyk)%Position(1))**2+&
(RecMolecule(k)%Position(2)-SykMolecule(iSyk)%Position(2))**2+&
(RecMolecule(k)%Position(3)-SykMolecule(iSyk)%Position(3))**2
if(distsq < MinDistNow .and.
sum(IgABindProb(1:AggRecCount))+sum(IgBBindProb(1:AggRecCount))>0) &
MinDistNow=distsq /
(sum(IgABindProb(1:AggRecCount))+sum(IgBBindProb(1:AggRecCount)))
! compare the sq distance with the BR^2 scaled by the factors
if(distsq <=
(sum(IgABindProb(1:AggRecCount))+sum(IgBBindProb(1:AggRecCount)))*Syk_Bind
Rad_Dimer**2 ) then
! ** implement the binding **
!choose the site (rec+itam) according to the relative probs
! build a vector of probs
SykBindProbVec(1:AggRecCount)=IgABindProb(1:AggRecCount)
SykBindProbVec(1+AggRecCount:2*AggRecCount)=IgBBindProb(1:AggRecCount)
SykBindProbVec = SykBindProbVec /
sum(SykBindProbVec(1:2*AggRecCount)) ! normalize
! pick a kosher random number (guaranteed in [0,1])
rannum=grnd()

187
! unfortunately this is necessary
do while(rannum > 1.0 .and. rannum < 0.0)
rannum = grnd()
enddo
CumSum=SykBindProbVec(1);
j=1
do while(CumSum < rannum .and. j <= 2*AggRecCount)
j=j+1
CumSum = CumSum + SykBindProbVec(j)
end do
if (j <= AggRecCount) then
! ** Syk binds to Iga on Syk_Agg(j) **
! update Syk molecule
SykMolecule(iSyk)%Receptor_ID = Syk_Agg(j)
SykMolecule(iSyk)%Position = RecMolecule(Syk_Agg(j))%Position
SykMolecule(iSyk)%Itam_site = 1
SykMolecule(iSyk)%Syk_site = RecMolecule(Syk_Agg(j))%Iga_Phos ! binding
state of Syk given by phos level of dock site
! update receptor
RecMolecule(Syk_Agg(j))%Iga_Syk = iSyk ! record Id of Syk molecule
elseif (j <= 2*AggRecCount) then
! ** Syk binds to Igb on Syk_Agg(j - AggRecCount) **
j = j - AggRecCount ! rec location on the chain
! update Syk molecule
SykMolecule(iSyk)%Receptor_ID = Syk_Agg(j)
SykMolecule(iSyk)%Position = RecMolecule(Syk_Agg(j))%Position
SykMolecule(iSyk)%Itam_site = 2
SykMolecule(iSyk)%Syk_site = RecMolecule(Syk_Agg(j))%Igb_Phos ! binding
state of Syk given by phos level of dock site
! update receptor
RecMolecule(Syk_Agg(j))%Igb_Syk = iSyk ! record Id of Syk molecule
endif
System_Info%Free_Syk_Count = System_Info%Free_Syk_Count - 1
if (System_Info%OutputLevel >=1) &
write(*,FMT="('T=',f14.8,' SykBind SykID=',i4,' RecID=',i3,'.',i1,' Agg=',i3,'
Sz=',i0,' Free Syk ',i0)") &
System_Info%Current_Simulation_Time,iSyk,
SykMolecule(iSyk)%Receptor_ID ,SykMolecule(iSyk)%Syk_site,&
RecMolecule(Syk_Agg(j))%Boss,&
RecMolecule(Syk_Agg(j))%Agg_Size,System_Info%Free_Syk_Count
System_Info%Reaction = .true.
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endif ! if distance is less than scaled BR^2
end if ! only check if receptor is a bossgregate
! TODO: randomize the order receptors are picked
if (System_Info%Reaction) exit ! break the loop / so only one binding reaction is
possible
end do ! loop over all receptors
if(System_Info%Reaction) then
Syk_Bind_Reaction = Syk_Bind_Reaction + 1
else
Syk_Bind_NoReaction = Syk_Bind_NoReaction + 1 ! calls that didn't lead to a
reaction
! report aggs and phos sites in the system but missed
Enc_BossCount=Enc_BossCount+BossCount ! aggregates in the system (add for
each call)
Enc_EligAggCount = Enc_EligAggCount + EligibleAggCount ! eligible aggregates
by call
Enc_SysPhosCount = Enc_SysPhosCount + SysPhosCount ! ph=1 and 2 phos sites in
the system this time (add for each call)
if(MinDistNow < SysMinDist) SysMinDist=MinDistNow
endif

if (System_Info%OutputLevel >=2) write(*,*) 'SykBind end'
END SUBROUTINE SykBind
!***********************************************************************
************************************************************************
************
SUBROUTINE SykUnbindReaction(iSyk)
USE ParticleInfo
USE ModelConstants
USE mtmod
IMPLICIT NONE
INTEGER, INTENT(IN)::iSyk
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DOUBLE PRECISION :: placeangle_one,placeangle_two, x1, y1, z1, rannum
INTEGER :: Receptor_bound_syk, Rec_Site
! receptor lyn is bound to
! SykMolecule(iSyk)%Receptor_ID = Receptor_bound_syk
Receptor_bound_syk = SykMolecule(iSyk)%Receptor_ID
Rec_Site = SykMolecule(iSyk)%Itam_site
! make sure the current position is set to that of the [boss of] the binding receptor
SykMolecule(iSyk)%Position =
RecMolecule(RecMolecule(Receptor_bound_syk)%Boss)%Position
if (System_Info%OutputLevel >=2) &
write(*,*) 'SykUnBind begin -- SykID ',iSyk, ' RecID', Receptor_bound_syk
placeangle_one = 2*Pi*grnd() ! full circle, in the xy plane
placeangle_two = (Pi/2)*grnd() ! angle from vertical to the direction of the velocity
x1 = sin(placeangle_two)*cos(placeangle_one)*Syk_UnbindRad_RestDimer
y1 = sin(placeangle_two)*sin(placeangle_one)*Syk_UnbindRad_RestDimer
z1 = cos(placeangle_two)*Syk_UnbindRad_RestDimer
!this will update Syk position
CALL PeriodicBC3(&
SykMolecule(iSyk)%Position(1)+x1,SykMolecule(iSyk)%Position(2)+y1, &
SykMolecule(iSyk)%Position(3)+z1, SykMolecule(iSyk)%Position(1), &
SykMolecule(iSyk)%Position(2),SykMolecule(iSyk)%Position(3))
! Update Receptor first
If (SykMolecule(iSyk)%Itam_site==1) then
RecMolecule(Receptor_bound_syk)%Iga_Syk = 0
else if (SykMolecule(iSyk)%Itam_site==2) then
RecMolecule(Receptor_bound_syk)%Igb_syk = 0
End if
! update Syk now
SykMolecule(iSyk)%Receptor_ID = 0
System_Info%Free_Syk_Count = System_Info%Free_Syk_Count + 1
SykMolecule(iSyk)%Itam_site = 0
SykMolecule(iSyk)%Syk_site = 0
if (System_Info%OutputLevel >=1) &
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write(*,FMT="('T=',f14.8,' SykUnBi SykID=',i3,' RecID=',i3,'.',i1,' Agg=',i3,' Sz=',i0'
Free Syk ',i0)") &
System_Info%Current_Simulation_Time,iSyk, Receptor_bound_syk,Rec_Site,&
RecMolecule( Receptor_bound_syk)%Boss, RecMolecule(
Receptor_bound_syk)%Agg_Size,&
System_Info%Free_Syk_Count
if (System_Info%OutputLevel >=2) &
write(*,*) 'SykUnBind end -- SykID ',iSyk, ' RecID', Receptor_bound_syk
END SUBROUTINE SykUnbindReaction
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